header logo image


Page 36«..1020..35363738..»

Archive for August, 2016

Personalized Medicine SFSU

Thursday, August 4th, 2016

Join us for Personalized Medicine 9.0: Gene Therapy & Genome Editing This changes everything! Thursday 26 May 2016 8:00 a.m. to 6:00 p.m. An exciting topic every year South San Francisco Conference Center Personalized medicine seeks to use genetic variation to develop new diagnostic tests and treatments and to identify the sub-groups of patients for whom they will work best. This approach can also help determine which groups of patients are more prone to developing some diseases and, ideally, help with the selection of lifestyle changes and/or treatments that can delay onset of disease or reduce its impact. This year, in our ninth annual conference on personalized medicine, we address the promise of technologies like genome editing for gene therapy and drug discovery. The correction of genetic disease has been elusive until very recently, but the process of genome editing through the CRISPR/Cas9 system has revolutionized the field with unprecedented speed, and unparalleled opportunities. CRISPR has also proved to be one of the most powerful tools in basic genetics and biology developed in the last century, and provides new ways to understand cellular function. Using this knowledge, we have the potential to create pharmaceuticals and diagnostic tests with a speed and accuracy never before imagined. We explore the science behind gene therapy and genome editing, the realization of new diagnostic tools and treatments, the ethics of germline gene manipulation, and the implications for the future of the pharmaceutical industry and the human species. For further information or to sponsor this event, email us at dnamed@sfsu.edu Personalized Medicine The Time is Now We are happy to accommodate persons with special access requirements. Please contact Mike Goldman at: goldman@sfsu.edu or 415.338.1549

Read the original post:
Personalized Medicine SFSU

Read More...

Personalized Medicine | Labcyte Inc.

Thursday, August 4th, 2016

FIMMs Individual Systems Medicine (ISM) approach relies on the Echo Liquid Handler from Labcyte, which uses acoustic energy to enable precise screening of potential therapies in a high-throughput, cost-effective manner.

FEATURED PUBLICATION

Journal of Laboratory Automation (JALA) Special Issue February 2016

Kristin Blom, et al. Department of Medical Sciences, Uppsala University

Although medical cancer treatment has improved during the past decades, it is difficult to choose between several first-line treatments supposed to be equally active in the diagnostic group. It is even more difficult to select a treatment after the standard protocols have failed. Any guidance for selection of the most effective treatment is valuable at these critical stages. We describe the principles and procedures for ex vivo assessment of drug activity in tumor cells from patients as a basis for tailored cancer treatment. Patient tumor cells are assayed for cytotoxicity with a panel of drugs. Acoustic drug dispensing provides great flexibility in the selection of drugs for testing; currently, up to 80 compounds and/or combinations thereof may be tested for each patient. Drug response predictions are obtained by classification using an empirical model based on historical responses for the diagnosis. The laboratory workflow is supported by an integrated system that enables rapid analysis and automatic generation of the clinical referral response.

Test combinations of drugs, antibodies, and siRNA molecules in low volumes to identify impacts to cell functioning or toxicity. Echo liquid handlers reliably transfer samples and reagents from any well to any well to improve assay sensitivity and reproducibility.

Recently identified associations between variants of cancer genes and drug resistance have increased the value for comprehensive drug sensitivity screening in combination with molecular profiling of cancer cells. In cancer research, the information from drug sensitivity screening is often used to improve the precision of therapy offered to patients. This can involve treatment with re-purposed therapeutics, novel therapeutics or combinations of therapeutics. Comparison of drug sensitivity information along with the molecular profile of certain cancer cells can enable the identification of underlying genetic links to drug resistance.

As these programs are scaled up, operational costs to prepare samples and perform screening can become rate limiting, delaying treatment decisions. Researchers have found that miniaturization from the use of acoustic liquid handling instead of traditional methods has increased the overall efficiency of drug sensitivity screening by lowering costs while improving data quality and throughput. Echo Dose-Response software enables direct dilution and normalization of simple or complex concentration curves from a range of sample types. With direct dilution, Echo Liquid Handlers produce dose-response assays without the risk of carryover or contamination common to tip-based serial dilution methods.

View post:
Personalized Medicine | Labcyte Inc.

Read More...

What Is Personalized Cancer Medicine? | Cancer.Net

Thursday, August 4th, 2016

Personalized medicine is used to learn about a persons genetic makeup and how their tumor grows. Using this data, doctors hope to find prevention, screening, and treatment strategies that may be more effective. They also want to find treatments that cause fewer side effects than the standard options. By performing genetic tests on the cancer cells and on normal cells, doctors may be able to customize treatment to each patients needs.

Creating a personalized cancer screening and treatment plan includes:

Determining the chances that a personwill develop cancer and selecting screening strategies to lower the risk

Matching patients with treatments thatare more likely to be more effective and cause fewer side effects

Predicting the risk of recurrence, whichis the return of cancer

Before personalized medicine, most patients with a specific type and stage of cancer received the same treatment. However, it became clear that some treatments worked better for some patients, than for others. The growth in the field of genetics has led researchers to find genetic differences in people and their tumors. In turn, this explained many of the different responses to treatment. A person with cancer may now still receive a standard treatment plan, such as surgery to remove a tumor. However, the doctor may also be able to recommend some type of personalized cancer treatment. Personalized cancer treatment is now an active part of the treatment plan or as part of a clinical trial. A clinical trial is a research study involving people.

Some examples of personalized medicine strategies for cancer include the following:

Targeted treatments. A targeted treatmenttargets a cancers specific genes and proteins that allow the cancer cells to grow and survive. Researchers are finding new targets each year and creating and testing new drugs for these targets. This is a few, but not all of the cancers where targeted treatments are used.

Breast cancer

Colorectal cancer

Gastrointestinal stromal tumor

Kidney cancer

Lung cancer

Melanoma

Multiple myeloma

Some types of leukemia and lymphoma

Some types of childhood cancers

Of course, treatment with a targeted therapy depends on finding out whether the tumor has the specific target. This is found by testing a sample of the tumor.

Pharmacogenomics. Pharmacogenomicslooks at how a persons genes affect the way the body processes and responds to drugs. These changes influence how effective and safe a drug is for a person. For example, some peoples bodies may process a medicine more quickly than others. This means that the person would require a higher dose of that drug for it to be effective. However, someone elses body may not process a drug as quickly. The drug would then stay in the bloodstream for a longer time and may cause more severe side effects.

How can pharmacogenomics be used for cancer treatments? Here is an example: People with colorectal cancer sometimes have a specific altered gene. These patients may have serious side effects when treated with the drug, irinotecan (Camptosar). This gene makes it harder for the body to break down the drug. In these patients, doctors prescribe lower amounts of the medicine so patients will have fewer side effects.

Despite the promises of personalized cancer treatments, not all types of cancer have personalized treatment options. Some of these are only offered through a clinical trial and are not yet standard treatment options. Genetic testing for patients and tumor samples may be costly and time-consuming. Also, many insurance plans may not cover the costs of these tests. In addition, some personalized treatments, such as targeted treatments, can also be expensive.

Personalized medicine is an evolving approach to cancer treatment. Doctors still dont know all about the genetic changes that occur in a cancer cell. They also dont know how some of these new cancer treatments work. A targeted therapy may stop working and a promising treatment is no longer effective. Talk with your doctor to learn if personalized cancer treatments may be a part of your treatment plan.

To learn more about personalized cancer care, consider asking your doctor the following questions:

What are my treatment options?

What clinical trials are open to me?

Are there tests available that can help guide treatment choices?

Is this treatment considered an example of personalized medicine? If so, how?

What are the benefits of this treatment?

What are the potential side effects ofthis treatment?

What is my chance of recovery?

Financial Considerations

Introduction to Cancer Research

Originally posted here:
What Is Personalized Cancer Medicine? | Cancer.Net

Read More...

Legal Issues – udel.edu

Thursday, August 4th, 2016

Legal Issues

Common-Law Protection of Genetic Information Privacy

Some protection for genetic information privacy is offered by common law tort remedies. The common law right of privacy prevents public disclosure of private facts. Most courts have, however, found that such a claim requires widespread disclosure to the public, which will not occur in most cases involving the release of personal genetic information. Another restrictive element of the public disclosure tort is that most courts require disclosure to someone without a "legitimate interest" in the information. Some courts consider employers to have such a legitimate interest in much of their worker's medical information.

The tort right of privacy also prevents intentional intrusions upon the private affairs or concerns of an individual. Such intrusions, however, must be "highly offensive." Miller v. Motorola illustrates the weakness of the intrusion tort action for protecting genetic information privacy. In this case, an employer disclosed sensitive medical information to the plaintiff's co-workers. The Illinois court found no "intrusion" on the plaintiff because she had "voluntarily provided" the information to her employer.

Statutory Protection of Genetic Information Privacy

United States Constitution

The act of genetic testing raises the issue of Fourth Amendment protection from unreasonable bodily intrusions. However, the Fourth Amendment provision against unreasonable searches and seizures is inapplicable to private organizations in the absence of state action. The effects of genetic testing may be attacked under two Fourteenth Amendment doctrines as well. The first is the Fourteenth Amendment's substantive due process protection of the right of privacy. The second is the guarantee of equal protection. Some genetic diseases are primarily confined to certain racial groups, raising the possibility of creating a suspect class. In addition, there may be a question of restrictions on procreative choice resulting from directive counseling. Such counseling could infringe fundamental liberty rights. Finally, the act of genetic testing may be contrary to certain religious beliefs. Mandatory genetic testing programs may violate the First Amendment's guarantee of religious freedom.

When the government collects personal data, a constitutional right to informational privacy applies to the data collected. This right was first identified in Whalen v. Roe, a case that involved medical data. Whalen concerned a New York State plan to collect and store information relating to the prescription of certain drugs that had both legitimate and illegitimate applications. In judging the constitutionality of this state scheme, the Supreme Court found that the United States Constitution included a right of informational privacy that prohibited "disclosure of personal matters" and protected "independence" in decision-making.

To check whether the nondisclosure interest had been violated, the Court examined the data security measures of New York. These measures included storing the prescription forms in a vault until their ultimate destruction; surrounding the room in which these data were received with a wire fence and protecting this area with an alarm system; and promulgating statutory and regulatory measures that prohibited disclosure to the public. The Court found such actions were well designed to ensure that the personal medical data collected by the state government would be kept from the public.

The second Whalen interest, independence in making certain types of important decisions, was implicated by the patient's decision whether to acquire and use needed medicine. Although the government's record-keeping had discouraged some use of the drugs in question, "the decision to prescribe, or to use" remained in the control of the physician and the patient. Therefore, the Court found that New York's data processing scheme did not violate interest of independence in decision making. The Whalen two-branch approach offers a model with potential for the protection of personal genetic information.

Unfortunately, lower courts analyzing governmental attempts to obtain or examine medical information have done so primarily with reference to the first Whalen interest. Indeed, some courts have even viewed Whalen as a decision that sanctions all "legitimate" governmental requests for medical data. The independence of decision making interest identified in Whalen has been almost entirely absent from case law. Thus, although Whalen offers a potentially useful element in the overall structure of a genetic information privacy protection law, it has not led to vigorous protection of medical or genetic information privacy. Finally, in the absence of state legislation, private parties may conduct across-the-board genetic testing without the constitutional implications faced by federally funded programs. Thus, private employers, insurers, and social organizations may test all applicants under existing law.

Americans With Disabilities Act[68]

The Americans With Disabilities Act ("ADA") serves to prevent discrimination against individuals with disabilities in critical areas like employment, housing, public accommodations, education, transportation, health services, and access to public services. If individuals subjected to genetic testing are discriminated against as a result of such testing, they are protected by the ADA because they are "perceived" to be disabled. Thus, even though the genetic disorder may not manifest itself physically to the point of limiting one or more of the major life activities of the individual, any person who is believed to be disabled would be protected by the ADA.

However, as a defense, the ADA permits employers to use techniques like genetic testing to screen individuals to find out if they have disabilities that pose a significant threat to the health and safety of other workers. The ADA can provide some protection against discrimination resulting from genetic testing in employment and other federally funded areas. However, it does not address the use of genetic information in law enforcement, adoption, insurance, or confidentiality and privacy issues.

The Human Genome Privacy Act[72]

The Human Genome Privacy Act ("HGPA") was introduced on September 17, 1990, to Congress by Representative John Conyers, Jr. (D-Mich.). The HGPA attempts to offer protection to genetic information by allowing greater individual control over the use and verification of genetic information.

First, the HGPA permits the individual to inspect any genetic information on himself or herself maintained by a government agency. Second, the HGPA allows an individual to request amendment of any personal genetic information maintained by the agency while granting the agency the right to refuse to amend. These provisions of the HGPA enable an individual to ensure that accurate results are maintained, and they also allow the individual to verify false positives and update his or her genetic database. Third, the HGPA requires all agencies maintaining genetic information to provide written notice of their practices, including the rights of an individual to inspect and amend genetic data. Section 143(a) of the HGPA provides that intentional and unauthorized disclosure, maintenance, or security of genetic information shall be punishable as a misdemeanor and carry a fine of up to $10,000 In addition, the HGPA provides declaratory and injunctive relief to individuals whose rights have been violated.

Requiring individuals to consent to disclosure of their information rather than simply notifying them of such disclosure would provide individuals with greater security and privacy. This provision would restrict the flow of genetic information and enable people to trace the source of leaked genetic data more easily. Disclosure without an individual's authorization is permitted under the HGPA only in medical emergencies, clinical-care circumstances, or adoption situations when "reasonable efforts to locate the individual" have failed, and when required by law.

While well intentioned and timely, the HGPA's effectiveness is doubtful. First, its operative language is vague. How far must one go to prevent misuse, including possible unlawful discrimination by third parties? The civil and criminal penalty provisions in the HGPA do not address this issue. Although the HGPA provides individuals with some autonomy in maintaining their genetic records, the HGPA does not give any guidelines as to when and how individuals may amend their records, or the use of the data before they are altered. The HGPA indicates that the agencies holding genetic data are the sole arbiters of all requests for information. This leaves the agencies with much discretion.

Our conclusion about the issues presented on this web site is presented here.

Back to Home

Read the original:
Legal Issues - udel.edu

Read More...

Psychological Stress and the Human Immune System: A Meta …

Thursday, August 4th, 2016

Psychol Bull. Author manuscript; available in PMC 2006 Feb 7.

Published in final edited form as:

PMCID: PMC1361287

NIHMSID: NIHMS4008

Suzanne C. Segerstrom, University of Kentucky;

The present report meta-analyzes more than 300 empirical articles describing a relationship between psychological stress and parameters of the immune system in human participants. Acute stressors (lasting minutes) were associated with potentially adaptive upregulation of some parameters of natural immunity and downregulation of some functions of specific immunity. Brief naturalistic stressors (such as exams) tended to suppress cellular immunity while preserving humoral immunity. Chronic stressors were associated with suppression of both cellular and humoral measures. Effects of event sequences varied according to the kind of event (trauma vs. loss). Subjective reports of stress generally did not associate with immune change. In some cases, physical vulnerability as a function of age or disease also increased vulnerability to immune change during stressors.

Since the dawn of time, organisms have been subject to evolutionary pressure from the environment. The ability to respond to environmental threats or stressors such as predation or natural disaster enhanced survival and therefore reproductive capacity, and physiological responses that supported such responses could be selected for. In mammals, these responses include changes that increase the delivery of oxygen and glucose to the heart and the large skeletal muscles. The result is physiological support for adaptive behaviors such as fight or flight. Immune responses to stressful situations may be part of these adaptive responses because, in addition to the risk inherent in the situation (e.g., a predator), fighting and fleeing carries the risk of injury and subsequent entry of infectious agents into the bloodstream or skin. Any wound in the skin is likely to contain pathogens that could multiply and cause infection (Williams & Leaper, 1998). Stress-induced changes in the immune system that could accelerate wound repair and help prevent infections from taking hold would therefore be adaptive and selected along with other physiological changes that increased evolutionary fitness.

Modern humans rarely encounter many of the stimuli that commonly evoked fight-or-flight responses for their ancestors, such as predation or inclement weather without protection. However, human physiological response continues to reflect the demands of earlier environments. Threats that do not require a physical response (e.g., academic exams) may therefore have physical consequences, including changes in the immune system. Indeed, over the past 30 years, more than 300 studies have been done on stress and immunity in humans, and together they have shown that psychological challenges are capable of modifying various features of the immune response. In this article we attempt to consolidate empirical knowledge about psychological stress and the human immune system through meta-analysis. Both the construct of stress and the human immune system are complex, and both could consume book-length reviews. Our review, therefore, focuses on those aspects that are most often represented in the stress and immunity literature and therefore directly relevant to the meta-analysis.

Despite nearly a century of research on various aspects of stress, investigators still find it difficult to achieve consensus on a satisfactory definition of this concept. Most of the studies contributing to this review simply define stress as circumstances that most people would find stressful, that is, stressors. We adopted Elliot and Eisdorfers (1982) taxonomy to characterize these stressors. This taxonomy has the advantage of distinguishing among stressors on two important dimensions: duration and course (e.g., discrete vs. continuous). The taxonomy includes five categories of stressors. Acute time-limited stressors involve laboratory challenges such as public speaking or mental arithmetic. Brief naturalistic stressors, such as academic examinations, involve a person confronting a real-life short-term challenge. In stressful event sequences, a focal event, such as the loss of a spouse or a major natural disaster, gives rise to a series of related challenges. Although affected individuals usually do not know exactly when these challenges will subside, they have a clear sense that at some point in the future they will. Chronic stressors, unlike the other demands we have described, usually pervade a persons life, forcing him or her to restructure his or her identity or social roles. Another feature of chronic stressors is their stabilitythe person either does not know whether or when the challenge will end or can be certain that it will never end. Examples of chronic stressors include suffering a traumatic injury that leads to physical disability, providing care for a spouse with severe dementia, or being a refugee forced out of ones native country by war. Distant stressors are traumatic experiences that occurred in the distant past yet have the potential to continue modifying immune system function because of their long-lasting cognitive and emotional sequelae (Baum, Cohen, & Hall, 1993). Examples of distant stressors include having been sexually assaulted as a child, having witnessed the death of a fellow soldier during combat, and having been a prisoner of war.

In addition to the presence of difficult circumstances, investigators also use life-event interviews and life-event checklists to capture the total number of different stressors encountered over a specified time frame. Depending on the instrument, the focus of these assessments can be either major life events (e.g., getting divorced, going bankrupt) or minor daily hassles (e.g., getting a speeding ticket, having to clean up a mess in the house). With the more sophisticated instruments, judges then code stressor severity according to how the average person in similar biographical circumstances would respond (e.g., S. Cohen et al., 1998; Evans et al., 1995).

A smaller number of studies enrolled large populations of adults who were not experiencing any specific difficulty and examined whether their immune responses varied according to their reports of perceived stress, intrusive thoughts, or both. Other studies have examined stressed populations, in which a larger range of subjective responses may be detected. This work grows out of the view that peoples biological responses to stressful circumstances are heavily dependent on their appraisals of the situation and cognitive and emotional responses to it (Baum et al., 1993; Frankenhauser, 1975; Tomaka, Blascovich, Kibler, & Ernst, 1997).

As many behavioral scientists are unfamiliar with the details of the immune system, we provide a brief overview. For a more complete treatment, the reader is directed to the sources for the information presented here (Benjamini, Coico, & Sunshine, 2000; Janeway & Travers, 1997; Rabin, 1999). Critical characteristics of various immune components and assays are also listed in .

Immune Parameters Reported and Critical Characteristics

There are several useful ways of dividing elements of the immune response. For the purposes of understanding the relationship of psychosocial stressors to the immune system, it is useful to distinguish between natural and specific immunity. Natural immunity is an immune response that is characteristic not only of mammals but also lower order organisms such as sponges. Cells involved in natural immunity do not provide defense against any particular pathogen; rather, they are all-purpose cells that can attack a number of different pathogens1 and do so in a relatively short time frame (minutes to hours) when challenged. The largest group of cells involved in natural immunity is the granulocytes. These cells include the neutrophil and the macrophage, phagocytic cells that, as their name implies, eat their targets. The generalized response mounted by these cells is inflammation, in which neutrophils and macrophages congregate at the site of injury or infection, release toxic substances such as oxygen radicals that damage invaders, and phagocytose both invaders and damaged tissue. Macrophages in particular also release communication molecules, or cytokines, that have broad effects on the organism, including fever and inflammation, and also promote wound healing. These proinflammatory cytokines include interleukin(IL)-1, IL-6, and tumor necrosis factor alpha (TNF). Other granulocytes include the mast cell and the eosinophil, which are involved in parasitic defense and allergy.

Another cell involved in natural immunity is the natural killer cell. Natural killer cells recognize the lack of a self-tissue molecule on the surface of cells (characteristic of many kinds of virally infected and some cancerous cells) and lyse those cells by releasing toxic substances on them. Natural killer cells are thought to be important in limiting the early phases of viral infections, before specific immunity becomes effective, and in attacking self-cells that have become malignant.

Finally, complement is a family of proteins involved in natural immunity. Complement protein bound to microorganisms can up-regulate phagocytosis and inflammation. Complement can also aid in antibody-mediated immunity (discussed below as part of the specific immune response).

Specific immunity is characterized by greater specificity and less speed than the natural immune response. Lymphocytes have receptor sites on their cell surfaces. The receptor on each cell fits with one and only one small molecular shape, or antigen, on a given invader and therefore responds to one and only one kind of invader. When activated, these antigen-specific cells divide to create a population of cells with the same antigen specificity in a process called clonal proliferation, or the proliferative response. Although this process is efficient in terms of the number of cells that have to be supported on a day-to-day basis, it creates a delay of up to several days before a full defense is mounted, and the body must rely on natural immunity to contain the infection during this time.

There are three types of lymphocytes that mediate specific immunity: T-helper cells, T-cytotoxic cells, and B cells. The main function of T-helper cells is to produce cytokines that direct and amplify the rest of the immune response. T-cytotoxic cells recognize antigen expressed by cells that are infected with viruses or otherwise compromised (e.g., cancer cells) and lyse those cells. B cells produce soluble proteins called antibody that can perform a number of functions, including neutralizing bacterial toxins, binding to free virus to prevent its entry into cells, and opsonization, in which a coating of antibody increases the effectiveness of natural immunity. There are five kinds of antibody: Immunoglobulin (Ig) A is found in secretions, IgE binds to mast cells and is involved in allergy, IgM is a large molecule that clears antigen from the bloodstream, IgG is a smaller antibody that diffuses into tissue and crosses the placenta, and IgD is of unknown significance but may be produced by immature B cells.

An important immunological development is the recognition that specific immunity in humans is composed of cellular and humoral responses. Cellular immune responses are mounted against intracellular pathogens like viruses and are coordinated by a subset of T-helper lymphocytes called Th1 cells. In the Th1 response, the T-helper cell produces cytokines, including IL-2 and interferon gamma (IFN). These cytokines selectively activate T-cytotoxic cells as well as natural killer cells. Humoral immune responses are mounted against extracellular pathogens such as parasites and bacteria; they are coordinated by a subset of T-helper lymphocytes called Th2 cells. In the Th2 response, the T-helper cell produces different cytokines, including IL-4 and IL-10, which selectively activate B cells and mast cells to combat extracellular pathogens.

Immune assays can quantify cells, proteins, or functions. The most basic parameter is a simple count of the number of cells of different subtypes (e.g., neutrophils, macrophages), typically from peripheral blood. It is important to have an adequate number of different types of immune cells in the correct proportions. However, the normal range for these enumerative parameters is quite large, so that correct numbers and proportions can cover a wide range, and small changes are unlikely to have any clinical significance in healthy humans.

Protein productioneither of antibody or cytokinescan be measured in vitro by stimulating cells and measuring protein in the supernatant or in vivo by measuring protein in peripheral blood. For both antibody and cytokine, higher protein production may represent a more robust immune response that can confer protection against disease. Two exceptions are levels of proinflammatory cytokines (IL-1, IL-6, and TNF) and antibody against latent virus. Proinflammatory cytokines are increased with systemic inflammation, a risk factor for poorer health resulting from cardiac disease, diabetes mellitus, or osteoporosis (Ershler & Keller, 2000; Luster, 1998; Papanicoloaou, Wilder, Manolagas, & Chrousos, 1998). Antibody production against latent virus occurs when viral replication triggers the immune system to produce antibodies in an effort to contain the infection. Most people become infected with latent viruses such as Epstein-Barr virus during adolescence and remain asymptomatically infected for the rest of their lives. Various processes can activate these latent viruses, however, so that they begin actively replicating. These processes may include a breakdown in cellular immune response (Jenkins & Baum, 1995). Higher antibody against latent viruses, therefore, may indicate poorer immune control over the virus.

Functional assays, which are performed in vitro, measure the ability of cells to perform specific activities. In each case, higher values may represent more effective immune function. Neutro-phils function can be quantified by their ability to migrate in a laboratory assay and their ability to release oxygen radicals. The natural killer cytotoxicity assay measures the ability of natural killer cells to lyse a sensitive target cell line. Lymphocyte proliferation can be stimulated with mitogens that bypass antigen specificity to activate cells or by stimulating the T cell receptor.

How could stress get inside the body to affect the immune response? First, sympathetic fibers descend from the brain into both primary (bone marrow and thymus) and secondary (spleen and lymph nodes) lymphoid tissues (Felten & Felten, 1994). These fibers can release a wide variety of substances that influence immune responses by binding to receptors on white blood cells (Ader, Cohen, & Felten, 1995; Felten & Felten, 1994; Kemeny, Solomon, Morley, & Herbert, 1992; Rabin, 1999). Though all lymphocytes have adrenergic receptors, differential density and sensitivity of adrenergic receptors on lymphocytes may affect responsiveness to stress among cell subsets. For example, natural killer cells have both high-density and high-affinity 2-adrenergic receptors, B cells have high density but lower affinity, and T cells have the lowest density (Anstead, Hunt, Carlson, & Burki, 1998; Landmann, 1992; Maisel, Fowler, Rearden, Motulsky, & Michel, 1989). Second, the hypothalamicpituitaryadrenal axis, the sympatheticadrenalmedullary axis, and the hypothalamicpituitaryovarian axis secrete the adrenal hormones epinephrine, norepinephrine, and cortisol; the pituitary hormones prolactin and growth hormone; and the brain peptides melatonin, -endorphin, and enkephalin. These substances bind to specific receptors on white blood cells and have diverse regulatory effects on their distribution and function (Ader, Felten, & Cohen, 2001). Third, peoples efforts to manage the demands of stressful experience sometimes lead them to engage in behaviorssuch as alcohol use or changes in sleeping patternsthat also could modify immune system processes (Kiecolt-Glaser & Glaser, 1988). Thus, behavior represents a potentially important pathway linking stress with the immune system.

Maier and Watkins (1998) proposed an even closer relationship between stress and immune function: that the immunological changes associated with stress were adapted from the immunological changes in response to infection. Immunological activation in mammals results in a syndrome called sickness behavior, which consists of behavioral changes such as reduction in activity, social interaction, and sexual activity, as well as increased responsiveness to pain, anorexia, and depressed mood. This syndrome is probably adaptive in that it results in energy conservation at a time when such energy is best directed toward fighting infection. Maier and Watkins drew parallels between the behavioral, neuroendo-crine, and thermoregulatory responses to sickness and stress. The common thread between the two is the energy mobilization and redirection that is necessary to fight attackers both within and without.

Conceptualizations of the nature of the relationship between stress and the immune system have changed over time. Selyes (1975) finding of thymic involution led to an initial model in which stress is broadly immunosuppressive. Early human studies supported this model, reporting that chronic forms of stress were accompanied by reduced natural killer cell cytotoxicity, suppressed lymphocyte proliferative responses, and blunted humoral responses to immunization (see S. Cohen, Miller, & Rabin, 2001; Herbert & Cohen, 1993;Kiecolt-Glaser, Glaser, Gravenstein, Malarkey, & Sheridan, 1996, for reviews). Diminished immune responses of this nature were assumed to be responsible for the heightened incidence of infectious and neoplastic diseases found among chronically stressed individuals (Andersen, Kiecolt-Glaser, & Glaser, 1994; S. Cohen & Williamson, 1991).

Although the global immunosuppression model enjoyed long popularity and continues to be influential, the broad decreases in immune function it predicts would not have been evolutionarily adaptive in life-threatening circumstances. Dhabhar and McEwen (1997, 2001) proposed that acute fight-or-flight stressors should instead cause redistribution of immune cells into the compartments in which they can act the most quickly and efficiently against invaders. In a series of experiments with mice, they found that during acute stress, T cells selectively redistributed into the skin, where they contributed to enhancement of the immune response. In contrast, during chronic stress, T cells were shunted away from the skin, and the immune response to skin test challenge was diminished (Dhabhar & McEwen, 1997). On the basis of these findings they proposed a biphasic model in which acute stress enhances, and chronic stress suppresses, the immune response.

A modification of this model posits that short-term changes in all components of the immune system (natural and specific) are unlikely to occur because they would expend too much energy to be adaptive in life-threatening circumstances. Instead, stress should shift the balance of the immune response toward activating natural processes and diminishing specific processes. The premise underlying this model is that natural immune responses are better suited to managing the potential complications of life-threatening situations than specific immune responses because they can unfold much more rapidly, are subject to fewer inhibitory constraints, and require less energy to be diverted from other bodily systems that support the fight-or-flight response (Dopp, Miller, Myers, & Fahey, 2000; Sapolsky, 1998).

Even with this modification of the biphasic model, neither it nor the global immunosuppression model sufficiently explains findings that link chronic stress with both disease outcomes associated with inadequate immunity (infectious and neoplastic disease) and disease outcomes associated with excessive immune activity (allergic and autoimmune disease). To resolve this paradox, some researchers have chosen to focus on how chronic stress might shift the balance of the immune response. The most well-known of these models hypothesizes that chronic stress elicits simultaneous enhancement and suppression of the immune response by altering patterns of cytokine secretion (Marshall et al., 1998). Th1 cytokines, which activate cellular immunity to provide defense against many kinds of infection and some kinds of neoplastic disease, are suppressed. This suppression has permissive effects on production of Th2 cytokines, which activate humoral immunity and exacerbate allergy and many kinds of autoimmune disease. This shift can occur via the effects of stress hormones such as cortisol (Chiappelli, Manfrini, Franceschi, Cossarizza, & Black, 1994). Th1-to-Th2 shift changes the balance of the immune response without necessarily changing the overall level of activation or function within the system. Because a diminished Th1-mediated cellular immune response could increase vulnerability to infectious and neoplastic disease, and an enhanced Th-2 mediated humoral immune response could increase vulnerability to autoimmune and allergic diseases, this cytokine shift model also is able to reconcile patterns of stress-related immune change with patterns of stress-related disease outcomes (Marshall et al., 1998).

If the stress response in the immune system evolved, a healthy organism should not be adversely affected by activation of this response because such an effect would likely have been selected against. Although there is direct evidence that stress-related immunosuppression can increase vulnerability to disease in animals (e.g., Ben Eliyahu, Shakhar, Page, Stefanski, & Shakhar, 2000; Quan et al., 2001; Shavit et al., 1985; Sheridan et al., 1998), there is little or no evidence linking stress-related immune change in healthy humans to disease vulnerability. Even large stress-induced immune changes can have small clinical consequences because of the redundancy of the immune systems components or because they do not persist for a sufficient duration to enhance disease susceptibility. In short, the immune system is remarkably flexible and capable of substantial change without compromising an otherwise healthy host.

However, the flexibility of the immune system can be compromised by age and disease. As humans age, the immune system becomes senescent (Boucher et al., 1998; Wikby, Johansson, Ferguson, & Olsson, 1994). As a consequence, older adults are less able to respond to vaccines and mount cellular immune responses, which in turn may contribute to early mortality (Ferguson, Wikby, Maxson, Olsson, & Johansson, 1995; Wayne, Rhyne, Garry, & Goodwin, 1990). The decreased ability of the immune system to respond to stimulation is one indicator of its loss of flexibility.

Loss of self-regulation is also characteristic of disease states. In autoimmune disease, for example, the immune system treats self-tissue as an invader, attacking it and causing pathology such as multiple sclerosis, rheumatoid arthritis, Crohns disease, and lupus. Immune reactions can also be exaggerated and pathological, as in asthma, and suggest loss of self-regulation. Finally, infection with HIV progressively incapacitates T-helper cells, leading to loss of the regulation usually provided by these cells. Although each of these diseases has distinct clinical consequences, the change in the immune system from flexible and balanced to inflexible and unbalanced suggests increased vulnerability to stress-related immune dysregulation; furthermore, dysregulation in the presence of disease may have clinical consequences (e.g., Bower, Kemeny, Taylor, & Fahey, 1998).

We performed a meta-analysis of published results linking stress and the immune system. We feel that this area is in particular need of a quantitative review because of the methodological nature of most studies in this area. For practical and economic reasons, many psychoneuroimmunology studies have a relatively small sample size, creating the possibility of Type II error. Furthermore, many studies examine a broad range of immunological parameters, creating the possibility of Type I error. A quantitative review, of which meta-analysis is the best example, can better distinguish reliable effects from those arising from both Type I and Type II error than can a qualitative review.

We combined studies in such a way as to test the models of stress and immune change reviewed above. First, we examined each stressor type separately, yielding separate effects for stressors of different duration and trajectory. Second, we examined both healthy and medical populations, allowing comparison of the effects of stress on resilient and vulnerable populations; along the same lines, we also examined the effects of age. Finally, we examined all immune parameters separately so that patterns of response (e.g., global immunosuppression vs. cytokine shift) would be clearer.

Articles for the meta-analysis were identified through computerized literature searches and searches of reference lists. MEDLINE and PsycINFO were searched for the years 1960 2001. Following the example of Herbert and Cohen (1993), we used the terms stress, hassles, and life events in combination with the term immune to search both databases. The reference lists of 11 review articles on stress and the immune system (Benschop, Geenen, et al., 1998; Biondi, 2001; Cacioppo, 1994; S. Cohen & Herbert, 1996; S. Cohen et al., 2001; Herbert & Cohen, 1993; Kiecolt-Glaser, Cacioppo, Malarkey, & Glaser, 1992; Kiecolt-Glaser, McGuire, Robles, & Glaser, 2002; Maier, Watkins, & Fleshner, 1994; OLeary, 1990; Zorrilla et al., 2001) were then searched to identify additional articles.

We selected only articles that met a number of inclusion criteria. The first criterion was that the work had to include a measure of stress. This criterion could be met if a sample experiencing a stressor was compared with an unstressed control group, if a sample experiencing a stressor was compared with itself at a baseline that could reasonably be considered low stress, or if differing degrees of stress in a sample were assessed with an explicit measure of stress. This criterion was not met if, for example, anxietyan affective statewas used as a proxy for stress, or it seemed likely that a baseline assessment occurred during periods of significant stress. The second criterion was that the stressor had to be psychosocial. Stressors that included a significant physical element such as pain, cold, or physical exhaustion were eliminated (e.g., Antarctic isolation, space flight, military training). The third criterion was that the work had to include a measure of the immune system. This criterion was met by any enumerative or functional in vitro or in vivo immune assay. However, clinical disease outcomes such as HIV progression or rhinovirus infection did not meet this criterion. Finally, we eliminated articles from which a meaningful effect size could not be abstracted. For example, when between- and within-subjects observations were treated as independent, the reported effect was likely to be inflated. In a few cases, effects of stress and clinical status were confoundedthat is, a stressed clinical group was compared with an unstressed healthy groupand hence these studies were excluded from the meta-analysis.

We coded stressors in the articles into five classes: acute time-limited, brief naturalistic, event sequence, chronic, and distant. The most difficult distinctions among event sequence, chronic, and distant stressors were based on temporal and qualitative considerations. Event sequences included discrete stressors occurring 1 year or less before immune assessment and could be of any severity. These were most often normative stressors such as bereavement. Chronic stressors were ongoing stressors such as caregiving and disability. Distant stressors were severe, traumatic events that could meet the stressor criterion for posttraumatic stress disorder (American Psychiatric Association, 1994), such as combat exposure or abuse, and had happened more than 1 year before immune assessment. Most stressors in this category occurred 5 to 10 years before immune assessment. Disagreements in stressor classification were resolved by consensus. Subgroups for moderator analyses were similarly decided.

Meta-analysis is a tool for synthesizing research findings. It proceeds in two phases. In the first, effect sizes are computed for each study. An effect size represents the magnitude of the relationship between two variables, independent of sample size. In this context it can be viewed as a measure of how much two groups, one experiencing a stressor and the other not, differ on a specific immune outcome. In the second phase, effect sizes from individual studies are combined to arrive at an aggregate effect size for each immune outcome of interest.

We used Pearsons r as the effect size metric in this meta-analysis. Effect sizes for individual studies were computed using descriptive statistics presented in the original published reports. When these statistics were not available, we requested them from authors. This strategy was successful in most circumstances. To compute Pearsons r from descriptive statistics in between-subjects designs, we subtracted the control group mean from the stressed group mean and divided this value by the pooled sample standard deviation. The value that emerged from this computation, known as Cohens d, was then converted into a Pearsons r by taking the square root of the quantity d2/(d2 + 4). (See Rosenthal, 1994.) To compute Pearsons r from descriptive statistics in within-subjects designs, we subtracted the group mean at baseline from the group mean during stress and divided this quantity by the sample standard deviation at baseline. This d value was converted into a Pearsons r by taking the square root of the quantity d2/(d2 + 4). In cases in which descriptive statistics were not available, Pearsons r was computed from inferential statistics using standard formulae (Rosenthal, 1994). These formulae had to be modified slightly for studies that used within-subjects designs because effect sizes are systematically overestimated when they are calculated from repeated measures test statistics (Dunlap, Cortina, Vaslow, & Burke, 1996). In these situations we derived effect size estimates using the formula d = tc[2 (1 r)]1/2, where tc corresponds to the value of the t statistic for correlated measures, and r corresponds to the value of the correlation between outcome measures at pretest and posttest (Dunlap et al., 1996). Because very few studies reported the value of r, we used a value of .60 to compute effect sizes in this meta-analysis. This represents the average correlation between pre-stress and poststress measures of immune function in a series of studies performed in our laboratories. To ensure that the meta-analytic findings were robust to variations in r, we conducted follow-up analyses using r values ranging from .45 to .75. Very similar findings emerged from these analyses, suggesting that the values we present below are reliable estimates of effect size. If anything, they are probably conservative estimates, because the prepost correlation between immune measures often is substantially lower than .60.

The effect size estimates from individual studies were subsequently aggregated using random-effects models with the software program Comprehensive Meta-Analysis (Borenstein & Rothstein, 1999). The random-effects model views each study in a meta-analysis as a random observation drawn from a universe of potential investigations. As such, it assumes that the magnitude of the relationship between stress and the immune system differs across studies as a result of random variance associated with sampling error and differences across individuals in the processes of interest. Because of these assumptions, random-effects models not only permit one to draw inferences about studies that have been done but also to generalize to studies that might be done in the future (Raudenbush, 1994; Shadish & Haddock, 1994). It also bears noting that in the population of studies on stress and immunity there is likely to be a fair amount of nonrandom variance, as researchers who examine ostensibly similar phenomena may still differ in terms of the samples they recruit, the operational definition of stress they use, and the laboratory methods they utilize to assess a specific immune process.

Separate random-effects models were computed for each immune outcome included in the meta-analysis. Prior to computing the random-effects model, r values derived from each study were z-transformed by the software program, as recommended by Shadish and Haddock (1994), to stabilize variance. The z values were later back-transformed into r values to facilitate interpretation of the meta-analytic findings. In the end, each random-effects model yielded an aggregate weighted effect size r, which can be interpreted the same way as a correlation coefficient, ranging in value from 1.00 to 1.00. Each r statistic was weighted before aggregation by multiplying its value by the inverse of its variance; this procedure enabled larger studies to contribute to effect size estimates to a greater extent than smaller ones. Weighting effect sizes is important because larger studies provide more accurate estimates of true population parameters (Shadish & Haddock, 1994). After each aggregate effect size had been derived, we computed 95% confidence intervals around it, assessed whether it was statistically significant, and computed a heterogeneity coefficient to determine whether the studies contributing to it had yielded consistent findings. Following convention, aggregate effect sizes were considered statistically different from zero when (a) their corresponding z value was greater than 1.96 and (b) the 95% confidence intervals around them did not include the value zero (Rosenthal, 1991; Shadish & Haddock, 1994).

To determine whether the studies contributing to each aggregate effect size shared a common population value, we computed the heterogeneity statistic Q (Shadish & Haddock, 1994). This statistic is chi-square distributed with k 1 degrees of freedom, where k represents the number of independent effect sizes included. When a statistically significant heterogeneity test emerged, we searched for moderators (characteristics of the participants, stressful experience, or measurement strategy) that could explain the variability across studies. The first step in this process involved estimating correlations between participant characteristics (e.g., mean age, percentage female) and immune effects to examine whether the strength of effects varied according to demographics. When it was possible to do so, we then stratified the studies according to characteristics of the stressful experience (e.g., duration, quality) or the measurement strategy (e.g., interview, checklist), and computed separate random-effects analyses for each subgroup.

Occasionally authors of studies failed to report the descriptive or inferential statistics needed to compute an effect size. In some of these cases, the authors noted that there was a significant difference between a stressed and control group. When this occurred, we computed effect sizes assuming that p values were equivalent to .05. This represents a conservative approach because the actual p values were probably smaller. In other cases, the authors noted that a stressed and control group did not differ with respect to an immune outcome, but failed to provide any further statistical information. When this occurred, we computed effect sizes assuming that there was no difference at all between the groups (r = .00). Because there is seldom no difference at all between two groups, this also represents a conservative strategy. Imputation was used in less than 7% of cases.

The validity of a meta-analysis rests on the assumption that each value contributing an aggregate effect size is statistically independent of the others (Rosenthal, 1991). We devised a number of strategies to avoid violating this independence assumption. First, in studies that assessed stimulated-lymphocyte proliferation at multiple mitogen dosages, we computed the average effect size across mitogen dosages, and we used this value to derive aggregate indices. We used an analogous strategy for studies that assessed natural killer cell cytotoxicity at multiple effector:target cell ratios. Second, in studies that utilized designs in which multiple laboratory stressors were compared with a control condition, the average effect size across stressor conditions was computed and later used to derive aggregate indices. Because this averaging procedure in most cases yielded an effect size that was smaller than that of the most potent stressor, we also computed meta-analyses using the larger of the effect sizes from each study rather than the average. Doing so did not alter any of the substantive findings we report. Third, in studies in which immune outcomes were assessed on multiple occasions during a stressful experience, the average effect size across occasions was used to derive aggregate indices. Note that we did not conduct meta-analyses of recovery effects, that is, immune values after a stressor had ended. Although such an analysis would answer interesting questions about the stress-recovery process, there were not enough studies that included similar immune outcomes assessed at similar time points after stress to permit a complete analysis. Fourth, because some data were published in more than one outlet, we contacted authors of multiple publications to determine sample independence or dependence.

The meta-analysis is based on effect sizes derived from 293 independent studies. These studies were reported in 319 separate articles in peer-reviewed scientific journals (see ). A total of 18,941 individuals participated in these studies. Their mean age was 34.8 years (SD = 15.9). Although the studies collectively included a broad range of age groups (range = 578 years), most focused heavily on younger adults. More than half of the studies (51.3%) had a mean age under 30.0 years, and more than four fifths (84.8%) had a mean age under 55.0 years. Slightly more than two thirds of the studies (68.5%) included women; in the average study almost half (42.8%) of the participants were female. The vast majority of studies (84.8%) focused on medically healthy adults.2 Of those that included medical populations, most focused on HIV/AIDS (k = 18; 38.3%), arthritis (k = 6; 12.8%), cancer (k = 5; 10.6%), or asthma (k = 4; 8.5%).

Studies Used in the Meta-Analysis by Type of Stressor

With respect to the kinds of stressors examined by studies in the meta-analysis, the most commonly utilized models were acute laboratory challenges (k = 85; 29.0%) and brief naturalistic stressors (k = 63; 21.5%). Stressful event sequences (k = 30; 10.2%), chronic stressors (k = 23; 7.8%), and distant traumatic experiences (k = 9; 3.1%) were explored less frequently. More than a quarter of the studies in the meta-analysis modeled the stress process by administering nonspecific life-event checklists (k = 53; 18.1%) and/or global perceived stress measures (k = 21; 7.1%) to participants. A small minority of studies examined whether reports of perceived stress or intrusive memories were associated with the extent of immune dysregulation within populations who had suffered a specific traumatic experience (k = 9; 3.1%).

The studies in the meta-analysis examined 292 distinct immune system outcomes. A minority of these outcomes were assessed in three or more studies (k = 87; 30.0%), and as such, they are the focus of the meta-analyses we present in the rest of this article (see ). The most commonly assessed enumerative outcomes were counts of T-helper lymphocytes (k = 90; 30.7%), T-cytotoxic lymphocytes (k = 81; 27.6%), natural killer cells (k = 67; 22.9%), and total lymphocytes (k = 52; 17.7%). The most commonly assessed functional outcomes were natural killer cell cytotoxicity (k = 94; 32.1%) and lymphocyte proliferation stimulated by the mitogens phytohemagglutinin (PHA; k = 65; 22.2%), concanavalin A (ConA; k = 39; 13.3%), and pokeweed mitogen (PWM; k = 26; 8.9%).

lists the immune parameters analyzed with the arm of the immune system to which they belong (natural or specific) and, briefly, their function. Where relevant, cell surface markers used to identify classes of immunocytes in flow cytometry are given. For example, the cell surface marker CD19 is used to identify B lymphocytes. Recall that different models of stress and the immune system posit differential effects of stress on subsets of the immune systemfor example, natural versus specific immunity or cellular (Th1) versus humoral (Th2) immunity. acts as a guide for interpreting the pattern of results in light of these models.

In the following sections we describe the meta-analytic results for each stressor category. A useful rule of thumb for judging effect sizes is to consider values of .10, .30, and .50 as corresponding to small, medium, and large effects, respectively (J. Cohen & Cohen, 1983); more generally, the aggregate effect size r can be interpreted in the same fashion as a correlation, with values ranging from 1.00 to 1.00. Positive values indicate that the presence of a stressor increases a particular immune parameter relative to some baseline (or control) condition. We should caution the reader that in some analyses, our statistics are derived from as few as three independent studies. Although meta-analyses of small numbers of studies do not pose any major statistical problems, it is important to remember that they have limited power to detect statistically significant effect sizes. What a meta-analysis can accurately provide in these instances, however, is an estimate of how much and what direction a given stressors presence influences a specific immune outcome (i.e., an effect size estimate).

Acute time-limited stressors included primarily experimental manipulations of stressful experiences, such as public speaking and mental arithmetic, that lasted between 5 and 100 min. Reliable effects on the immune system included increases in immune parameters, especially natural immunity. The most robust effect of this kind of experience was a marked increase in the number of natural killer cells (r =.43) and large granular lymphocytes (r =.53) in peripheral blood (see ). This effect is consistent with the view that acute stressors cause immune cells to redistribute into the compartments in which they will be most effective (Dhabhar & McEwen, 1997). However, other types of lymphocytes did not show robust redistribution effects: B cells and T-helper cells showed very little change (rs = .07 and .01, respectively), and this change was not statistically significant across studies. T-cytotoxic lymphocytes did tend to increase reliably in peripheral blood, though to a lesser degree than their natural immunity counterparts (r =.20); this increase drove a reliable decline in the T-helper:T-cytotoxic ratio (r = .23). However, natural killer cells as well as T-cytotoxic cells can express CD8, the marker most often used to define the latter population. Because some studies did not use the T cell receptor (CD3) to differentiate between CD3CD8+ natural killer cells and CD3+CD8+ T-cytotoxic cells, it is possible that the effect for T-cytotoxic cells is actually being driven by natural killer cells (Benschop, Rodriguez-Feuerhahn, & Schedlowski, 1996).

Meta-Analysis of Immune Responses to Acute Time-Limited Stress in Healthy Participants

The results for cell percentages roughly parallel those for number. However, the percentage data are harder to interpret because any given parameter is linearly dependent on the other parameters: For example, the enumerative data suggest that the decrease in percentage T-helper cells (r = .24) is probably an artifact of the increases in percentage natural killer cells (r = .24) and percentage T-cytotoxic cells (r = .09).

Another effect that may be considered a redistribution effect is the significant increase in secretory IgA in saliva (r = .22). The time frame of these acute stressors is too short for the synthesis of a significant amount of new antibody; therefore, this increase is probably due to release of already-synthesized antibody from plasma cells and increased translocation of antibody across the epithelium and into saliva (Bosch, Ring, de Geus, Veerman, & Amerongen, 2002). This effect therefore represents relocation, albeit of an immune protein rather than an immune cell.

There were also a number of functional effects. First, natural killer cell cytotoxicity significantly increased with acute stressors (r = .30), but only when the concomitant increase in proportion of natural killer cells in the effector mix was not removed statistically. When examined on a per-cell basis, cytotoxicity did not significantly increase (r = .12). One could, therefore, consider the increase in cytotoxicity a methodological artifact of the definition of effector in effector:target ratios. However, to the degree that one is interested in the general cytotoxic potential of the contents of peripheral blood rather than that of a specific natural killer cell, the uncorrected value is more illustrative. Second, mitogen-stimulated proliferative responses decreased significantly. Again, this could be a methodological artifact of the mix of cells in the assay. However, the proportion of total T and B cells, which are responsible for the proliferative response to PWM and ConA, did not decrease as reliably or as much as did the proliferative response (rs = .05 to .11 vs. .10 to .17), suggesting that acute stressors do decrease this function of specific immunity. Finally, the production of two cytokines, IL-6 and IFN, was increased significantly following acute stress (rs = .28 and .21, respectively).

The data for acute stressors, therefore, support an upregulation of natural immunity, as reflected by increased number of natural killer cells in peripheral blood, and potential downregulation of specific immunity, as reflected by decreased proliferative responses. Other indicators of upregulated natural immunity include increased neutrophil numbers in peripheral blood (r = .30), increased production of a proinflammatory cytokine (IL-6), and increased production of a cytokine that potently stimulates macrophages and natural killer cells as well as T cells (IFN). The only exception to this pattern was the increased secretion of IgA antibody, which is a product of the specific immune response. An interesting question for future research is whether this effect is part of a larger nonspecific protein release in the oral cavity in response to acute stress (cf. Bosch et al., 2002).

It bears noting that a number of the findings presented in are accompanied by significant heterogeneity statistics. To identify moderating variables that might explain some of this heterogeneity, we examined whether effect sizes varied according to demographic characteristics of the sample (mean age and percentage female) or features of the acute challenge (its duration and nature). Neither of the demographic characteristics showed a consistent relationship with immune outcomes. Although these findings suggest that acute time-limited stressors elicit a similar pattern of immune response for men and women across the life span, this conclusion needs to be viewed somewhat cautiously given the narrow range of ages found in these studies. We also did not find a consistent pattern of relationships between features of the acute challenge and immune outcomes. Acute stressors elicited similar patterns of immune change across a wide spectrum of durations ranging from 5 though 100 min and irrespective of whether they involved social (e.g., public speaking), cognitive (e.g., mental arithmetic), or experiential (e.g., parachute jumping) forms of stressful experience.

presents the meta-analysis of brief naturalistic stressors for medically healthy adults. The vast majority of these stressors (k = 60; 95.2%) involved students facing academic examinations. In contrast to the acute time-limited stressors, examination stress did not markedly affect the number or percentage of cells in peripheral blood. Instead, the largest effects were on functional parameters, particularly changes in cytokine production that indicate a shift away from cellular immunity (Th1) and toward humoral immunity (Th2). Brief stressors reliably changed the profile of cytokine production via a decrease in a Th1-type cytokine, IFN (r = .30), which stimulates natural and cellular immune functions, and increases in the Th2-type cytokines IL-6 (r = .26), which stimulates natural and humoral immune functions, and IL-10 (r = .41), which inhibits Th1 cytokine production. Note that IFN and IL-6 share the property of stimulating natural immunity but differentially stimulate cytotoxic versus inflammatory effector mechanisms. Their dissociation after brief naturalistic stress indicates differential effects between Th1 and Th2 responses rather than natural and specific responses.

Meta-Analysis of Immune Responses to Brief Naturalistic Stress in Healthy Participants

The functional assay data are consistent with this suggestion of suppression of cellular immunity via decreased Th1 cytokine production: The T cell proliferative response significantly decreased with brief stressors (r = .19 to .32), as did natural killer cell cytotoxicity (r = .11). Increased antibody production to latent virus, particularly Epstein-Barr virus (r = .20), is also consistent with suppression of cellular immunity, enhancement of humoral immunity, or both.

There was also evidence that age contributed to vulnerability to stress-related immune change during brief naturalistic stressors, even within a limited range of relatively young ages. When we examined whether effect sizes varied according to demographic characteristics of the sample, sex ratio did not show a consistent pattern of relations with immune processes. However, the mean age of the sample was strongly related to study effect size. To the extent that a study enrolled participants of older ages, it was likely to observe more pronounced decreases in natural killer cell cytotoxicity (r = .58, p = .04; k = 14), T lymphocyte proliferation to the mitogens PHA (r = .58, p = .04; k = 13) and ConA (r = .31, p = .38; k = 9), and production of the cytokine IFN (r = .63, p = .09; k = 8) in response to brief naturalistic stress. The strength of these findings is particularly surprising given the narrow range of ages found in studies of brief natural stress; the mean participant age in this literature ranged from 15.7 to 35.0 years.

We also calculated effect sizes for three studies examining the effects of examination stress on individuals with asthma (see ). These three studies, all emanating from a team of investigators at the University of WisconsinMadison, found that stress reliably increased superoxide release (r = .20 to .37) and decreased natural killer cell cytotoxicity (r = .33). Because natural killer cells are stimulated by Th1 cytokines, this change is consistent with a Th1-to-Th2 shift. However, stress also reliably increased T cell proliferation to PHA (r = .32), which is not consistent with such a shift. The generally larger effect sizes are consistent with the idea that individuals with immunologically mediated disease are more susceptible to stress-related immune dysregulation, but the reversed sign for T cell proliferation also indicates that that pattern of dysregulation may also be more disorganized. That is, the organized pattern of suppression of Th1 but not Th2 immune responses in healthy individuals undergoing brief stressors may reflect regulation in the healthy immune system. In contrast, the lack of regulation in a diseased immune system may lead to more chaotic changes during stressors.

Meta-Analysis of Immune Responses to Brief Naturalistic Stress in Participants With Asthma

The meta-analysis of stressful event sequences is presented in . With the exception of significant increases in the number of circulating natural killer cells and the number of antibodies to the latent Epstein-Barr virus, the findings indicate that stressful event sequences are not associated with reliable immune changes. For many immune outcomes, however, significant heterogeneity statistics are evident. Studies of healthy adults generally fell into two categories that yielded disparate patterns of immune findings. The largest group of studies focused on the death of a spouse as a stressor and, as such, used samples consisting primarily of older women. Collectively, these studies found that losing a spouse was associated with a reliable decline in natural killer cell cytotoxicity (r = .23, p = .01; k = 6) but not with alterations in stimulated-lymphocyte proliferation by the mitogens ConA (r = .04, p = .45; k = 4), PHA (r = .01, p = .93; k = 7), or PWM (r = .08, p = .76; k = 3) or with changes in the number of T-helper lymphocytes (r = .07, p = .52; k = 6) or T-cytotoxic lymphocytes (r = .13, p = .45; k = 5) in peripheral blood. The next largest group of studies in this area examined immune responses to disasters, which may have different neuroendocrine consequences than loss; whereas loss is generally associated with increases in cortisol, trauma may be associated with decreases in cortisol (Yehuda, 2001; Yehuda, McFarlane, & Shalev, 1998). Natural disaster samples tended to focus on middle-aged adults of both sexes who were direct victims of the disaster, rescue workers at the scene, or personnel at nearby medical centers. There were medium-size effects suggesting increases in natural killer cell cytotoxicity (r = .25, p = .53; k = 4) and stimulated-lymphocyte proliferation by the mitogen PHA (r = .26, p = .33; k = 2), as well as decreases in the number of T-helper lymphocytes (r = .20, p = .43; k = 2) and T-cytotoxic lymphocytes (r = .23, p = .55; k = 2) in the circulation. However, none of them was statistically significant because of the small number of studies involved, and therefore these effects should be considered suggestive but not reliable.

Meta-Analysis of Immune Responses to Stressful Event Sequences in Healthy Participants

An additional group of studies in this area examined immune responses to a positive initial biopsy for breast cancer in primarily middle-aged female participants before and after the procedure. The three studies of this nature did not yield a consistent pattern of relations with any of the immune outcomes.

In summary, stressful event sequences did not elicit a robust pattern of immune changes when considered as a whole. When these sequences are broken down into categories reflecting the stressors nature, the meta-analysis yields evidence of declines in natural immune response following the loss of a spouse, nonsignificant increases in natural and specific immune responses following exposure to natural disaster, and no immune alterations with breast biopsy. Unfortunately, we cannot determine whether these disparate patterns of immune response are attributable to features of the stressors, demographic or medical characteristics of the participants, or some interaction between these factors.

Chronic stressors included dementia caregiving, living with a handicap, and unemployment. Like other nonacute stressors, they did not have any systematic relationship with enumerative measures of the immune system. They did, however, have negative effects on almost all functional measures of the immune system (see ). Both natural and specific immunity were negatively affected, as were Th1 (e.g., T cell proliferative responses) and Th2 (e.g., antibody to influenza vaccine) parameters. The only nonsignificant change was for antibody to latent virus; this effect size was substantial (r = .44), but there was also substantial heterogeneity. Further analyses showed that demographics did not moderate this effect: Immune responses to chronic stressors were equally strong across the age spectrum as well as across sex.

Meta-Analysis of Immune Responses to Chronic Stress in Healthy Participants

Distant stressors were traumatic events such as combat exposure or abuse occurring years prior to immune assessment. The meta-analytic results for distant stressors appear in . The only immune outcome that has been examined regularly in this literature is natural killer cell cytotoxicity, and it is not reliably altered in persons who report a distant traumatic experience.

Meta-Analysis of Immune Responses to Distant Stressors and Posttraumatic Stress Disorder in Healthy Participants

Most of the studies in this area examined whether immune responses varied as a function of the number of life events a person endorsed on a standard checklist, a persons rating of the impact of those events, or both. As illustrates, this methodology yielded little in the way of significant outcomes in healthy participants. To determine whether vulnerability to life events might vary across the life span, we divided studies into two categories on the basis of a natural break in the age distribution. These analyses provided evidence that older adults are especially vulnerable to life-eventinduced immune change. In studies that used samples of adults who had a mean age above 55, life events were associated with reliable declines in lymphocyte-proliferative responses to PHA (r = .40, p = .05; k = 2) and natural killer cell cytotoxicity (r = .59, p = .001; k = 2). These effects were much weaker in studies with a mean age below 55: Life events were not associated with proliferative responses to PHA (r = .22, p = .24; k = 2), and showed a reliable but modest relationship with natural killer cell cytotoxicity (r = .10, p = .03; k = 8). The differences in effect size between older and younger adults were statistically significant for natural killer cell cytotoxicity ( p < .001) but not PHA-induced proliferation ( p <.15). None of the other moderators we examinedsex ratio, kind of life event assessed (daily hassle vs. major event), or the method used to do so (checklist vs. interview)was related to immune outcomes.

Meta-Analysis of Immune Responses to Major and Minor Life Events of Unknown Duration in Healthy Participants

presents the relationship between life events and immune parameters in participants with HIV/AIDS. The presence of life events was associated with a significant reduction in the number of natural killer cells and a marginal reduction in the number of T-cytotoxic lymphocytes. It is unrelated to the number of T-helper lymphocytes, the percentage of T-cytotoxic lymphocytes, and the T-helper:T-cytotoxic ratio, all of which are recognized indicators of disease progression for patients with HIV/AIDS.

Meta-Analysis of Immune Responses to Major and Minor Life Events of Unknown Duration in Participants With HIV/AIDS

We have already proposed that immunological disease diminishes the resilience and self-regulation of the immune system, making it more vulnerable to stress-related disruption, and this may be the case in HIV-infected versus healthy populations. However, studies of HIV-infected populations also utilized more refined measures of life events (interviews that factor in biographical context) than did studies of healthy populations (typically, checklist measures). Unfortunately, we cannot differentiate between these explanations on the basis of the available data.

The meta-analysis of stress appraisals and intrusive thoughts is displayed in . These studies generally enrolled large populations of adults who were not experiencing any specific form of stress and examined whether their immune responses varied according to stress appraisals and/or intrusive thoughts. This methodology was unsuccessful at documenting immune changes related to stress. Because of the small number of studies in this category, moderator analyses could not be performed.

Meta-Analysis of Immune Responses to Global Stress Appraisals in Healthy Participants

The meta-analysis results shown in address a similar question with regard to persons who are in the midst of a specific event sequence or a chronic stressor. To the extent that they appraise their lives as stressful or report the occurrence of intrusive thoughts, these individuals exhibit a significant reduction in natural killer cell cytotoxicity. Although this effect does not extend to the number of T-helper and T-cytotoxic lymphocytes in the circulation, it suggests that a persons subjective representation of a stressor may be a determinant of its impact on the immune response.

Meta-Analysis of Immune Responses to Stress Appraisals and Intrusive Thoughts Within Healthy Stressed Populations

The large number of effect sizes generated by the meta-analysis raises the possibility of Type I error. One strategy for evaluating this concern involves dividing the number of significant findings in a meta-analysis by the total number of analyses conducted. When we performed this calculation, a value of 25.6% emerged, suggesting that more than one fourth of the analyses yielded reliable findings. This exceeds the 5% value at which investigators typically become concerned about Type I error rates and gives us confidence that the meta-analytic findings presented here are robust.

A second concern arises from the publication bias toward positive findings, which could skew meta-analytic results toward larger effect sizes. Fortunately, recent advances in meta-analysis enable one to evaluate the extent of this publication bias by using graphical techniques. A funnel plot can be drawn in which effect sizes are plotted against sample sizes for any group of studies. Because most studies in any given area have small sample sizes and therefore tend to yield more variable findings, the plot should end up looking like a funnel, with a narrow top and a wide bottom. If there is a bias against negative findings in an area, the plot is shifted toward positive values or a chunk of it will be missing entirely.

We drew funnel plots for all of the immune outcomes in the meta-analysis for which there were a sufficient number of observations. Although not all of them yielded perfect funnels, there was no systematic evidence of publication bias. Space limitations prevent us from including all plots; however, displays three plots that are prototypical of those we drew. As is evident from the data in the figure, psychoneuroimmunology researchers seem to be reporting positive and negative findingsand not hiding unfavorable outcomes when they do emerge. Thus, we do not have any major concerns about publication bias leading this meta-analysis to dramatically overestimate effect sizes.

Funnel plots depicting relationship between effect size and sample size. PHA = phytohemagglutinin.

The immune system, once thought to be autonomous, is now known to respond to signals from many other systems in the body, particularly the nervous system and the endocrine system. As a consequence, environmental events to which the nervous system and endocrine system respond can also elicit responses from the immune system. The results of meta-analysis of the hundreds of research reports generated by this hypothesis indicate that stressful events reliably associate with changes in the immune system and that characteristics of those events are important in determining the kind of change that occurs.

Selyes (1975) seminal findings suggested that stress globally suppressed the immune system and provided the first model for how stress and immunity are related. This model has recently been challenged by views that relations between stress and the immune system should be adaptive, at least within the context of fight-or-flight stressors, and an even newer focus on the balance between cellular and humoral immunity. The present meta-analytic results support three of these models. Depending on the time frame, stressors triggered adaptive upregulation of natural immunity and suppression of specific immunity (acute time-limited), cytokine shift (brief naturalistic), or global immunosuppression (chronic).

When stressors were acute and time-limitedthat is, they generally followed the temporal parameters of fight-or-flight stressorsthere was evidence for adaptive redistribution of cells and preparation of the natural immune system for possible infection, injury, or both. In evolution, stressor-related changes in the immune system that prepared the organisms for infections resulting from bites, puncture wounds, scrapes, or other challenges to the integrity of the skin and blood could be selected for. This process would be most adaptive when it was also efficient and did not divert excess energy from fight-or-flight behavior. Indeed, changes in the immune system following acute stress conformed to this pattern of efficiency and energy conservation. Acute stress upregu-lated parameters of natural immunity, the branch of the immune system in which most changes occurred, which requires only minimal time and energy investment to act against invaders and is also subject to the fewest inhibitory constraints on acting quickly (Dopp et al., 2000; Sapolsky, 1998). In contrast, energy may actually be directed away from the specific immune response, as indexed by the decrease in the proliferative response. The specific immune response in general and proliferation in particular demand time and energy; therefore, this decrease might indicate a redirection away from this function. Similar redirection occurs during fight-or-flight stressors with regard to other nonessential, future-oriented processes such as digestion and reproduction. As stressors became more chronic, the potential adaptiveness of the immune changes decreased. The effect of brief stressors such as examinations was to change the potency of different arms of specific immunityspecifically, to switch away from cellular (Th1) immunity and toward humoral (Th2) immunity.

The stressful event sequences tended to fall into two substantive groups: bereavement and trauma. Bereavement was associated with decreased natural killer cell cytotoxicity. Trauma was associated with nonsignificantly increased cytotoxicity and increased proliferation but decreased numbers of T cells in peripheral blood. The different results for loss and trauma mirror neuroendocrine effects of these two types of adverse events. Lossmaternal separation in nonhuman animals and bereavement in humansis commonly associated with increased cortisol production (Irwin, Daniels, Risch, Bloom, & Weiner, 1988; Laudenslager, 1988; McCleery, Bhagwagar, Smith, Goodwin, & Cowen, 2000). In contrast, trauma and posttraumatic stress disorder are commonly associated with decreased cortisol production (see Yehuda, 2001; Yehuda et al., 1998, for reviews). To the degree that cortisol suppresses immune function such as natural killer cell cytotoxicity, these results have the potential to explain the different effects of loss and trauma event sequences.

The most chronic stressors were associated with the most global immunosuppression, as they were associated with reliable decreases in almost all functional immune measures examined. Increasing stressor duration, therefore, resulted in a shift from potentially adaptive changes to potentially detrimental changes, initially in cellular immunity and then in immune function more broadly. It is important to recognize that although the effects of chronic stressors may be due to their duration, the most chronic stressors were associated with changes in identity or social roles (e.g., acquiring the role of caregiver or refugee or losing the role of employee). These chronic stressors may also be more persistent, that is, constantly rather than intermittently present. Finally, chronic stressors may be less controllable and afford less hope for control in the future. These qualities could contribute to the severity of the stressor in terms of both its psychological and physiological impact.

Increasing stressor chronicity also impacted the type of parameter in which changes were seen. Compared with the natural immune system, the specific immune system is time and energy intensive and as such is expected to be invoked only when circumstances (either a stressor or an infection; cf. Maier & Watkins, 1998) persist for a longer period of time. Affected immune domainsnatural versus specificwere consistent with the duration of the stressorsacute versus chronic. Furthermore, changing immune responses via redistribution of cells can happen much faster than changes via the function of cells. The time frames of the stressor and the immune domain were also consistent; acute stress affected primarily enumerative measures, whereas stressors of longer duration affected primarily functional measures.

The results of these analyses suggest that the dichotomization of the immune system into natural and specific categories and, within specific immunity, into cellular and humoral measures, is a useful starting point with regard to understanding the effects of stressors. Categorizing an immune response is a difficult process, as each immune response is highly redundant and includes natural, specific, cellular, and humoral immune responses acting together. Given this redundancy, the differential results within these theoretical divisions were remarkably, albeit not totally, consistent. As further immunological research defines these divisions more subtly, the results with regard to stressors may become even clearer. However, the present results suggest that the categories used here are meaningful.

The results of this meta-analysis reflect the theoretical and empirical progress of this literature over the past 4 decades. Increased differentiation in the quality of stressors and the immunological parameters investigated have allowed complex models to be tested. In contrast, previous meta-analyses were bound by a small number of more homogenous studies. Herbert and Cohen (1993) reported on 36 studies published between 1977 and 1991, finding broadly immunosuppressive effects of stress. Zorrilla et al. (2001) reported on 82 studies published between 1980 and 1996, finding potentially adaptive effects of acute stressors in addition to evidence for immunosuppression with longer stressors. It is important to note that meta-analytic findings are bound by the models tested in the literature. As more complex models are tested, more complex relationships emerge in meta-analysis. We next consider some such areas of complexity that should be considered in future psychoneuroimmunology research.

The meta-analytic results indicate that organismic variables such as age and disease status moderate vulnerability to stress-related decreases in functional immune measures. Both aging and HIV are associated with immune senescence and loss of responsiveness (Effros et al., 1994; Effros & Pawelec, 1997), and both are also associated with disruption of neuroendocrine inputs to the immune system (Kumar et al., 2002; Madden, Thyagarajan, & Felten, 1998). The loss of self-regulation in disease and aging likely makes affected people more susceptible to negative immunological effects of stress. Finally, the meta-analysis did not reveal effects of sex on immune responses to stressors. However, these comparisons simply correlated the sex ratio of the studies with effect sizes. Grouping data by sex would afford a more powerful comparison, but few studies organized their data that way. Gender may moderate the effects of stress on immunity by virtue of the effects of sex hormones on immunity; generally, men are considered to be more biologically vulnerable (Maes, 1999), and they may be more psychosocially vulnerable (e.g.,Scanlan, Vitaliano, Ochs, Savage, & Borson, 1998).

It seems likely to us that individual differences in subjective experience also make a substantive contribution to explaining this phenomenon. Studies have convincingly demonstrated that peoples cardiovascular and neuroendocrine responses to stressful experience are dependent on their appraisals of the situation and the presence of intrusive thoughts about it (Baum et al., 1993; Frankenhauser, 1975; Tomaka et al., 1997). Although the same logic should apply to peoples immune responses to stressful experience, few of the studies in this area have included measures of subjective experience, and those reports were limited by methodological issues such as aggregation across heterogeneous stressors. As a consequence, measures of subjective experience were not significantly associated with immune parameters in healthy research participants, with the exception of a modest (r = .10) relationship between intrusive thoughts and natural killer cell cytotoxicity. Psychological variables such as personality and emotion can give rise to individual differences in psychological and concomitant immunological responses to stress. Optimism and coping, for example, moderated immunological responses to stressors in several studies (e.g., Barger et al., 2000; Bosch et al., 2001; Cruess et al., 2000; Segerstrom, 2001; Stowell, Kiecolt-Glaser, & Glaser, 2001).

Virtually nothing is known about the psychological pathways linking stressors with the immune system. Many theorists have argued that affect is a final common pathway for stressors (e.g., S. Cohen, Kessler, & Underwood, 1995; Miller & Cohen, 2001), yet studies have enjoyed limited success in attempting to explain peoples immune responses to life experiences on the basis of their emotional states alone (Bower et al., 1998; Cole, Kemeny, Taylor, Visscher, & Fahey, 1996; Miller, Dopp, Myers, Stevens, & Fahey, 1999; Segerstrom, Taylor, Kemeny, & Fahey, 1998). Furthermore, many studies have focused on the immune effects of emotional valence (e.g., unhappy vs. happy; Futterman, Kemeny, Shapiro, & Fahey, 1994), but the immune system may be even more closely linked to emotional arousal (e.g., stimulated vs. still), especially during acute stressors (S. Cohen et al., 2000). Finally, it is possible that emotion will prove to be relatively unimportant and that other mental processes such as motivational states or cognitive appraisals will prove to be the critical psychological mechanisms linking stress and the immune system (cf. Maier, Waldstein, & Synowski, 2003).

In terms of biological mechanisms, the field is further along, but much remains to be learned. A series of studies in the mid-1990s was able to show via beta-adrenergic blockade that activation of the sympathetic nervous system was responsible for the immune system effects of acute stressors (Bachen et al., 1995; Benschop, Nieuwenhuis, et al., 1994). Apart from these findings, however, little is known about biological mechanisms, especially with regard to more enduring stressors that occur in the real world. Studies that have attempted to identify hormonal pathways linking stressors and the immune system have enjoyed limited success, perhaps because they have utilized snapshot assessments of hormones circulating in blood. Future studies can maximize their chances of identifying relevant mediators by utilizing more integrated measures of hormonal output, such as 24-hr urine collections or diurnal profiles generated through saliva collections spaced throughout the day (Baum & Grunberg, 1995; Stone et al., 2001).

Future studies could also benefit from a greater emphasis on behavior as a potential mechanism. This strategy has proven useful in studies of clinically depressed patients, in which decreased physical activity and psychomotor retardation (Cover & Irwin, 1994; Miller, Cohen, & Herbert, 1999), increased body mass (Miller, Stetler, Carney, Freedland, & Banks, 2002), disturbed sleep (Cover & Irwin, 1994; Irwin, Smith, & Gillin, 1992), and cigarette smoking (Jung & Irwin, 1999) have been shown to explain some of the immune dysregulation evident in this population. There is already preliminary evidence, for instance, that sleep loss might be responsible for some of the immune system changes that accompany stressors (Hall et al., 1998; Ironson et al., 1997).

The most pressing question that future research needs to address is the extent to which stressor-induced changes in the immune system have meaningful implications for disease susceptibility in otherwise healthy humans. In the 30 years since work in the field of psychoneuroimmunology began, studies have convincingly established that stressful experiences alter features of the immune response as well as confer vulnerability to adverse medical outcomes that are either mediated by or resisted by the immune system. However, with the exception of recent work on upper respiratory infection (S. Cohen, Doyle, & Skoner, 1999), studies have not yet tied these disparate strands of work together nor determined whether immune system changes are the mechanism through which stressors increase susceptibility to disease onset. In contrast, studies of vulnerable populations such as people with HIV have shown changes in immunity to predict disease progression (Bower et al., 1998).

To test an effect of this nature, researchers need to build clinical outcome assessments into study designs where appropriate. For example, chronic stressors reliably diminish the immune systems capacity to produce antibodies following routine influenza vaccinations (see ). Yet as far as we are aware, none of these studies has tracked illness to explore whether stress-related disparities in vaccine response might be sufficient to heighten susceptibility to clinical infection with influenza. Cytokine expression represents a relatively new and promising example of an avenue for research linking stress, immune change, and disease. For example, chronic stress may elicit prolonged secretion of cortisol, to which white blood cells mount a counterregulatory response by downregulating their cortisol receptors. This downregulation, in turn, reduces the cells capacity to respond to anti-inflammatory signals and allows cytokine-mediated inflammatory processes to flourish (Miller, Cohen, & Ritchey, 2002). Stress therefore might contribute to the course of diseases involving excessive nonspecific inflammation (e.g., multiple sclerosis, rheumatoid arthritis, coronary heart disease) and thereby increase risk for excess morbidity and mortality (Ershler & Keller, 2000; Papanicoloaou et al., 1998; Rozanski, Blumenthal, & Kaplan, 1999). Another example of the importance of cytokines to clinical pathology is in asthma and allergy, in which emerging evidence implicates excess Th2 cytokine secretion in the exacerbation of these diseases (Busse & Lemanske, 2001; Luster, 1998).

Sapolsky (1998) wrote,

Stress-related disease emerges, predominantly, out of the fact that we so often activate a physiological system that has evolved for responding to acute physical emergencies, but we turn it on for months on end, worrying about mortgages, relationships, and promotions. (p. 7)

Read the rest here:
Psychological Stress and the Human Immune System: A Meta ...

Read More...

Stem Cell Therapy – Kidney -cares

Thursday, August 4th, 2016

Stem cell therapy is a biotherapy. It brings new hope for people with refractory and incurable diseases. In clinic, it has showed enormous curative effects in treating kidney disease.

Stem cell therapy is the infusion, or injection, of healthy stem cells into your body to replace damaged or diseased body cells. In treating kidney disease,stem cells can differentiate into new cells to replace the impaired renal intrinsic cells, thus reversing impaired kidney structure.

Stem cells are multifunctional cells with the ability of self-renewal and multi-directional differentiation.In certain condition,they can differentiate into various kinds of functioning cells.According to the developmental stage of stem cells,they can divide into embryonic stem cell and somatic stem cell.Based on the developmental potential of stem cells, they can divide into totipotent stem cell,pluripotent stem cell and unipotent stem cell.As they can generate all kinds of tissues and organs,they are called "universal cell".

In kidney disease,the kidneys are impaired significantly,thus resulting in high level of waste products and toxins in body. In such a bad environment,it is not possible for stem cells to differentiate and regenerate.Before stem cell therapy is performed,Blood Purification and Micro-Chinese Medicines Osmotherapy will be used to purify blood by removing all kinds of toxins and waste products from body.

Based on the homing ability,stem cells can differentiate into new cells to replace the impaired renal intrinsic cells.This can regenerate the impaired kidney tissues,thus restoring kidney structure.Thereby,the renal function will be improved.

1. It is widely used to treat diseases and conditions.

2. The best carrier of immunization and gene therapy.

3. Free of toxicity and immune rejection.

4. It can be used before patient understanding pathogenesis completely.

With stem cell therapy,the patients do not need have surgery. So there is no surgical risk in treating disease.As stem cells are primary cells with weak antigenicity on the surface, they will not cause rejection reaction after after being injected into body.

If you want to learn more about stem cell therapy, you can email to kidneycares@hotmail.com .

Stem cell therapy is an advanced technology with the characteristics of safety,non-toxity or low-toxity,and no side effect.The most common clinical adverse reaction is anaphlaxis, but which will recover in several hours by itself.Slightly high fever may occur and the patients do not need to worry about it.

I. Primary kidney disease such as Primary Nephrotic Syndrome, Acute Glomerulonephritis,Chronic Glomerulonephritis,IgA Nephropathy,MPGN,FSGS,and Membrane Proliferative Glomerulonephritis.

II. Renal injury caused by Autoimmune Diseases and connective tissue disease: Lupus Nephritis, Anaphylactic Purpura Nephritis, Glomerular Basement Membrane Disease, Primary Renal Vasculitis, Chronic Infectious Arthritis, Ankylosing Spondylitis, Psoriasis, Sicca Syndrome, Scleroderma, Polymyositis, Dermatomyositis, Behcet's Disease Etc.

III. Renal injury caused by Metabolic Diseases: Diabetic Nephropathy, Hyperuricemic Nephropaihy and hypokalemic nephropathy.

IV. Renal tubular disease and renal interstitial disease: Renal Tubular Acidosis, various kinds of acute and chronic interstitial nephritis;

V. Renal injury caused by infectious diseases: hepatitis B Virus associated glomerulonephritis, hepatitis C Virus associated glomerulonephritis

VI. cardiac function and IV

VII. Cardiorenal Syndrome and Hepatorenal Syndrome

VIII.Renal Injury caused by hypertension.

IX.Hereditary kidney diseases: Alport nephritis, thin glomerular basement membrane disease, Fabry disease etc.;

X. Polycystic Kidney Disease

I. Patient who is allergic to stem cell or patient with serious allergy;

II. pregnant women (woman in lactation period is allowed)

III. Infected patients who is still out of control;

IV. Serious mental illness patient, including patient with tristimania;

V. Severe Hypertension (BP is higher than 160/100mmHg)

VI. Patient with III and IV cardiac function, coronary disease, unstable angina, myocardial ischemia

VII. Patients with obvious renal atrophy

VIII. Patients with severe bleeding tendency

IX. Patients who are taking part in clinical research.

X. Polycystic Kidney Disease

Not all the patients are suitable to the stem cell therapy our hospital own strict selection system to ensure our curative effect.If you are interested in the therapy, you can consult with our online doctor now!

The rest is here:
Stem Cell Therapy - Kidney -cares

Read More...

Stem Cell Transplant Complications: Graft Failure

Thursday, August 4th, 2016

The first three and half months following a stem cell transplant pose the greatest risk of developing complications associated with a stem cell transplant (whether bone marrow or cord blood). However, the risk of developing stem cell transplant complications varies and depends on several factors. Among these potential stem cell transplant complications is graft failure, which is more likely to occur in some cases than others. The risk of graft failure often depends on the patients medical state prior to a stem cell transplant, the type of stem cell transplant performed, and the type of treatable disease involved.

What is Graft Failure? High-dose chemotherapy which accompanies a stem cell transplant destroys the ability for bone marrow to produce white blood cells, red blood cells and platelets. Graft failure is a condition in which normal bone marrow function does not return following a stem cell transplant.

Following transplant, the graft may fail to grow in the patients body, which will result in bone marrow failure and the absence of new blood cell production. This can lead to side effects such as repeated infections, anemia, bruising and bleeding.

In general, doctors define graft failure as the absence of engraftment forty-two days following a stem cell transplant. In other words, the body does not accept the donated cells; however, total graft failure is considered to be rare.

Graft Failure vs. GVHD Graft failure and graft-versus-host disease (GVHD) represent two different types of potential complications following a stem cell transplant. In the case of GVHD, the patients immune system will respond adversely to the donated stem cells, and white blood cells will begin to destroy the transplanted graft. This differs from the bodys failure to accept the graft and restore blood cell production that occurs in graft failure.

GVHD is a potential side effect associated with allogeneic stem cell transplants, in which stem cells are derived from a donor source such as cord blood. In the case of autologous stem cell transplants in which the patients own stem cells are infused into the body there is generally no risk of GVHD. However, the risk of graft failure following an autologous stem cell transplant is 5%.

Graft Failure Risks There are a number of factors that may contribute to the risk of graft failure in patients undergoing a stem cell transplant. Factors that may contribute to an increased risk of graft failure include the following:

The type pf disease being treated may play a role in the risk of developing graft failure. For example, one study found that the risk of graft failure was much higher (33%) in patients undergoing a stem cell transplant for osteoporosis than in patients being treated for leukemia. This may be due to the fact that leukemia stem cell therapy is a more established treatment procedure.

In leukemia patients, however, graft failure is usually associated with the recurrence of cancer as the leukemic cells may hinder the growth of the transplanted stem cells.

For some patients who develop graft failure, the cause of graft failure is unknown.

Graft Failure Treatment While considered relatively rare, graft failure is a serious and ultimately fatal complication that will likely require a second stem cell transplant. Stem cells used in the second transplant may be derived from either the same donor source or a different stem cell source. In patients undergoing an umbilical cord blood stem cells transplant, the same cord blood unit cannot be used. A different cord blood unit or another adult stem cell source may be used in these cases.

More here:
Stem Cell Transplant Complications: Graft Failure

Read More...

Stem Cell Conferences | Stem Cell Congress | Regenerative …

Thursday, August 4th, 2016

Conference Series LLC International Conferences invites all the participants from all over the world to attend Annual Conference on Stem Cell and Regenerative Medicine during Aug 4-5, 2016 at Manchester, UK which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Track 1:Stem Cell Therapy

Stem cell therapy is used to treat or prevent diseases by using stem cells. It has potential in a wide range of territories of potential and restorative examination. This treatment is by and large used to supplant or repair harmed cells or tissues . It additionally helps in transplanting immature microorganisms or giving medications that objective undifferentiated organisms as of now in the body. Undeveloped cell treatment is a rising innovation, the recovery of body part is not really another idea.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

2ndWorld Congress on Infectious DiseasesAugust 25-27, 2016 Philadelphia, USA; 4th Internationalconference on Bacteriology May 16-18, 2016 San Antonio, USA; 3rd World Congress onHepatitis October 17-19, 2016 Dubai, UAE; 2nd InternationalConference on InfluenzaSeptember 12-14, 2016 Berlin, Germany; 2nd InternationalConference on RetrovirusesJune 30-July 01, 2016 Cape Town, South Africa; 26th European Congress ofClinical Microbiology , April 912 2016, Istanbul, Turkey; Conference on Metabolic disorders, April 1721 2016, Newport, USA; Banff, Canada; Conference onCellu Growth and Regeneration, Jan 1014 2016, Breckenridge, USA ; Conference onHuman and Veterinary Tropical Diseases, May 2226 2016, Cape Town, South Africa;

Track 2:Stem cell

An undifferentiated cell of a multicellular creature which is fit for offering ascend to inconclusively more cells of the same sort, and from which certain different sorts of cell emerge by separation. The most entrenched and generally utilized undifferentiated organism treatment is the transplantation of blood foundational microorganisms to treat infections and states of the blood and invulnerable framework, or to restore the blood framework after medications for particular growths. Subsequent to the 1970s, skin undifferentiated organisms have been utilized to develop skin joins for patients with serious smolders on expansive territories of the body. Just a couple of clinical focuses can do this treatment and it is normally held for patients with life-debilitating blazes. It is likewise not a flawless arrangement: the new skin has no hair follicles or sweat organs. Research went for enhancing the strategy is continuous.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

8thWorld Congress on Stem Cell ResearchMarch 20-22, 2017 Orlando, USA; 5th International Conference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking September12-13, 2016 Philadelphia USA;Conference on Cardiac Development, Regeneration and RepairApril 3 7, 2016 Snowbird, Utah, USA; The Conference onStem Cell Development,May 22-26, 2016 Hillerd, Denmark;Conference onHematopoietic Stem Cells: June 3-5, 2016 Heidelberg, Germany; ISSCR Pluripotency Conference March 22-24, 2016 Kyoto, Japan

Track 3:Stem cell treatment

The most entrenched and broadly utilized undifferentiated organism treatment is the transplantation of blood foundational microorganisms to treat illnesses and states of the blood and invulnerable framework, or to restore the blood framework after medicines for particular malignancies. Subsequent to the 1970s, skin undifferentiated organisms have been utilized to develop skin unites for patients with extreme blazes on substantial territories of the body. Just a couple of clinical focuses can do this treatment and it is normally held for patients with life-undermining smolders. It is additionally not an immaculate arrangement: the new skin has no hair follicles or sweat organs. Research went for enhancing the method is progressing.

RelatedStem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

8thWorld Congress on Stem Cell ResearchMarch 20-22, 2017 Orlando, USA; 5th International Conference and Exhibition onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking September12-13, 2016 Philadelphia USA;Conference on Cardiac Development, Regeneration and RepairApril 3 7, 2016 Snowbird, Utah, USA; TheStem Cell DevelopmentMay 22-26, 2016 Hillerd, Denmark;Hematopoietic Stem Cells: From the Embryo to the Aging Organism, June 3-5, 2016 Heidelberg, Germany; ISSCR Pluripotency: From basic science to therapeutic applications March 22-24, 2016 Kyoto, Japan

Track 4:Somatic Cell Therapy

Somatic cell treatment is the organization to people of autologous, allogeneic, or xenogeneic living cells which have been controlled or prepared ex vivo. Assembling of items for substantial cell treatment includes the ex vivo proliferation, development, choice. Substantial cell treatment is seen as a more moderate, more secure methodology since it influences just the focused on cells in the patient, and is not went on to future eras. Substantial quality treatment speaks to standard essential and clinical exploration, in which helpful DNA (either incorporated in the genome or as an outside episome or plasmid) is utilized to treat illness. Most concentrate on extreme hereditary issue, including immunodeficiencies, hemophilia, thalassaemia and cystic fibrosis. Such single quality issue are great possibility for substantial cell treatment.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

5th International Conference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA;; 3rdWorld Congress onHepatitis , October 17-19, 2016 Dubai, UAE; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking September12-13, 2016 Philadelphia USA; 26thEuropean Congress ofClinical Microbiology, April 912 2016, Istanbul, Turkey;Conference onCell Growth and Regeneration, Jan 1014 2016, Breckenridge, USA ;

Track 5:Tissue Regeneration

Tissue Engineering is the investigation of the development of new connective tissues, or organs, from cells and a collagenous platform to create a completely useful organ for implantation over into the contributor host. Effective improvements in the multidisciplinary field of tissue building have created a novel arrangement of tissue new parts and execution approaches. Investigative advances in biomaterials, foundational microorganisms, development and separation components, and biomimetic situations have made special chances to manufacture tissues in the research facility from blends of designed extracellular networks cells, and organically dynamic particles.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

8thWorld Congress on Stem Cell ResearchMarch 20-22, 2017 Orlando, USA;5th InternationalConference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd International Conference onTissue preservation and Bio-bankingSeptember 12-13, 2016 Philadelphia, USA; Conference onCell Growth and Regeneration, Jan 1014 2016, Breckenridge, USA; Conference on Cell Culture 2016, Feb 24 2016, London, UK;Stem Cell Summit, Apr 2527 2016, Boston, USA;ISBER 2016Annual Meeting, April 5-8, 2016, Berlin, Germany;Biobanking 2016, Jan 57 2016, London, UK

Track 6:Regeneration and Therapeutics

Tissue regenaration therapeutics, making foundational microorganisms for supportive application in regenerative pharmaceutical. Regenerative solution is to offer the body some help with recuperating itself more sufficiently. In regenerative pharmaceutical, cell, tissue and organ substitutes are made to restore normal limit that has been lost.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

8thWorld Congress on Stem Cell ResearchMarch 20-22, 2017 Orlando, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd International Conference onTissue preservation and Bio-bankingSeptember 12-13, 2016 Philadelphia, USA; 18th International conference on Neuroscience, April 26 2016, Sweden, Austria; 6th Annual Traumatic Brain Injury Conference, May 1112 2016, Washington, D.C., USA; Conference on Common Mechanisms of Neurodegeneration, June 1216 2016, Keystone, USA; Annual Meeting of the German Society ofNeurosurgery(DGNC), June 1215 2016, Frankfurt am Main, Germany

Track 7:Tumour cell science

An irregular mass of tissue, tumours are a great indication of aggravation, and can be favourable or threatening. Tumour for the most part mirror the sort of tissue they emerge in. Treatment is likewise particular to the area and kind of the tumour. Benevolent tumours can once in a while essentially be overlooked, destructive tumours; choices incorporate chemotherapy, radiation, and surgery.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

5th International Conference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA;; 3rdWorld Congress onHepatitis and Liver Diseases October 17-19, 2016 Dubai, UAE; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking September12-13, 2016 Philadelphia USA; 26thEuropean Congress ofClinical Microbiology and Infectious Diseases, April 912 2016, Istanbul, Turkey;Conference onCellular Basis of Growth and Regeneration, Jan 1014 2016, Breckenridge, USA ;

Track 8:Stem Cell & Gene therapy

Gene therapy remains a fairly new and still experimental procedure for the treatment of disease. In addition stem cells are still a relatively new concept and remain a confusing and complicated technology that much of the public struggles to understand. The potential for stem cells to be used in gene therapies is however, a valid one that has important ramifications for treating a range of diseases, many of which currently have no cure.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

InternationalConference on Case ReportsMarch 31-April 02, 2016 Valencia, Spain; 2nd International Meeting onClinical Case ReportsApril 18-20, 2016 Dubai, UAE; 3rd Experts Meeting onMedical Case ReportsMay 09-11, 2016 New Orleans, Louisiana, USA; 12thEuro BiotechnologyCongress November 7-9, 2016 Alicante, Spain; 2nd International Conference onTissue preservation and BiobankingSeptember 12-13, 2016 Philadelphia, USA; 11thWorld Conference BioethicsOctober 20-22, 2015 Naples, Italy;Annual Conference Health Law and Bioethics, May 6-7 2016 Cambridge, MA, USA; 27th Maclean Conference on Clinical Medical Ethics, Nov 13-14, 2015, Chicago, USA; CFP: Global Forum on Bioethics in Research, Nov 3-4, 2015, Annecy, France

Track 9:Stem Cell Biomarkers

Stem Cell Biomarker is characterized as a quality or their proteins that are utilized to disengage and recognize immature microorganisms. The other approach to distinguish the undifferentiated organisms is by utilizing utilitarian assays.Molecular biomarkers serve as profitable apparatuses to arrange and segregate embryonic immature microorganisms (ESCs) and to screen their separation state by immunizer based systems. ESCs can offer ascent to any grown-up cell sort and in this way offer colossal potential for regenerative medication and drug revelation. Various biomarkers, for example, certain cell surface antigens, are utilized to dole out pluripotent ESCs

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

5th International Conference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA;; 3rdWorld Congress onHepatitis and Liver Diseases October 17-19, 2016 Dubai, UAE; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking September12-13, 2016 Philadelphia USA; 26thEuropean Congress ofClinical Microbiology and Infectious Diseases, April 912 2016, Istanbul, Turkey;Conference onCellular Basis of Growth and Regeneration, Jan 1014 2016, Breckenridge, USA ;

Track 10:Stem Cell Biobanking & Tissue preservation

Biobanks play a crucial role in biomedical research. The wide array of biospecimens (including blood, saliva, plasma, and purified DNA) maintained in biobanks can be described as libraries of the human organism.he process by which a tissue or aggregate of cells is kept alive outside of the organism from which it was derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

4thCongress on Bacteriology and Infectious DiseasesMay 16-18, 2016 San Antonio, USA; 2ndWorld Congress on Applied MicrobiologyOctober 31-November 02, 2016 Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic MicrobiologyOct 3-5, 2016 Vancouver, Canada; InternationalConference on Water MicrobiologyJuly 18-20, 2016 Chicago, USA; 5th InternationalConference on Clinical MicrobiologyOctober 24-26, 2016 Rome, Italy; Axons: FromCell Biologyto Pathology Conference, 2427 January 2016, Santa Fe, USA; 26th EuropeanCongress of Clinical MicrobiologyApril 912 2016, Istanbul, Turkey;Conference on Gut Microbiota, Metabolic Disorders and Beyond, April 1721 2016, Newport, USA; 7th EuropeanSpores Conference, April 1820 2016, Egham, UK; New Approaches to Vaccines forHuman and Veterinary Tropical Diseases, May 2226 2016, Cape Town, South Africa

Track 11:Stem Cell Technologies

Cell separation is the movement, while a cell changes starting with one cell sort then onto the next. Variety happens various times amid the advancement of a multicellular living being as it changes from a straightforward zygote to a perplexing arrangement of tissues and cell sorts. Separation proceeds in adulthood as grown-up undifferentiated organisms isolate and make completely separated girl cells amid tissue repair and amid typical cell turnover. Some separation happens in light of antigen introduction. Separation drastically changes a phone's size, shape, film potential, metabolic movement, and responsiveness to flags. These progressions are to a great extent because of very controlled changes in quality expression and are the investigation of epigenetics. With a couple of exemptions, cell separation never includes an adjustment in the DNA succession itself. Along these lines, diverse cells can have altogether different physical attributes in spite of having the same genome.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

2ndWorld Congress on Applied MicrobiologyOctober 31-November 02, 2016 Istanbul, Turkey; InternationalConference on Infectious Diseases & Diagnostic MicrobiologyOct 3-5, 2016 Vancouver, Canada;18th International conference on Neuroscience, April 26 2016, Sweden, Austria; 6th Annual Traumatic Brain Injury Conference, May 1112 2016, Washington, D.C., USA; Common Mechanisms of Neurodegeneration, June 1216 2016, Keystone, USA; Neurology Caribbean Cruise, Aug 2128 2016, Fort Lauderdale, USA; Annual Meeting of the German Society ofNeurosurgery(DGNC), June 1215 2016, Frankfurt am Main, Germany

Track 12:Stem Cell Nano-Technology

In recent years, the inter crossing of nanotechnology in stem cell biology and biomedicine has led to an emerging new research field, known as stem cell nanotechnology. Stem cell nanotechnology is defined as the application of nanotechnology in stem cells research and development, and it is characterized as highly rapid in development, highly interdisciplinary, and highly controversial.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

InternationalConference on Genetic Counseling and Genomic MedicineAugust 11-12, 2016 Birmingham, UK;World Congress on Human GeneticsOctober 31- November 02, 2016 Valencia, Spain; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 3rd InternationalConference on Genomics & PharmacogenomicsSeptember 21-23, 2015 San Antonio, USA; EuropeanConference on Genomics and Personalized MedicineApril 25-27, 2016 Valencia, Spain;Genomics and Personalized Medicine, Feb 711 2016, Banff, Canada; Drug Discovery for Parasitic Diseases, Jan 2428 2016, Tahoe City, USA; Heart Failure: Genetics,Genomics and Epigenetics, April 37 2016, Snowbird, USA; Understanding the Function ofHuman Genome Variation, May 31 June 4 2016, Uppsala, Sweden; 5thDrug Formulation SummitJan2527,2016,PhiladelphiaUSA

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

Track 14: Stem Cell Apoptosis and Signal Transduction

Self-reestablishment and multiplication of foundational microorganism populaces is controlled, to some degree, by affectation of apoptosis. The quantity of foundational microorganisms is thusly a harmony between those lost to separation/apoptosis and those increased through multiplication. Apoptosis of immature microorganisms is accepted to be a dynamic procedure which changes because of natural conditions.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

8thWorld Congress on Stem Cell ResearchMarch 20-22, 2017 Orlando, USA; 5th International Conference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking September12-13, 2016 Philadelphia USA;Conference on Cardiac Development, Regeneration and RepairApril 3 7, 2016 Snowbird, Utah, USA; Stem Cell DevelopmentMay 22-26, 2016 Hillerd, Denmark; Conference onHematopoietic Stem Cells, June 3-5, 2016 Heidelberg, Germany; ISSCR Pluripotency - March 22-24, 2016 Kyoto, Japan

Track 15: Tissue science & Engineering

Tissue Science and Engineering employs physical, chemical, and biological factors to replace and/or improve biological functions of the cell. The interdisciplinary field of tissue engineering has been one of the most active and quickly expanding disciplines during the past two decades.

Global stem cell market is dominating the healthcare industry with its reliable and cost effective method of treatment with fewer side effects. Current market for cord blood therapeutics accounts for $6.5 billion, which is expected to grow at 33.4% CAGR from 2013-2020. Other segments of this market include - Adult stem cell and embryonic stem cells. Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

4th InternationalCongress on BacteriologyMay 16-18, 2016 San Antonio, USA; 2nd World Congress on Applied MicrobiologyOctober 31-November 02, 2016 Istanbul, Turkey; InternationalConference on Infectious Diseases and Diagnostic MicrobiologyOct 3-5, 2016 Vancouver, Canada; InternationalConference on Water Microbiology July 18-20, 2016 Chicago, USA; 5th InternationalConference on Clinical MicrobiologyOctober 24-26, 2016 Rome, Italy;AnnualMeeting of the German Society for Gene Therapy12 - 13 March 2015 Vienna, Austria;International Bone-Tissue-Engineering Congress8 - 10 October 2015. Stuttgart, Germany; 9th InternationalSymposium on Neuroprotection and NeurorepairApril 19 to April 22, 2016 Magdeburg, Germany;Craniofacial Morphogenesis & Tissue RegenerationMarch 12-18, 2016 California, USA

Track 16: Novel Approaches in GTR

GTR is defined as procedures that are used to regenerate the lost periodontal structure by using different tissue responses. Many methods are used for tissue regeneration by using different materials like collagen, calcium sulphate, poly tetra flouro ethylene, polyglactin etc.It has become a standard of care in Periodontology and also used in periapical surgery.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

5th International Conference onCell and Gene TherapyMay 19-21, 2016 San Antonio, USA; InternationalConference on Restorative MedicineOctober 24-26, 2016 Chicago, USA;; 3rdWorld Congress onHepatitis and Liver Diseases October 17-19, 2016 Dubai, UAE; InternationalConference on Molecular BiologyOctober 13-15, 2016 Dubai, UAE; 2nd InternationalConference on Tissue preservation and Biobanking September12-13, 2016 Philadelphia USA; 26thEuropean Congress ofClinical Microbiology, April 912 2016, Istanbul, Turkey;Conference onCell Growth and Regeneration, Jan 1014 2016, Breckenridge, USA ;

Track 17: Potential Applications of Stem cell Therapy

Foundational microorganisms are utilized to recuperate the body , advance recuperation. It has more helpful potential applications. It is utilized as a part of Cell Replacement Therapy which is particularly intended to taget the specific organs.Improvements of medications that advance cell expansion and separationIt is likewise used to deliver foundational microorganisms from the patient's skin and blood utilizing Ips innovation

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

InternationalConference on Next Generation SequencingJuly 21-22, 2016 Berlin, Germany; 5th InternationalConference on Computational Systems BiologyAugust 22-23, 2016 Philadelphia, USA; 7th InternationalConference on BioinformaticsOctober 27-28, 2016 Chicago, USA; InternationalConference on Synthetic BiologySeptember 28-30, 2015 Houston, USA; 4th InternationalConference on Integrative BiologyJuly 18-20, 2016 Berlin, Germany; 1st InternationalConference on Pharmaceutical BioinformaticsJan 2426 2016, Pattaya, Thailand; EMBL Conference: TheEpitranscriptome, Apr 2022 2016, Heidelberg, Germany; 2016Whole-Cell ModelingSummer School, Apr 38 2016, Barcelona, Spain; 3rd InternationalMolecular Pathological Epidemiology, May 1213 2016, Boston, USA; 5thDrug FormulationSummit, Jan 2527 2016, Philadelphia, USA

Track 18:Regenerative Medicine and Market

Regenerative pharmaceuticals have the one of a kind capacity to repair , supplant and recover tissues and organs , influenced because of some harm , infection. These drugs are ability of restoring the usefulness of cells and tissues. These medications have wide appropriateness in treating degenerative scatters including dermatology, cardio vascular, neurodegenerative sicknesses.

Cell treatment is the quickest developing fragment of regenerative drug. This undeveloped cell treatment is making up the biggest part of this business sector.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

InternationalConference on Next Generation SequencingJuly 21-22, 2016 Berlin, Germany; 5th InternationalConference on Computational Systems BiologyAugust 22-23, 2016 Philadelphia, USA; 7th InternationalConference on BioinformaticsOctober 27-28, 2016 Chicago, USA; InternationalConference on Synthetic BiologySeptember 28-30, 2015 Houston, USA; 4th InternationalConference on Integrative BiologyJuly 18-20, 2016 Berlin, Germany; 1st InternationalConference on Pharmaceutical BioinformaticsJan 2426 2016, Pattaya, Thailand; EMBL Conference: TheEpitranscriptome, Apr 2022 2016, Heidelberg, Germany; 2016Whole-Cell ModelingSummer School, Apr 38 2016, Barcelona, Spain; 3rd InternationalMolecular Pathological Epidemiology, May 1213 2016, Boston, USA; 5thDrug FormulationSummit, Jan 2527 2016, Philadelphia, USA

Track 19:Stem cell-Bioinformatics

Computational Biology, sometimes referred to as bioinformatics, is the science of using biological data to develop algorithms and relations among various biological systems. Bioinformatics groups use computational methods to explore the molecular mechanisms underpinning stem cells. To accomplish this bioinformatics develop and apply advanced analysis techniques that make it possible to dissect complex collections of data from a wide range of technologies and sources.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

4th InternationalConference on Plant GenomicsJuly 14-15, 2016 Brisbane, Australia; 8thWorld Congress on Stem Cell ResearchMarch 20-22, 2017 Orlando, USA; 2nd InternationalConference on Tissue preservation and BiobankingSeptember 12-13, 2016 Philadelphia, USA, USA;World Congress on Human GeneticsOctober 31- November 02, 2016 Valencia, Spain; 12thEuro Biotechnology CongressNovember 7-9, 2016 Alicante, Spain; 2nd InternationalConference on Germplasm of Ornamentals, Aug 8-12, 2016, Atlanta, USA; 7th Internationalconference on Crop Science, Aug 1419 2016, Beijing, China;Plant Epigenetics: From Genotype to Phenotype, Feb 1519 2016, Taos, USA;Germline Stem Cells Conference, June 1921 2016, San Francisco, USA;Conference on Water Stressin Plants, 29 May 3 June 2016, Ormont-Dessus, Switzerland

Track 20:Biomaterial Engineering

Abiomaterialis any matter, surface, or construct that interacts with living systems. As a science,biomaterialsis about fifty years old. The study of biomaterials is calledbiomaterials science or biomaterials engineering. It has experienced steady and strong growth over its history, with many companies investing large amounts of money into the development of new products.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

2nd InternationalConference on AntibodiesJuly 14-15, 2016 Philadelphia, USA; 2nd InternationalConference on Innate ImmunityJuly 21-22, 2016 Berlin, Germany; 2ndInternational Congress on Neuroimmunology March 31-April 02, 2016 Atlanta, USA; InternationalConference on Cancer Immunology July 28-30, 2016 Melbourne, Australia; 5th InternationalConference on ImmunologyOctober 24-26, 2016 Chicago, USA;Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, Mar 610 2016, Whistler, Canada;Systems Immunology: From Molecular Networks to Human Biology, Jan 1014 2016, Big Sky, USA;Novel Immunotherapeutics Summit, Jan 2526 2016, San Diego, USA;Stromal Cells in Immunity, Feb 711 2016, Keystone, USA; 26th European Congress ofClinical Microbiology, April 912 2016, Istanbul, Turkey

Track 19: Ethics inStem cellResearch

Stem cell research offers incredible guarantee for comprehension fundamental systems of human improvement and separation, and additionally the expectation for new medications for maladies, for example, diabetes, spinal string damage, Parkinson's ailment, and myocardial localized necrosis. Be that as it may, human undifferentiated organism (hSC) explore likewise raises sharp moral and political debates. The induction of pluripotent undifferentiated organism lines from oocytes and fetuses is laden with question about the onset of human personhood. The reinventing of substantial cells to deliver affected pluripotent undifferentiated organisms maintains a strategic distance from the moral issues particular to embryonic foundational microorganism research. In any hSC research, in any case, troublesome situations emerge with respect to delicate downstream research, agree to give materials for hSC research, early clinical trials of hSC treatments, and oversight of hSC examination. These moral and approach issues should be examined alongside exploratory difficulties to guarantee that undifferentiated cell examination is done in a morally fitting way. This article gives a basic investigation of these issues and how they are tended to in current arrangements.

Related Stem Cell Conferences|Stem Cell Congress|Regenerative Medicine Conferences|Conference Series LLC

4th InternationalConference on Plant GenomicsJuly 14-15, 2016 Brisbane, Australia; 8thWorld Congress on Stem Cell ResearchMarch 20-22, 2017 Orlando, USA; 2nd InternationalConference on Tissue preservation and BiobankingSeptember 12-13, 2016 Philadelphia, USA, USA;World Congress on Human GeneticsOctober 31- November 02, 2016 Valencia, Spain; 12thEuro Biotechnology CongressNovember 7-9, 2016 Alicante, Spain; 2nd InternationalConference on Germplasm of Ornamentals, Aug 8-12, 2016, Atlanta, USA; 7th Internationalconference on Crop Science, Aug 1419 2016, Beijing, China;Plant Epigenetics: FromGenotype to Phenotype, Feb 1519 2016, Taos, USA;Germline Stem Cells Conference, June 1921 2016, San Francisco, USA;Conference on Water Stressin Plants, 29 May 3 June 2016, Ormont-Dessus, Switzerland

With the trail of success of the previous conference, OMICS International hosted the 5thWorld Congress on Cell and Stem Cell Research during March 23-25, 2015, at Double Tree by Hilton Chicago - North Shore, Chicago, USA with the theme Advanced Approaches in Cell Science and Stem Cell Research. Benevolent response and active participation was received from the Editorial Board Members of OMICS Group Journals as well as from the Stem Cell researchers, scientists, doctors, students and leaders from the fields of Cell and Stem Cell Research, who made this event successful.

The meeting was carried out through various sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

The conference was embarked with an opening ceremony followed by workshops symposiums and a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were;

Dr. James L. Sherley, Asymmetrex LLC, USA

Dr. Ornella Parolini, International Placenta Stem Cell Society (IPLASS), Italy

Dr. Paul J. Davis, Albany Medical College, USA

Dr. Haval Shirwan, University of Louisville, USA

Dr. Diana Anderson, University of Bradford, United Kingdom

Conference Proceedings

Best Poster Awardees:

Read the rest here:
Stem Cell Conferences | Stem Cell Congress | Regenerative ...

Read More...

Stem cells from fat outperform those from bone marrow in …

Thursday, August 4th, 2016

Durham, NC A new study appearing in the current issue of STEM CELLS Translational Medicine indicates that stem cells harvested from fat (adipose) are more potent than those collected from bone marrow in helping to modulate the bodys immune system.

The finding could have significant implications in developing new stem-cell-based therapies, as adipose tissue-derived stem cells (AT-SCs) are far more plentiful in the body than those found in bone marrow and can be collected from waste material from liposuction procedures. Stem cells are considered potential therapies for a range of conditions, from enhancing skin graft survival to treating inflammatory bowel disease.

Researchers at the Leiden University Medical Centers Department of Immunohematology and Blood Transfusion in Leiden, The Netherlands, led by Helene Roelofs, Ph.D., conducted the study. They were seeking an alternative to bone marrow for stem cell therapies because of the low number of stem cells available in marrow and also because harvesting them involves an invasive procedure.

Adipose tissue is an interesting alternative since it contains approximately a 500-fold higher frequency of stem cells and tissue collection is simple, Dr. Roelofs said.

Moreover, Dr. Sara M. Melief added, 400,000 liposuctions a year are performed in the U.S. alone, where the aspirated adipose tissue is regarded as waste and could be collected without any additional burden or risk for the donor.

For the study, the team used stem cells collected from the bone marrow and fat tissue of age-matched donors. They compared the cells ability to regulate the immune system in vitro and found that the two performed similarly, although it took a smaller dose for the AT-SCs to achieve the same effect on the immune cells.

When it came to secreting cytokines the cell signaling molecules that regulate the immune system the AT-SCs also outperformed the bone marrow-derived cells.

This all adds up to make AT-SC a good alternative to bone marrow stem cells for developing new therapies, Dr. Roelofs concluded.

Cells from bone marrow and from fat were equivalent in terms of their potential to differentiate into multiple cell types, said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of Wake Forest Institute for Regenerative Medicine. The fact that the cells from fat tissue seem to be more potent at suppressing the immune system suggest their promise in clinical therapies.

Read the original here:
Stem cells from fat outperform those from bone marrow in ...

Read More...

What is the future of biotechnology?

Thursday, August 4th, 2016

In extraordinary ways, today the research and developement in biotechnology is demonstrating the power of scientific ideas to change the world ! The future of biotechnology is not only good but it is great ! Why only future , the present of biotech is so bright that its development will further make it to shine more and more. Today biotechnology is inspiring new students to go ahead with their biotechnology knowledge on such platforms were sky is the limit. Biotechnology has a very strong and promising future. The simple reason for this is it covers the entire field of science and its applications. These includes but not limited to filed as medical, agricultural, engineering, computational, and industrial process all together are now using a integrated approach to improve product quality, efficiency, cost, and environmental sustainability. Nanotechnology, information technology are also helping biotechnology in various way to improve the standards of product and reduce the side effects, cycle time of production with safety measures of patients, society and environment.

With the help of Biotechnology new era is on the way to emerge with the self-directed evolutions. Mankind is on its way to develop self-engineered organism, biochemical pathways, rDNA, self-design proteins, genetically engineered vegetables for improved productivity and nutritional values. Now with the help of Biotechnology new thinking & implementation of biotechnology applications in physiology of body, gene alterations, protein study, and nanotechnology are being done. All this will help to curb all types of diseases; disorders will help to build the humanity with self-protected and controlled evolution.

The area of application of biotechnology is vast. Few examples it includes unique products development, today Monoclonal antibodies which are new tools to detect and localize specific biomolecules. The biotechnology had today developed such monoclonal anitbiotics which In principle, can be made against any macromolecule and used to specifically locate, purify or even potentially destroy molecule as for example with anticancer drugs.

Biotechnology is helping and is being worldwide utilized in solving crimes with DNA identifications. It also allows scientists and other to produce banks of DNA, RNA and proteins, while mapping the human genome. Tracers are used to synthesize specific DNA or RNA probes, which are very essential to specify sequences which is involved in genetic disorders.

With genetic engineering & biotechnology, new proteins are increasingly synthesized globally and used for variuos therapies. They can be introduced into other forms of life like plants or animal genomes, thus a new type of disease resistant plants are generated, capable of living in extreme unfavorable environments (i.e. temperature, Ph, Salt, Desert extremes,...). When introduced into bacteria, these proteins have also produced new antibiotics and useful therapeutic drugs.

With biotechnology today cloning are being done successfuly and it generate large quantities of pure and efficient human proteins, which are used to treat diseases like diabetes and hormonal disorders. In the future, a resource bank for rare human proteins or other molecules will be available. For example, technique like DNA sequences which are modified to correct a mutation or phenotypes , to increase the production of a specific protein, anitbiotics and biomolecues or to produce a new type of protein can be stored for longer period of time. This technique will be play a key role in gene therapy and curing of genetic disorders. Really the furture of biotechnology is very bright.

Taking consideration of the breadth and depth of advances underway in biotechnology, there is a strong potential and capacity for a reemergent, neosymbolist era. Similarly, fundamental drivers based on biotechnology will shape this new era of self-reconsideration and self dependant. The complete decoding of human genome with the help of biotechnology and indirectly of our physiology down to individual genes or nucleotides, proteins, and even individual thoughts and emotions may greatly impact our self-perception of life, health, aging ,disease, personality, and nature.

Today through biotechnology in agriculture we had changed the capacity of our planet earch in feeding the large popullation with agricultural quality and nutritive products. This capasity development and balancing will improve our relationship with ecology and the nature.There is a great progress in industrial manufacturing, materials science,medical field , disastor management and bioengineering which is only possible due to biotechnology and will deeply & positively impact both the nature and the survival capacity of humans. We the humans are the drivers of biotechnology and our ability to use biotechnology to create a better world for well being of mankind and also for all other living creatures like plants, animals of our planet and mother planet Earth will show a new way to evolution which will be towards infinity and well being of mankind ! Really the future of biotechnology is Great and is further coming up with flying colors for students ,researcher ,scientists ,professionals in this field & ultimately to the mankind !

The rest is here:
What is the future of biotechnology?

Read More...

life span | Britannica.com

Thursday, August 4th, 2016

Alternative title: longevity

Life span, mayflyG.E. HydeNHPA/EB Inc.the period of time between the birth and death of an organism.

longevity: animalsEncyclopdia Britannica, Inc.It is a commonplace that all organisms die. Some die after only a brief existence, like that of the mayfly, whose adult life burns out in a day, and others like that of the gnarled bristlecone pines, which have lived thousands of years. The limits of the life span of each species appear to be determined ultimately by heredity. Locked within the code of the genetic material are instructions that specify the age beyond which a species cannot live given even the most favourable conditions. And many environmental factors act to diminish that upper age limit.

The maximum life span is a theoretical number whose exact value cannot be determined from existing knowledge about an organism; it is often given as a rough estimate based on the longest lived organism of its species known to date. A more meaningful measure is the average life span; this is a statistical concept that is derived by the analysis of mortality data for populations of each species. A related term is the expectation of life, a hypothetical number computed for humans from mortality tables drawn up by insurance companies. Life expectancy represents the average number of years that a group of persons, all born at the same time, might be expected to live, and it is based on the changing death rate over many past years.

The concept of life span implies that there is an individual whose existence has a definite beginning and end. What constitutes the individual in most cases presents no problem: among organisms that reproduce sexually the individual is a certain amount of living substance capable of maintaining itself alive and endowed with hereditary features that are in some measure unique. In some organisms, however, extensive and apparently indefinite growth takes place and reproduction may occur by division of a single parent organism, as in many protists, including bacteria, algae, and protozoans. If these divisions are incomplete, a colony results; if the parts separate, genetically identical organisms are formed. In order to consider life span in such organisms, the individual must be defined arbitrarily since the organisms are continually dividing. In a strict sense, the life spans in such instances are not comparable to those forms that are sexually produced.

The beginning of an organism can be defined by the formation of the fertilized egg in sexual forms; or by the physical separation of the new organism in asexual forms (many invertebrate animals and many plants). In animals generally, birth is considered to be the beginning of the life span. The timing of birth, however, is so different in various animals that it is only a poor criterion. In many marine invertebrates the hatchling larva consists of relatively few cells, not nearly so far along toward adulthood as a newborn mammal. For even among mammals, variations are considerable. A kangaroo at birth is about an inch long and must develop further in the pouch, hardly comparable to a newborn deer, who within minutes is walking about. If life spans of different kinds of organisms are to be compared, it is essential that these variations be accounted for. The end of an organisms existence results when irreversible changes have occurred to such an extent that the individual no longer actively retains its organization. There is thus a brief period during which it is impossible to say whether the organism is still alive, but this time is so short relative to the total length of life that it creates no great problem in determining life span.

Some organisms seem to be potentially immortal. Unless an accident puts an end to life, they appear to be fully capable of surviving indefinitely. This faculty has been attributed to certain fishes and reptiles, which appear to be capable of unlimited growth. Without examining the various causes of death in detail (see death) a distinction can be made between death as a result of internal changes (i.e., aging) and death as a result of some purely external factor, such as an accident. It is notable that the absence of aging processes is correlated with the absence of individuality. In other words, organisms in which the individual is difficult to define, as in colonial forms, appear not to age.

Plants grow old as surely as do animals. However, a generally accepted definition of age in plants has not yet been realized. If the age of an individual plant is that time interval between the reproductive process that gave rise to the individual and the death of the individual, the age attained may be given readily for some kinds of plants but not for others. The Table lists maximum ages, both estimated and verified, for some seed plants.

Maximum ages for some seed plants

An English oak that has 1,000 annual rings in the trunk is 1,000 years old. But age is less certain in the case of an arctic lupine that germinated from a seed that, containing the embryo, had been lying in a lemmings burrow in the arctic permafrost for 10,000 years.

The mushroom caps that appear overnight last for only a few days, but the network of fungus filaments in the soil (the mycelia) may be as old as 400 years. Because of important differences in structure, the life span of higher plants cannot be compared with that of higher animals. Normally, embryonic cells (that is, cells capable of changing in form or becoming specialized) cease to exist very early in the life of an animal. In plants, however, embryonic tissuethe plant meristemsmay contribute to growth and tissue formation for a much longer time, in some cases throughout the life of the plant. Thus the oldest known trees, bristlecone pines of California and Nevada, have one meristem (the cambium) that has been adding cells to the diameter of these trees for, in many cases, more than 4,000 years and another meristem (the apical) that has been adding cells to the length of these trees for the same period. These meristematic tissues are as old as the plant itself; they were formed in the embryo. The wood, bark, leaves and cones, however, live for only a few years. The wood of the trunk and roots, although dead, remains a part of the tree indefinitely, but the bark, leaves, and cones are continually in the process of dying and sloughing off.

Among the lower plants only a few mosses possess structures that enable an estimate of their age to be made. The haircap moss (Polytrichum) grows through its own stem tip each year, leaving a ring of scales that marks the annual growth. Three to five years growth in this moss is common, but life spans of 10 years have been recorded. The lower portions of such a moss are dead, though intact. Peat moss (Sphagnum) forms extensive growths that fill acid bogs with a peaty turf consisting of the dead lower portions of mosses whose living tops continue growing. Mosses that become encrusted with lime (calcium carbonate) and form tufa beds several metres thick also have living tips and dead lower portions. On the basis of their observed annual growth, some tufa mosses are estimated to have been growing for as long as 2,800 years.

No reliable method for determining the age of ferns exists, but on the basis of size attained and growth rate, some tree ferns are thought to be several decades old. Some club mosses, or lycopsids, have a storied growth pattern similar to that of the haircap moss. Under favourable conditions some specimens live five to seven years.

The woody seed plants, such as conifers and broadleaf trees, are the most amenable to determination of age. In temperate regions, where each years growth is brought to an end by cold or dryness, every growth period is limited by an annual ringa new layer of wood added to the diameter of the tree. These rings may be counted on the cut ends of a tree that has been felled or, using a special instrument, a cylinder of wood can be cut out and the growth rings counted and studied. In the far north growth rings are so close together that they are difficult to count. In the moist tropics growth is more or less continuous, so that clearly defined rings are difficult to find.

Often the age of a tree is estimated on the basis of its diameter, especially when the average annual increase in diameter is known. The source of greatest error in this method is the not infrequent fusing of the trunks of more than one tree, as, for example, occurred in a Montezuma cypress in Santa Mara del Tule, a little Mexican village near Oaxaca. This tree, described by the Spanish explorer Hernan Corts in the early 1500s, was earlier estimated on the basis of its great thickness to be 6,000 years old; later studies, however, proved it to be three trees grown together. Estimates of the age of some English yews have been as high as 3,000 years, but these figures, too, have turned out to be based on the fusion of close-growing trunks, none of which is more than 250 years old. Increment borings of bristlecone pines have shown specimens in the western United States to be 4,600 years old.

Plants, usually herbaceous, that live for only one growing season and produce flowers and seeds in that time are called annuals. They may be represented by such plants as corn and marigolds, which spend a period of a few weeks to a few months rapidly accumulating food materials. As a result of hormonal changesbrought about in many plants by changes in environmental factors such as day length and temperatureleaf-producing tissues change abruptly to flower-producing ones. The formation of flowers, fruits, and seeds rapidly depletes food reserves and the vegetative portion of the plant usually dies. Although the exhaustion of food reserves often accompanies death of the plant, it is not necessarily the cause of death.

These plants, too, are usually herbaceous. They live for two growing seasons. During the first season, food is accumulated, usually in a thickened root (beets, carrots); flowering occurs in the second season. As in annuals, flowering exhausts the food reserves, and the plants die after the seeds mature.

These plants have a life span of several to many years. Some are herbaceous (iris, delphinium), others are shrubs or trees. The perennials differ from the above-mentioned groups in that the storage structures are either permanent or are renewed each year. Perennials require from one to many years growth before flowering. The preflowering (juvenile) period is usually shorter in trees and shrubs with shorter life spans than in those with longer life spans. The long-lived beech tree (Fagus sylvatica), for example, passes 3040 years in the juvenile stage, during which time there is rapid growth but no flowering.

Some plantscotton and tomatoes, for exampleare perennials in their native tropical regions but are capable of blooming and producing fruits, seeds, or other useful parts in their first year. Such plants are often grown as annuals in the temperate zones.

Although there is great variety in the longevity of seeds, the dormant embryo plant contained within the seed will lose its viability (ability to grow) if germination fails to occur within a certain time. Reports of the sprouting of wheat taken from Egyptian tombs are unfounded, but some seeds do retain their viability a long time. Indian lotus seeds (actually fruits) have the longest known retention of viability. On the other hand, seeds of some willows lose their ability to germinate within a week after they have reached maturity.

The loss of viability of seeds in storage, although hastened or retarded by environmental factors, is the result of changes that take place within the seed itself. The changes that have been investigated are: exhaustion of food supply; gradual denaturing or loss of vital structure by protoplasmic proteins; breakdown of enzymes; accumulation of toxins resulting from the metabolism of the seed. Some self-produced toxins may cause mutations that hamper seed germination. Since seeds of different species vary greatly in structure, physiology, and life history, no single set of age factors can apply to all seeds.

Much of what is known of the length of life of animals other than man derives from observations of domesticated species in laboratories and zoos. One has only to consider how few animals reveal their age to appreciate the difficulties involved in answering the apparently simple question of how long they live in nature. In many fishes, a few kinds of clams, and an occasional species of other groups, growth is seasonal, so that annual zones of growth, much like tree rings, are produced in some part of the organism. Among game species, methods of determining relative age by indicators such as the amount of tooth wear or changes in bone structure have yielded valuable information. Bird bands and other identifying marks also make age estimation possible. But one of the consequences of the fact that animals move is that very little is known about the life span of most species as they exist in nature.

The extreme claims of longevity that are occasionally made for one species or another have consistently been proven false when subjected to critical scrutiny. Although the maximum life span that has been observed for a particular species cannot be considered absolute, since a limited number of individuals at best has been studied, this datum probably provides a fair approximation of the greatest age attainable for this kind of animal under favourable conditions. Animals in captivity, which provide most of the records of extreme age, are exposed to far fewer hazards than those in the wild. In the accompanying table of maximum longevity, particular species have been so selected as to encompass the known range of longevity of other members of the taxonomic group to which they belong.

Maximum longevity of animals in captivity

Life span usually is measured in units of time. Although this may seem eminently logical, certain difficulties may arise. In cold-blooded animals in general, the rate of metabolism that determines the various life processes varies with the temperatures to which they are exposed. If aging depends on the expenditure of a fixed amount of vital energy, an idea first proposed in 1908, life span will vary tremendously depending on temperature or other external variables that influence life span. There is considerable evidence attesting at least to the partial cogency of this argument. So long as a certain range is not exceeded, cold-blooded invertebrates do live longer at low than at high temperatures. Rats in the laboratory live longest on a somewhat restricted diet that does not permit maximum metabolic rate. Of perhaps even greater significance is the fact that many animals undergo dormant periods. Many small mammals hibernate; a number of arthropods have life cycles that include periods during which development is arrested. Under both conditions the metabolic rate becomes very low. It is questionable whether such periods should be included in computing the life span of a particular organism. Comparisons between species, some of which have such inactive periods while others do not, are dangerous. It is possible that life span could be measured more adequately by total metabolism; however, the data that are necessary for this purpose are almost entirely lacking.

Length of life is controlled by a multitude of factors, which collectively may be termed environment, operating on a genetic system that determines how the individual will respond. It is impossible to list all the environmental factors that may lead to death. For analytical purposes it is, however, useful to make certain formal separations. Every animal is exposed to (1) a pattern of numerous events, each with a certain probability of killing the individual at any moment and, in the aggregate, causing a total probability of death or survival; (2) climatic and other changes in the habitat, modifying the frequency with which the various potentially fatal events occur; and (3) progressive systemic change, inasmuch as growth, reproduction, development, and senescence are characteristics intrinsic in the organism and capable of modifying the effects of various environmental factors.

Consider a group of similar animals of the same age. Although no two individuals can have precisely the same environment, let it be assumed that the environment of the group remains effectively constant. If the animals undergo no progressive physiological changes, the factors causing death will produce a death rate that will remain constant in time. Under these conditions, it will take the same amount of time for the population to become reduced to one-half its former number, no matter how many animals remain at the beginning of the period considered. The animals therefore survive according to the pattern of an accident curve. This is the sense in which many of the lower animals are immortal. Although they die, they do not age; how long they have already lived has no influence on their further life expectation.

Another group of animals may consist of individuals that differ markedly in their responses to the constant environment. They may be genetically different, or their previous development may have caused variations to arise. Those individuals that are most poorly suited to the new environment will die, leaving survivors that are better adapted. The same result can also be achieved in other ways. If the environment varies geographically, those individuals that happen to find areas in which existence can be maintained will survive, while the remainder will die. Or, as a result of their own properties, animals in a constant environment may acclimate in a variety of ways, thus adjusting to the existing conditions. The pattern of survival that results in each of these cases is one in which the death rate declines with time, as illustrated by the selectionacclimation curve.

In the absence of death from other causes, all members of a population may exist in their environment until the onset of senescence, which will cause a decline in the ability of individuals to survive. In a sense they can be considered to wear out as does a machine. Their survival is best described by individual differences among members of the population that determine the curvature of the survival line (wearing-out curve). The more the population varies, the less abrupt is the transition from total survival to total death.

Under the actual conditions of existence of animals the three types of survival (accident pattern, selectionacclimation pattern, wearing-out pattern) above all enter as components of the realized survival pattern. Thus in animals that are carefully maintained in the laboratory, survival is approximately that of the wearing-out pattern. Environmental accidents can be kept to a minimum under these conditions, and survival is almost complete during the major part of the life span. In all known cases, however, the early stages of the life span are characterized by a noticeable contribution of the selectionacclimation pattern. This must be interpreted as a result of developmental changes that accompany the early life of the individuals and of selective processes that operate on those organisms whose genetic constitutions are ill fitted for that environment.

In some of the larger mammals in nature, the existing evidence points to a similar survival pattern. In a variety of other animals, however, and including fishes and invertebrates, mortality in the young stages is so high that the selectionacclimation curve predominates. One estimate places the mortality of the Atlantic mackerel during its first 90 days of life as high as 99.9996 percent. Since some mackerel do live for several years, a mortality rate that decreases with age is indicated. Similar considerations probably apply to all those animals that have larval stages that serve as dispersal mechanisms.

When the postjuvenile portion of the life span is considered by itself, a number of animals for which such information has been gatheredincluding primarily fishes and birdshave survivorship curves that are dominated by the accident pattern. In these species in nature, death from old age apparently is rare. Their chance of surviving to an advanced age is so small that it may be statistically negligible. In modern times, human predation is a large factor in the mortality of these species in many cases. Since deaths from fishing and hunting are largely independent of age, once an animal has reached a certain minimum size, such a factor only makes the survival curve steeper but does not change its shape. One consequence of such increased mortality is that fewer old and large individuals are noticed in a population.

More complex survival patterns, such as the hypothetical one illustrated, undoubtedly exist. They should be looked for in those species in which extensive reorganization of the animal is part of the normal life cycle. In effect, these animals change their environment radically, in some cases several times during a lifetime. The frog offers a familiar example. During its period of early development and until shortly after hatching, the animal is subject to major internal, and some external, change. As a tadpole it is adjusted to an aquatic, herbivorous life. The metamorphosis to the terrestrial, carnivorous adult form is accompanied by varied physiological stresses that must be expected to produce a temporary increase in mortality rate. In some insects the eggs, larvae, pupae, and adults are exposed to and respond to quite different environments, and a survivorship pattern even more complex than that described by the composite curve may exist.

The same species will exhibit changed survival in different environments. In captivity an animal population may approach the wearing-out pattern; in its natural habitat survivorship may vary with age in a quite different way. Although one can assign a maximum potential life span to an individualwhile realizing that this maximum may not be attainedit is impossible to specify the survivorship pattern unless the environment is also specified. This is another way of saying that life span is the joint property of the animal and the environment in which it lives.

Corrections? Updates? Help us improve this article! Contact our editors with your Feedback.

Read more from the original source:
life span | Britannica.com

Read More...

stemcellbioethics – Legal and Political History of Stem …

Thursday, August 4th, 2016

The legal battle began in 1973 when the Supreme Court ruled in Roe v. Wade that a fetus in the mothers uterus is not considered a person with rights under the Fourteenth Amendment (US Supreme Court, Roe V. Wade, 1973). Many assumed that this ruling would extend to embryos outside the mothers uterus (Wilberforce, Forsythe et al. 2011). In addition, there was an attempt to understand the implications for how states might limit the practice of the destruction of embryos, as they did with abortion, out of an interest in protecting potential life. While indeed, some states have enacted restrictions, the court has yet to issue a ruling on the status of embryos outside the mothers uterus.

Courts recently entered the debate to address assertions that federal funding of hESC research is in violation of the Dickey-Wicker Amendment. Return to Top

Given that the acceptability of hESC research hinges on the issue of destroying early embryos, the discussion was quickly drawn into the well-rehearsed abortion debates that have long occupied the American conscience (Robertson 2010). As such, political lines were similarly drawn, with the more conservative-minded opposing abortion and hESC research, and the more liberal-minded in favor. Political and social divisions regarding hESC research and abortion may be rooted more in differences in religious ideologies. Return to Top

With the midterm elections of 1994, however, Republicans regained control of Congress, and progress toward the start of embryo research was slowed due to pressure from the new conservative majority.

In 1996, an additional concept was added in the amendment indicating that all federal funding in support of research with human embryos is illegal. Moreover, the Dickey-Wicker amendment defines embryos as any organism, not protected as a human subject under 45 CFR 46. The Dickey-Wicker Amendment provides that no federal funds can be expended by the National Institutes of Health (NIH) for:

With the first derivation of human embryonic stem cell (hESC) lines in 1998 (toward the end of the Clinton administration), the question became whether funding of research on hESCs would be in violation of the Dickey-Wicker amendment.

Roger F. Wicker (1951 - ) the 1st term Republican junior senator of Mississippi who was appointed by then- Governor Haley Barbour in 2007 to fill the seat vacated by Trent Lott, the former Senator. In a 2008 special election, Wicker won for the remainder of Lotts term. Wicker is also known for the appropriations bill, the Dickey-Wicker Amendment, which he co-sponsored while representing Mississippis conservative 1st congressional district (1995 to 2007) prior to his Senate post (Congress 2007).

The first was to draw a distinction between the creation of hESC lines and research using those lines; she maintained that if the derivation of the lines was privately funded, federal funding of later research would not pose a problem regarding the creation of embryos.

As to the second issue related to the destruction of embryos during the research, she further argued that the Dickey-Wicker amendment specifically referred to the embryos in question as organisms, and embryonic stem cells, in her opinion, were not legally organisms because they cannot develop into viable embryos outside a womans uterus or, once cultured as stem cells, even inside the uterus (Marshall 1999; Dunn 2005).

Given the legal opinion of Harriet Rabb that established Clinton Administration policy about funding of hESC research, the NIH then began to develop guidelines to fund research, and was ready to begin issuing grants.

President George W. Bush adopted a more conservative variation of Harriet Rabbs approach. In his first public address regarding a human embryonic stem cell (hESC) policy, he announced that human ESC research would be allowed to go forward, but only on stem cell lines derived prior to August 9, 2001, the date of his address (Bush 2001). This approach was remarkable, seeming to favor hESC research while at the same time limiting it.

The policy proved to be more restrictive than it initially seemed. While between 60 and 70 lines had been previously derived and were available for use, over the duration of President Bushs two terms in office, only 21 lines proved viable, greatly reducing access to the basic material needed to conduct stem cell research.

In 2006, in an effort to overturn the funding ban, the Senate passed a bill allowing funding of research on lines derived after 2001, but President Bush vetoed the bill. He vetoed a similar bill the following year in 2007.

While the restriction of federal funding for hESC funding served to limit embryo research because the blastocyst must be destroyed to obtain the stem cells, embryo research actively continued with private and certain state funding (e.g., California). Moreover, despite its intent to limit research, the restriction served as an impetus for researchers to focus their efforts on novel ways to create stem cells using adult cells that did not require destruction of the embryo (Loike and Fischbach 2009).

The restrictions on stem cell research also resulted in many scientists changing research direction or going abroad to be able to continue their work. Some states like California and New York allocated substantial state and private funds in order to provide strong opportunities for scientists and to establish their states leadership in stem cell science.

The development of induced pluripotent stem (iPS) cells, as well as the use of adult stem cell sources such as cord blood, amniotic fluid, adipose tissue, and bone marrow have led to promising developments. Scientists have been able to do with adult stem cells many of the things they might have done with embryonic stem cells, while avoiding the controversial and divisive destruction of human embryos.

Political conservative Nancy Reagan (pictured left with President Reagan) has advocated in favor of embryonic stem cell science to address Alzheimers disease, which afflicted her late husband, former President Ronald Reagan.

Return to Top

President Obama signed an order reversing the Bush administration's strict limits on human embryonic stem cell research. (See the New York Times Topics - Stem Cells)

In 2009, a few weeks after the new NIH guidelines went into effect, a group of plaintiffs that included two adult stem cell researchers (James Sherley and Theresa Deisher), an embryo adoption agency, and actual embryos, filed a lawsuit against the Department of Health and Human Services and the NIH, insisting that federal funding of human ESC research is in violation of the Dickey-Wicker Amendment (contradicting Harriet Rabbs interpretation of a decade earlier). The case was initially dismissed by Chief Judge Royce Lamberth, but after an appeal, his ruling was reversed and the case was sent back to him for reconsideration regarding the competitive standing of Sherley and Deisher. (Vogel and Couzin-Frankel 2011).

With the Lamberth ruling, the NIH scrambled to put on hold new grants and renewals while struggling to fund all existing human embryonic stem cell research it supported, waiting for the Justice Department to appeal the ruling.

In September of 2010, after having been denied by the court a motion to stay the preliminary injunction, the Department of Justice filed an emergency motion with the Court of Appeals again to stay the injunction (United-States-Court-of-Appeals-for-the-DC-Circuit 2010). The Washington DC Appellate Court then blocked the temporary injunction of Judge Lamberth which has allowed funding of hESC research to continue in the interim, following the guidelines developed by the NIH.

In what may be the final word, at least as of 2011, Judge Lamberth, on July 27th, issued a ruling that the US government can continue funding embryonic stem cell research. This decision threw out the 2009 lawsuit by researchers Sherley and Deisher that had challenged President Obamas expansion of funding. The Judges latest decision came after the D.C. Circuit of Appeals removed his temporary injunction of such grants.

Lamberth stated in his opinion that the Appeals Court decision constrains this court which compelled him to dismiss the researchers challenge. Importantly, the Judge ruled that allowing federal funding for research using stem cells created using private funds is not a violation of the Dickey-Wicker Amendment because such research is not research in which a human embryo or embryos are destroyed (Bohan, 2011).

Click here to download the Lamberth Ruling (via nature.com).

Scientists involved in embryonic stem cell research applauded Lamberths ruling. We clearly think its the right decision, said Dr. Jonathan Thomas of the California Institute for Regenerative Medicine. It will now lift the cloud thats been hanging over researchers around the country (Bohan, 2011)

The Lamberth ruling is a big relief for many scientists who have been anxious about their NIH funding. For the 2011 fiscal year, the NIH estimated that $358 million of its budget would go toward human non-embryonic stem cell research and $126 million would go toward human embryonic stem cell research (http://www.aaas.org/spp/cstc/briefs/stemcells).

But Dr. David Prentice, a senior fellow for Life Sciences at the conservative Family Research Council, called the Lamberth July 2011 ruling unfortunate, saying that it allowed the flow of taxpayer funds to continue for this unethical, scientifically unworthy embryonic stem cell research. He added that it was also a sad day for patients, because it is not embryonic stem cells, but only adult stem cells that are currently treating patients and offering real hope for the future. (Bohan, 2011)

Informal Online Poll Results (Phillips, 2010)

Return to Top

Read the original post:
stemcellbioethics - Legal and Political History of Stem ...

Read More...

Recognizing Early Arthritis Symptoms

Thursday, August 4th, 2016

Early arthritis symptoms can be vague and confusing, but they are important to recognize. Newly diagnosed arthritis patients quickly realize that early symptoms are just the first layer to be uncovered before a definitive diagnosis and treatment plan can be established.

Early symptoms linked to arthritis usually include:

Though early symptoms are the first indication of an arthritic condition, there is much more information which needs to be gathered. There are more than 100 types of arthritis and related rheumatic conditions. For a patient to obtain a specific diagnosis (i.e., the specific type of arthritis), a doctor must evaluate the patient's:

Together, the criteria formulate a clinical picture which must be routinely re-assessed by your doctor. It's important for you to learn the major differences between the various types of arthritis. An understanding of the primary characteristics associated with each type of arthritis will help you recognize what is and is not important to report to your doctor with regard to your own condition.

A basic knowledge of the major types of arthritis and symptoms also will better prepare you for doctor appointments. You will find it easier to formulate questions and communicate with your doctor once you are confident that you understand basic facts about arthritis symptoms.

Rheumatoid Arthritis

Rheumatoid arthritis is an inflammatory type of arthritis. The joints are primarily affected, but there can be systemic effects (i.e. organs) as well. Morning stiffness lasting more than an hour, involvement of the small bones of the hands and feet, extreme fatigue, rheumatoid nodules, and symmetrical joint involvement (i.e. both knees not one knee) are all characteristics of rheumatoid arthritis.

Osteoarthritis

Osteoarthritis predominantly affects the joints, unlike other types of arthritis which may have systemic effects. The most common symptom associated with osteoarthritis is pain in the affected joint after repeated use. Joint pain is often worse later in the day. The affected joints can swell, feel warm, and become stiff after prolonged inactivity. Osteoarthritis can occur with other forms of arthritis simultaneously. Bone spurs and bony enlargements are also characteristic of osteoarthritis.

Psoriatic Arthritis

Psoriatic arthritis is a type of arthritis associated with psoriasis (a skin condition characterized by red, patchy, raised, or scaly areas) and chronic joint symptoms. The symptoms of psoriasis and joint inflammation often develop separately. Symptoms associated with psoriatic arthritis vary in how they occur (i.e. symmetrical or asymmetrical) and what joints are affected. Any joint in the body can be affected. When psoriasis causes pitting and thickened or discolored fingernails, the joints nearest the fingertips are likely to become arthritic.

Ankylosing Spondylitis

Ankylosing spondylitis is commonly associated with inflammation which starts at the lower spine or sacroiliac joints. The earliest symptoms are often chronic pain and stiffness in the lower back region and hips. Typical ankylosing spondylitis pain in the back worsens following rest or inactivity. As symptoms of pain and stiffness progress up the spine to the neck, possibly including the rib cage area, bones may fuse.

Lupus

Lupus can affect the joints, skin, kidneys, lungs, heart, nervous system, and other organs of the body. It is not uncommon for symptoms associated with lupus to resemble symptoms associated with other types of arthritis and rheumatic disease, making lupus difficult to diagnose. A butterfly-shaped rash appearing on the cheeks and over the bridge of the nose (malar rash) is just one of the distinguishing characteristics of lupus.

Gout

Gout is considered one of the most intensely painful types of arthritis. Gout is characterized by sudden onset of severe pain, tenderness, warmth, redness, and swelling from inflammation of the affected joint. Gout usually affects a single joint, and most often the big toe is affected. The knee, ankle, foot, hand, wrist, and elbow may also be affected. Shoulders, hips, and spine may eventually be affected by gout, but rarely. Often the first gout attack occurs at night.

There are other types of arthritis and joint inflammation conditions to consider as well:

As you learn about them, you and your doctor will decide which of your symptoms matches the diagnostic scheme of a particular type of arthritis. The process of identifying a specific type of arthritis is not always quick. Individual symptoms and symptom patterns can make diagnosing arthritis tricky. Being aware of early symptoms is a definite advantage, however.

Sources:

Kelley's Textbook of Rheumatology. Elsevier. Ninth edition.

Arthritis Foundation, Diseases and Conditions. http://www.arthritis.org

American College of Rheumatology. Diseases. http://www.rheumatology.org

2016 About, Inc. All rights reserved.

Link:
Recognizing Early Arthritis Symptoms

Read More...

National Human Genome Research Institute (NHGRI) – Homepage

Thursday, August 4th, 2016

New NIH studies seek adults and families affected by sickle cell disease/trait People with sickle cell disease (SCD) can experience excruciating pain, kidney problems, a higher risk of stroke and, in rare cases, chronic leg ulcers. Little is known about why the severity of these symptoms varies throughout a lifetime or why these symptoms differ from person to person. NHGRI researchers are seeking help from people affected by SCD to find the factors - environmental, social and genetic - that impact the severity of the symptoms. Read more Investigational Device Exemptions (IDE) and Genomics Workshop On Friday, June 10, 2016, the National Human Genome Research Institute (NHGRI) hosted the Investigational Device Exemptions (IDE) and Genomics Workshop. The workshop brought together perspectives from investigators, institutional review boards (IRB), the FDA and NHGRI on how to determine if a study requires an IDE, and how to fulfill IDE requirements if the FDA should require an IDE for research involving the use of genomic technologies, including next-generation sequencing (NGS). View agenda The Genomics Landscape Clinical Sequencing: Beyond Exploration The Genomics Landscape for June features exciting developments with NHGRI's Clinical Sequencing Exploratory Research Program. We also highlight the new director of the National Library of Medicine, recently funded studies on the ethical, legal and social implications of genomic information, the final seminar commemorating the 25th anniversary of the launch of the Human Genome Project and available online videos for genome analysis lectures. Read more Bacterial toxins make the body go boom By outward appearances, plants and animals don't seem to have much in common. When it comes to their immune systems, however, they might be more similar than their exteriors suggest. Researchers at the National Human Genome Research Institute have discovered an immune mechanism in humans, known as a "guard" mechanism, which was once thought to exist only in plants. They've published their results in the June 6 online journal Nature Immunology. Read more Perspective: Precision medicine may move us beyond the use of race in prescribing drugs Health care providers have long struggled with considering race when prescribing and dosing medications. In a May 26 New England Journal of Medicine perspective, Vence L. Bonham, J.D., an investigator with NHGRI's Social and Behavioral Research Branch, and his colleagues, are asking if the precision medicine approach will reduce or eliminate the role that race plays in prescribing drugs and in health care overall. Read more

See original here:
National Human Genome Research Institute (NHGRI) - Homepage

Read More...

Stem Cell Therapy in Mexico for Chronic Heart Failure …

Thursday, August 4th, 2016

Home Blogs Stem Cell Treatment Mexico Stem Cell Therapy in Mexico for Chronic Heart Failure

Stem cell therapy in Mexico for chronic heart failure can help reduce the risk of heart attack at an affordable price. Though heart stem cell treatment in Mexico is yet to find many takers, patients will be glad to know that the Latin American country is home to numerous state-of-the art hospitals offering stem cell therapy.

Medical tourism in Mexicois a growing industry and one can undergo quality, yet affordable treatments in the country.

The study showed that patients with low-functioning hearts could improve their condition with the help of ACP stem cell therapy, which is also available in Mexico.

Management of congestive heart failure in Mexico is a good alternative to undergoing treatment in the developed countries of the world. Some of the reasons why patients choose stem cell therapy for chronic heart failure in Mexico are as follows:

Stem cell therapy in Mexico for chronic heart failure can be a low cost solution to leading a healthier life. And if you are an American or a Canadian, all you need to do is a bit of traveling for getting treated at a state-of-the-art facility.

Submit the free quote request form on the right for more information.

Continue reading here:
Stem Cell Therapy in Mexico for Chronic Heart Failure ...

Read More...

Stem cell therapy gives hope to MS patients | Society …

Thursday, August 4th, 2016

Adult stem cells stored at a laboratory. A new treatment led to long-standing remission for MS patients. Photograph: MedicImage/Alamy

A radical and risky stem cell therapy has been shown to halt and even reverse some of the symptoms of those worst affected by multiple sclerosis, a disease that in many people has proved untreatable.

Doctors in Canada conducted an experimental stem cell transplant with 24 patients who were expected to be confined to a wheelchair within 10 years. After receiving the treatment most of the patients regained control of their lives, becoming able to walk, play sport and drive.

To succeed, the transplant required the destruction and rebooting of each persons immune system such a high risk approach that one of the patients died. But the others, followed up for between four and 13 years, had no further progression of the disease. The disease normally entails worsening symptoms over time.

To the surprise of their doctors, some patients recovered functions that had been eroded by the disease, including their sight and balance. Six returned to work or college, five married or became engaged and two had children using banked sperm or eggs, as the aggressive treatment had made them infertile.

Mark Freedman, a neurologist at the University of Ottawa, who co-led the trial, said he would not say his patients were cured. I hesitate to use the c-word. A cure would be stopping all disease moving forward and repairing all damage that has occurred. As far as we can ascertain no new damage seems to occur beyond the treatment and patients dont need to take any medication, so in that sense I think it has induced a long-standing remission. Some patients did recover substantial function and it allowed them to do things they couldnt do for years, but others did not.

However, the long-term results of the trial in Canada, published in the Lancet medical journal, have been universally applauded by scientists and support groups and will lead to a worldwide clamour for the transplants to be more widely available.

Stephen Minger, a stem cell biologist and independent consultant, said: The clinical results are truly impressive, in some cases close to being curative, though we need longer-term follow-up to know for certain whether the patients continue to do well or if there is a chance of relapse. And of course this trial will need replication by other groups too.

For a life-long progressive disease like MS with few treatment options this is really exciting data. It offers the hope of having a long-lasting treatment which may halt disease progression though, again, this is a very invasive therapy and not without risks. Still I would consider it a breakthrough therapy, and the clinical group and the patients should be congratulated for this success.

The doctors say this treatment is not for everyone with MS because of the dangers. Modern drugs can control the symptoms for most people with the disease, but they do not work in people who have a sudden onset of very aggressive disease with frequent relapses. Freedman said the transplants they had been doing in Ontario were suitable for perhaps 5-10% of MS patients. It is needless if the disease can be controlled with mild medicines that dont carry those kind of risks, he said.

Multiple sclerosis is caused by a malfunction of the immune system, which ordinarily defends the body against bacteria, viruses and disease. The disease attacks instead the insulating myelin sheath, which is essential for the proper functioning of the nervous system. Those who are badly affected, usually young, progressively lose the ability to control their limbs.

Stem cell transplants have been carried out before in MS patients, but those people had a relapse after a couple of years. Never before have doctors used the aggressive drug regimen used in Canada a therapy that totally destroys the immune system, putting patients at risk for a while from life-threatening infections.

The patient in the transplant group who died suffered very severe liver damage and a bacterial infection which caused sepsis, or blood poisoning.

In the process, the Canadian doctors removed stem cells from the bone marrow of the patients and processed these in a laboratory. They then used a combination of three toxic drugs to destroy each patients immune system before transplanting the cleaned-up stem cells in to the body.

There were some fairly profound and wonderful changes that some of them experienced, said Freedman. Some people hadnt walked and started walking. Some people who had lost their vision were seeing. More than half the patients returned to gainful employment, maintained their relationships, got back their drivers licence.

Some, however, had disease that was progressing like a runaway train, he said. They continued to get worse for a couple of years but then their disease also stopped progressing. But nobody developed any new inflammation at all, he said. Their brain scans showed no new lesions, he added.

People with MS have been going to clinics in Mexico and elsewhere in the world in search of stem cell treatments they hope will turn out to bring a cure. But doctors emphasised that the regimen used in Canada, being very dangerous, had to be restricted to very specialised centres, and needed to be tested in more people before it became more widely available.

In the UK, Paolo Muraro, a neurologist at Imperial College London, who met Freedman last week to discuss the results, is hoping to start his own international trial, involving about 180 people with MS. That trial would try a slightly less intense drug regime in the hope of reducing the risks, he said. He was still seeking funding for it and said the treatment might have been more widely available by now if it had been a drug.

Related: 'It was really the last option': one woman's multiple sclerosis recovery

The treatment does not rely on any proprietary drug, so it is not a treatment that has received any support from the pharmaceutical industry. People like Mark Freedman and myself have had to work with very limited resources to try to develop this treatment really from charitable funding and academia-driven units.

The Canadian results were indeed very good news, he said, although, he added, it was important to avoid raising false hopes, because of the risks and the need for more trials.

The study in Ontario was funded by the MS Society of Canada. Charities in the UK also welcomed the findings but warned that people with MS who might think of having a stem cell transplant should speak to their doctor.

Emma Gray, head of clinical trials at the MS Society, said: This treatment does offer hope, but its also an aggressive procedure that comes with substantial risks and requires specialist aftercare. If anyone is considering [a stem cell transplant] wed recommend they speak to their neurologist.

Amy Bowen, at the Multiple Sclerosis Trust, said the results were extremely interesting and encouraging. She added: Stem cell therapy is still very experimental, and is not suitable for everyone. However, it could be a potentially very effective therapy, holding great promise for people living with MS. Its also a long way from being a routine treatment for MS.

Read the original here:
Stem cell therapy gives hope to MS patients | Society ...

Read More...

Risky stem cell treatment reverses MS in 70% of patients …

Thursday, August 4th, 2016

MS brain lesion as seen on an MRI.

By obliterating the broken immune systems of patients with severe forms of multiple sclerosis, then sowing fresh, defect-free systems with transplanted stem cells, researchers can thwart the degenerative autoimmune diseasebut it comes at a price.

In a small phase II trial of 24 MS patients, the treatment halted or reversed the disease in 70 percent of patients for three years after the transplant. Eight patients saw that improvement last for seven and a half years, researchers report in the Lancet. This means that some of those patients went from being wheelchair-bound to walking and being active again. But to reach that success, many suffered through severe side effects, such as life threatening infections and organ damage from toxicity brought on by the aggressive chemotherapy required to annihilate the bodys immune system. One patient died from complications of the treatment, which represents a four percent fatality rate.

Moreover, while the risks may be worthwhile to some patients with rapidly progressing forms of MSa small percentage of MS patientsthe researchers also caution that the trial was small and did not include a control group.

Larger clinical trials will be important to confirm these results, study coauthor Mark Freedman of University of Ottawa said in a statement. Since this is an aggressive treatment, the potential benefits should be weighed against the risks of serious complications associated with [this stem cell transplant], and this treatment should only be offered in specialist centres experienced both in multiple sclerosis treatment and stem cell therapy, or as part of a clinical trial, he added.

Similar treatments have been used before in other trials, which also showed positivethough not as dramaticresults. Generally, researchers start by harvesting a patients haematopoietic stem cells, which give rise to the bodys immune system. Then researchers use chemotherapy to knock back the patients misbehaving immune system. In MS patients, defective immune responses rip off the insulation from nerve cells in the brain and spinal cord, causing inflammation, lesions, and nerve damage that eventually lead to physical and mental disabilities. The disease can progress in bouts over decades or continuously over months.

With that defective immune system weakened, researchers can replace the patient's stem cells, which are distant enough predecessors that they don't carry the glitches that trigger MS. Thus, they can potentially spawn a flaw-free immune system.

Freedman and colleagues took this general treatment strategy a step further by not just knocking back the patients defective immune system, but byannihilating it completely with a cocktail of powerful drugs.

It's important to stress that this is a very early study, Stephen Minger, a stem cell biologist not involved with the study, told the BBC. Nevertheless, the clinical results are truly impressive, in some cases close to being curative.

Freedman added that future research will be geared not only to replicating the results in larger trials, but to figuring out how to make it safer for patients.

Lancet, 2016. DOI: 10.1016/S0140-6736(16)30169-6 (About DOIs).

Follow this link:
Risky stem cell treatment reverses MS in 70% of patients ...

Read More...

Worlds leading Stem Cell Conference | Global Meetings …

Thursday, August 4th, 2016

Conference Series LLCinvites all the participants from all over the world to attend '8th World Congress on Cell & Stem Cell Research during March 20-22, 2017 in Orlando, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Stem cellsare cells originate in all multi-cellular organisms. They were isolated in mice in 1981 and in humans in 1998. In humans there are several types of stem cells, each with variable levels of potency. Stem cell treatments are a type of cell therapy that introduces new cells into adult bodies for possible treatment of cancer, diabetes, neurological disorders and other medical conditions. Stem cells have been used to repair tissue damaged by disease or age.

Objective

Stem Cell Research-2017 has the platform to fulfill the prevailing gaps in the transformation of this science of hope, to serve promptly with solutions to all in the need. Stem Cell Research 2017 will have an anticipated participation of 120+ delegates across the world to discuss the conference goal.

Success Story: Cell Science Conference Series

The success of the Cell Science conference series has given us the prospect to bring the gathering inOrlando,USA. Since its commencement in 2011 Cell Science series has witnessed around 750 researchers of great potentials and outstanding research presentations from around the world. Awareness of stem cells and its application is becoming popular among the general population. Parallel offers of hope add woes to the researchers of cell science due to the potential limitations experienced in the real-time.

About Organizers

Conference Series LLCis one of the leadingOpen Access publishersand organizers of international scientificconferences and events every year across USA, Europe & Asia Conference Series LLChas so far organized 3000+Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business with 700+ peer-reviewed open accessjournalsin basic science, health, and technology. OMICS International is also in association with more than 1000 International scientific and technological societies and associations and a team of 30,000 eminent scholars, reputed scientists as editorial board members.

Scientific Sessions

Stem Cell Research-2017 will encompass recent researches and findings in stem cell technologies, stem cell therapies and transplantations, current understanding of cell plasticity in cancer and other advancements in stem cell research and cell science.Stem Cell Research-2017 will be a great platform for research scientists and young researchers to share their current findings in this field of applied science. The major scientific sessions in Stem Cell Research-2017will focus on the latest and exciting innovations in prominent areas of cell science and stem cell research.

Target Audience:

Eminent personalities, Directors, CEO, President, Vice-president, Organizations, Associations heads and Professors, Research scientists, Stem Cell laboratory heads, Post-docs, Students other affiliates related to the area of Stem cell research, stem cell line companies can be as Target Audience.

8th World Congress on Cell & Stem Cell Research

The success of the 7 Cell Science conferences series has given us the prospect to bring the gathering one more time for our 8thWorld Congress 2017 meet in Orlando, USA. Since its commencement in 2011 cell science series has perceived around 750 researchers of great potentials and outstanding research presentations around the globe. The awareness of stem cells and its application is increasing among the general population that also in parallel offers hope and add woes to the researchers of cell science due to the potential limitations experienced in the real-time.

Stem Cell Research-2017has the goal to fill the prevailing gaps in the transformation of this science of hope to promptly serve solutions to all in the need.World Congress 2017 will have an anticipated participation of 100-120 delegates from around the world to discuss the conference goal.

History of Stem cells Research

Stem cells have an interesting history, in the mid-1800s it was revealed that cells were basically the building blocks of life and that some cells had the ability to produce other cells. Efforts were made to fertilize mammalian eggs outside of the human body and in the early 1900s, it was discovered that some cells had the capacity to generate blood cells. In 1968, the first bone marrow transplant was achieved successfully to treat two siblings with severe combined immunodeficiency. Other significant events in stem cell research include:

1978: Stem cells were discovered in human cord blood 1981: First in vitro stem cell line developed from mice 1988: Embryonic stem cell lines created from a hamster 1995: First embryonic stem cell line derived from a primate 1997: Cloned lamb from stem cells 1997: Leukaemia origin found as haematopoietic stem cell, indicating possible proof of cancer stem cells

Funding in USA:

No federal law forever did embargo stem cell research in the United States, but only placed restrictions on funding and use, under Congress's power to spend. By executive order on March 9, 2009, President Barack Obama removed certain restrictions on federal funding for research involving new lines of humanembryonic stem cells. Prior to President Obama's executive order, federal funding was limited to non-embryonic stem cell research and embryonic stem cell research based uponembryonic stem celllines in existence prior to August 9, 2001. In 2011, a United States District Court "threw out a lawsuit that challenged the use of federal funds for embryonic stem cell research.

Members Associated with Stem Cell Research:

Discussion on Development, Regeneration, and Stem Cell Biology takes an interdisciplinary approach to understanding the fundamental question of how a single cell, the fertilized egg, ultimately produces a complex fully patterned adult organism, as well as the intimately related question of how adult structures regenerate. Stem cells play critical roles both during embryonic development and in later renewal and repair. More than 65 faculties in Philadelphia from both basic science and clinical departments in the Division of Biological Sciences belong to Development, Regeneration, and Stem Cell Biology. Their research uses traditional model species including nematode worms, fruit-flies, Arabidopsis, zebrafish, amphibians, chick and mouse as well as non-traditional model systems such as lampreys and cephalopods. Areas of research focus include stem cell biology, regeneration, developmental genetics, and cellular basis of development, developmental neurobiology, and evo-devo (Evolutionary developmental biology).

Stem Cell Market Value:

Worldwide many companies are developing and marketing specialized cell culture media, cell separation products, instruments and other reagents for life sciences research. We are providing a unique platform for the discussions between academia and business.

Global Tissue Engineering & Cell Therapy Market, By Region, 2009 2018

$Million

Why to attend???

Stem Cell Research-2017 could be an outstanding event that brings along a novel and International mixture of researchers, doctors, leading universities and stem cell analysis establishments creating the conference an ideal platform to share knowledge, adoptive collaborations across trade and world, and assess rising technologies across the world. World-renowned speakers, the most recent techniques, tactics, and the newest updates in cell science fields are assurances of this conference.

A Unique Opportunity for Advertisers and Sponsors at this International event:

http://stemcell.omicsgroup.com/sponsors.php

UAS Major Universities which deals with Stem Cell Research

University of Washington/Hutchinson Cancer Center

Oregon Stem Cell Center

University of California Davis

University of California San Francisco

University of California Berkeley

Stanford University

Mayo Clinic

Major Stem Cell Organization Worldwide:

Norwegian Center for Stem Cell Research

France I-stem

Stem Cell & Regenerative Medicine Ctr, Beijing

Stem Cell Research Centre, Korea

NSW Stem Cell Network

Monash University of Stem Cell Labs

Australian Stem Cell Centre

Target Audience:

Eminent personalities, Directors, CEO, President, Vice-president, Organizations, Associations heads and Professors, Research scientists, Stem Cell laboratory heads, Post-docs, Students other affiliates related to the area of Stem cell research, stem cell line companies can be as Target Audience

Market Analysis of Stem Cell Therapy:

The global market for stem cell products was $3.8 billion in 2011. This market is expected to reach nearly $4.3 billion in 2012 and $6.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 11.7% from 2011 to 2016.

Americas is the largest region of global stem cell market, with a market share of about $2.0 billion in 2013. The region is projected to increase to nearly $3.9 billion by 2018, with a CAGR of 13.9% for the period of 2013 to 2018

Europe is the second largest segment of the global stem cell market and is expected to grow at a CAGR of 13.4% reaching about $2.4 billion by 2018 from nearly $1.4 billion in 2013.

Figure 2:Global Market

Companies working for Stem Cells:

Company

Location

Business Type

Cynata Therapeutics

Armadale, Australia

Stem Cell Manufacturing Technology

Mesoblast

Melbourne, Australia

Regenerative Medicine

Activartis

Vienna, Austria

Dendritic Cell-Based Cancer Immunotherapy

Aposcience

Vienna, Austria

Treatments composed of mixture of cytokines, growth factors and other active components

Cardio3 Biosciences

Mont-Saint-Guibert, Belgium

Stem Cell Differentiation

Orthocyte (BioTime)

Alameda, CA

Cellular Therapies

Capricor

Beverly Hills, CA

Stem Cell Heart Treatments

Life Stem Genetics

Beverly Hills, CA

Autologous stem cell therapy

International Stem Cell

Carlsbad, CA

Proprietary Stem Cell Induction

Targazyme

Carlsbad, CA

Cell Therapy

DaVinci Biosciences

Costa Mesa, CA

Cellular Therapies

Invitrx Therapeutics

Irvine, CA

Autologous Stem Cell Therapy, Therapeutic & Cosmetic

Stem Cell Softwares :

Products Manufactured By Industry Related to Stem Cell:

Original post:
Worlds leading Stem Cell Conference | Global Meetings ...

Read More...

Stem Cell Niches for Skin Regeneration

Thursday, August 4th, 2016

Int J Biomater. 2012; 2012: 926059.

1Department of Surgery, Oregon Health & Science University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA

2Hagey Laboratory for Pediatric Regenerative Medicine, Department of Surgery, Stanford University, 257 Campus Drive, Stanford, CA 94305, USA

3Department of Surgery, Plastic and Reconstructive Surgery Division, Division of Burn Surgery, University of Michigan Health Systems, 1500 East Medical Center Drive, Ann Arbor, MI 48104, USA

4The Biomaterials and Advanced Drug Delivery (BioADD) Laboratory, Stanford University, 300 Pasteur Drive, Grant Building, Room S380, Stanford, CA 94305, USA

Academic Editor: Kadriye Tuzlakoglu

Received 2012 Jan 15; Accepted 2012 Apr 8.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Stem cell-based therapies offer tremendous potential for skin regeneration following injury and disease. Functional stem cell units have been described throughout all layers of human skin and the collective physical and chemical microenvironmental cues that enable this regenerative potential are known as the stem cell niche. Stem cells in the hair follicle bulge, interfollicular epidermis, dermal papillae, and perivascular space have been closely investigated as model systems for niche-driven regeneration. These studies suggest that stem cell strategies for skin engineering must consider the intricate molecular and biologic features of these niches. Innovative biomaterial systems that successfully recapitulate these microenvironments will facilitate progenitor cell-mediated skin repair and regeneration.

Skin serves as the interface with the external world and maintains key homeostatic functions throughout life. This regenerative process is often overlooked until a significant exogenous and/or physiologic insult disrupts our ability to maintain skin homeostasis [1]. Complications of normal repair often result in chronic wounds, excessive scarring, or even malignant transformation, cutaneous diseases that contribute substantially to the global health burden [2, 3]. As human populations prone to inadequate healing (such as the aged, obese, and diabetics) continue to expand, novel therapies to treat dysfunctional skin repair and regeneration will become more critical.

Tissue regeneration has been demonstrated in multiple invertebrate and vertebrate species [4]. In humans, even complex tissues can regenerate without any permanent sequelae, such as liver, nerves, and skin. Although the typical result after significant organ injury is the formation of scar, regeneration after extensive skin and soft tissue trauma has been reported, most notably after digit tip amputation [5]. It is well accepted that human skin maintains the ability to regenerate; the question for researchers and clinicians is how to harness this potential to treat cutaneous injury and disease.

The integumentary system is a highly complex and dynamic system composed of myriad cell types and matrix components. Numerous stem cell populations have been identified in skin and current research indicates that these cells play a vital role in skin development, repair, and homeostasis [1, 6, 7]. In general, stem cells are defined by their ability to self-renew and their capacity to differentiate into function-specific daughter cells. These progenitor cells have been isolated from all skin layers (epidermis, dermis, hypodermis) and have unique yet complimentary roles in maintaining skin integrity. The promise of regenerative medicine lies in the ability to understand and regulate these stem cell populations to promote skin regeneration [4].

Wound healing is a highly regulated process that is thought to be mediated in part by stem cells [8, 9]. This has prompted researchers to examine the use of stem cells to augment skin repair following injury. Preclinical studies have suggested that the secretion of paracrine factors is the major mechanism by which stem cells enhance repair [10, 11]. Consistent with this hypothesis, conditioned media from mesenchymal stem cells (MSCs) have been shown to promote wound healing via activation of host cells [11, 12]. Clinical studies have suggested that topical delivery of MSCs may improve chronic wound healing [1315] and multiple groups have demonstrated the benefit of using recombinant cytokines (many of which are known to be secreted by stem cells) in patients with recalcitrant wounds [16]. However, more research is needed to determine the mechanisms by which stem cell therapies might improve wound healing in humans.

For example, the extent of stem cell engraftment and differentiation following topical delivery remains unclear. In one study, bone-marrow-derived allogeneic MSCs injected into cutaneous wounds in mice were shown to express keratinocyte-specific proteins and contributed to the formation of glandular structures after injury [17]. Although long-term engraftment was poor (only 2.5% of MSCs remained engrafted after four weeks), levels of secreted proangiogenic factors were greater in MSC-treated wounds. Our laboratory has demonstrated that local injection of allogeneic MSCs improved early wound closure in mice but that injected MSCs contributed to less than 1% of total wound cells after four weeks [18]. Taken together, these studies suggest that the benefits observed with stem cell injections are the result of early cytokine release rather than long-term engraftment and differentiation.

One potential reason for the transient presence of exogenous stem cells is the absence of proper contextual cues after cells are delivered into the wound. The dynamic microenvironment, or niche, of stem cells is responsible for regulating their stem-like behavior throughout life [19, 20]. This niche is comprised of adjacent cells (stem and nonstem cells), signaling molecules, matrix architecture, physical forces, oxygen tension, and other environmental factors (). A useful analogy is the seed versus soil paradigm in which seeds (stem cells) will only thrive in the proper chemical and physical soil environment (wound bed) [4]. Clearly, we need to better define what these niches are and how they dictate cell behavior to fully realize the potential of progenitor cell therapies.

Potential components of the skin stem cell niche. Features common to skin stem cell niches include dynamic regulation of matrix ligands, intercellular interactions, and biochemical gradients in the appropriate three-dimensional contexts. Engineered biomaterials ...

The epidermis is comprised of at least three major stem cell populations: the hair follicle bulge, the sebaceous gland, and the basal layer of interfollicular epithelium [21]. Because these subpopulations are responsible for regulating epithelial stratification, hair folliculogenesis, and wound repair throughout life [22], the epidermis has become a model system to study regeneration. Elegant lineage tracing and gene mapping experiments have elucidated key programs in epidermal homeostasis. Specifically, components of the wingless-type (Wnt)/-catenin, sonic hedgehog (Shh), and transforming growth factor (TGF)-/bone morphogenetic protein (BMP) pathways appear to be particularly relevant to epidermal stem cell function [1, 22, 23]. Microarray analyses have even indicated that hair follicle stem cells share some of the same transcriptomes as other tissue-specific stem cells [24], suggesting that conserved molecular machinery may control how environmental stimuli regulate the stem cell niche [25].

Epithelial stem cells from the bulge, sebaceous gland, and basal epithelium have common features, including expression of K5, K14, and p63, and their intimate association with an underlying basement membrane (BM) [26]. These cells reside in the basal layer of stratified epithelium and exit their niche during differentiation [26]. This process is mediated in part by BM components such as laminin and cell surface transmembrane integrins that control cell polarity, anchorage, proliferation, survival, and motility [27, 28]. Epithelial progenitor cells are also characterized by elevated expression of E-cadherin in adherens junctions and reduced levels of desmosomes [29], underscoring the importance of both extracellular and intercellular cues in stem cell biology.

In addition to complex intraepithelial networks, signals from the dermis (e.g., periodic expression of BMP2 and BMP4) are thought to regulate epithelial processes [30]. Dermal-derived stem cells may even differentiate into functional epidermal melanocytes [31], suggesting that mesenchymal-epithelial transitions may underlie skin homeostasis, as has been shown in hepatic stem cells [32]. Recently, it has been demonstrated that irreversibly committed progeny from an epithelial stem cell lineage may be recycled and contribute back to the regenerative niche [33], further highlighting the complexity of the epidermal regeneration.

In contrast to the highly cellular nature of the epidermis, the dermis is composed of a heterogeneous matrix of collagens, elastins, and glycosaminoglycans interspersed with cells of various embryonic origin. Recent studies suggest that a cell population within the dermal papilla of hair follicles may function as adult dermal stem cells. This dermal unit contains at least three unique populations of progenitor cells differentiated by the type of hair follicle produced and the expression of the transcription factor Sox2 [34]. Sox2-expressing cells are associated with Wnt, BMP, and fibroblast growth factor (FGF) signaling whereas Sox2-negative cells utilize Shh, insulin growth factor (IGF), Notch, and integrin pathways [35, 36]. Skin-derived precursor (SKP) cells have also been isolated from dermal papillae and can be differentiated into adipocytes, smooth myocytes, and neurons in vitro [37, 38]. These cells are thought to originate in part from the neural crest and have been shown to exit the dermal papilla niche and contribute to cutaneous repair [39].

Researchers have also demonstrated that perivascular sites in the dermis may act as an MSC-like niche in human scalp skin [40]. These perivascular cells express both NG2 (a pericyte marker) and CD34 (an MSC and hematopoietic stem cell marker) and are predominantly located around hair follicles. Perivascular MSC-like cells have been shown to protect their local matrix microenvironment via tissue-inhibitor-of-metalloproteinase (TIMP-) mediated inhibition of matrix metalloproteinase (MMP) pathways, suggesting the importance of the extracellular matrix (ECM) niche in stem cell function [41]. Interestingly, even fibroblasts have been shown to maintain multilineage potential in vitro and may play important roles in skin regeneration that have yet to be discovered [42, 43].

The ability to harvest progenitor cells from adipose tissues is highly appealing due to its relative availability (obesity epidemic in the developed world) and ease of harvest (lipoaspiration). Secreted cytokines from adipose-derived stem cells (ASCs) have been shown to promote fibroblast migration during wound healing and to upregulate VEGF-related neovascularization in animal models [44]. ASCs have even been harvested from human burn wounds and shown to engraft into cutaneous wounds in a rat model [45]. Although these multipotent cells have only been relatively recently identified, they exhibit significant potential for numerous applications in skin repair [46].

ASCs are often isolated from the stromal vascular fraction (SVF) of homogenized fat tissue. These multipotent cells are closely associated with perivascular cells and maintain the potential to differentiate into smooth muscle, endothelium, adipose tissue, cartilage, and bone [47, 48]. Researchers have attempted to recreate the ASC niche using fibrin matrix organ culture systems to sustain adipose tissue [49]. Using this in vitro system, multipotent stem cells were isolated from the interstitium between adipocytes and endothelium, consistent with the current hypothesis that ASCs derive from a perivascular niche.

Detailed immunohistological studies have demonstrated that stem cell markers (e.g., STRO-1, Wnt5a, SSEA1) are differentially expressed in capillaries, arterioles, and arteries within adipose tissue, suggesting that ASCs may actually be vascular stem cells at diverse stages of differentiation [50]. Adipogenic and angiogenic pathways appear to be concomitantly regulated and adipocytes secrete multiple cytokines that induce blood vessel formation including vascular endothelial-derived growth factor (VEGF), FGF2, BMP2, and MMPs [51, 52]. Additionally, cell surface expression of platelet-derived growth factor receptor (PDGFR) has been linked to these putative mural stem cells [53]. Reciprocal crosstalk between endothelial cells and ASCs may regulate blood vessel formation [54] and immature adipocytes have been shown to control hair follicle stem cell activity through PDGF signaling [55]. Taken together, these studies indicate that the ASC niche is intimately associated with follicular and vascular homeostasis but further studies are needed to precisely define its role in skin homeostasis [48].

Strategies to recapitulate the complex microenvironments of stem cells are essential to maximize their therapeutic potential. Biomaterial-based approaches can precisely regulate the spatial and temporal cues that define a functional niche [56]. Sophisticated fabrication and bioengineering techniques have allowed researchers to generate complex three-dimensional environments to regulate stem cell fate. As the physicochemical gradients, matrix components, and surrounding cells constituting stem cell niches in skin are further elucidated (), tissue engineered systems will need to be increasingly scalable, tunable, and modifiable to mimic these dynamic microenvironments [5761]. A detailed discussion of different biomaterial techniques for tissue engineering is beyond the scope of this paper, but we refer to reader to several excellent papers on the topic [6270].

Skin-specific stem cells and putative features of their niche.

One matrix component thought to regulate interactions between hair follicle stem cells and melanocyte stem cells is the hemidesmosomal collagen XVII [71]. Collagen XVII controls their physical interactions and maintains the self-renewal capacity of hair follicles via TGF-, indicating that biomaterial scaffolds containing collagen XVII may be necessary for stem cell-mediated hair follicle therapies. Another matrix component implicated in the hair follicle niche is nephronectin, a protein deposited into the underlying basement membrane by bulge stem cells to regulate cell adhesion via 81 integrins [72]. Hyaluronic acid fibers have been incorporated into collagen hydrogels to promote epidermal organization following keratinocyte seeding [73], and in vitro studies have demonstrated the critical role of collagen IV in promoting normal epithelial architecture when keratinocytes are grown on fibroblast-populated dermal matrices [74]. These studies collectively suggest that tissue engineered matrices for skin regeneration will need to recapitulate the complex BM-ECM interactions that define niche biology [75].

The role of MSCs in engineering skin equivalents has been studied using either cell-based or collagen-based dermal equivalents as the scaffolding environment [76]. When these constructs were grown with keratinocytes in vitro, only the collagen-based MSCs promoted normal epidermal and dermal structure, leading the authors to emphasize the necessity of an instructive biomaterial-based scaffold to direct stem cell differentiation, proliferation, paracrine activity [and] ECM deposition [76]. Our laboratory has reported that MSCs seeded into dermal-patterned hydrogels maintain greater expression of the stem cell transcription factors Oct4, Sox2, and Klf4 as compared to those grown on two-dimensional surfaces [18]. MSCs seeded into these niche-like scaffolds also exhibited superior angiogenic properties compared to injected cells [18], indicating that stem cell efficacy may be enhanced with biomaterial strategies to recapitulate the niche. Another study demonstrated that ASC delivery in natural-based scaffolds (dermis or small intestine submucosa) resulted in improved wound healing compared to gelatin-based scaffolds, suggesting the importance of biologically accurate architecture for stem cell delivery [77].

Researchers have developed novel three-dimensional microfluidic devices to study perivascular stem cell niches in vitro [78]. For example, MSCs seeded with endothelial cells in fibrin gels were able to induce neovessel formation within microfluidic chambers through 61 integrin and laminin-based interactions. Fibrin-based gels have also been used to study ASC and endothelial cell interactions in organ culture [49] and to control ASC differentiation in the absence of exogenous growth factors, demonstrating the importance of the three-dimensional matrix environment in regulating the ASC niche [79]. These studies indicate that the therapeutic use of ASCs in skin repair will likely be enhanced with biomaterial systems that optimize these cell-cell and cell-matrix contacts.

Finally, it must be recognized that the wound environment is exceedingly harsh and often characterized by inflammation, high bacterial loads, disrupted matrix, and/or poor vascularity. In this context, it should not be surprising that injection of naked stem cells into this toxic environment does not produce durable therapeutic benefits. Our laboratory has shown that the high oxidative stress conditions of ischemic wounds can be attenuated with oxygen radical-quenching biomaterial scaffolds that also deliver stem cells [80]. Other researchers have shown that oxygen tension, pH levels, and even wound electric fields may influence stem cell biology, suggesting that the future development of novel sensor devices will allow even finer control of chemical microgradients within engineered niches [70, 81]. It is also important to acknowledge that current research on niche biology has been performed largely in culture systems or rodent models, findings that will need to be rigorously confirmed in human tissues before clinical use.

As interdisciplinary fields such as material science, computer modeling, molecular biology, chemical engineering, and nanotechnology coordinate their efforts, multifaceted biomaterials will undoubtedly be able to better replicate tissue-specific niche environments. Recent studies suggest that the cells necessary for skin regeneration are locally derived [5], indicating that adult resident cells alone may have the ability to recreate skin (). Thus, the ability to engineer the proper environment for skin stem cells truly has the potential to enable regenerative outcomes. We believe that next-generation biomaterial scaffolds will not only passively deliver stem cells but also must actively modify the physicochemical milieu to create a therapeutic niche.

Locally derived skin stem cells may harbor the potential to regenerate skin. Stem cells populations have been identified in various niches throughout the skin, including the epidermal stem cell in the hair follicle bulge, sebaceous glands, and interfollicular ...

Current research indicates that skin regeneration is highly dependent upon interactions between resident progenitor cells and their niche. These microenvironmental cues dictate stem cell function in both health and disease states. Early progress has been made in elucidating skin compartment-specific niches but a detailed understanding of their molecular and structural biology remains incomplete. Biomaterials will continue to play a central role in regenerative medicine by providing the framework upon which to reconstruct functional niches. Future challenges include the characterization and recapitulation of these dynamic environments using engineered constructs to maximize the therapeutic potential of stem cells.

Articles from International Journal of Biomaterials are provided here courtesy of Hindawi Publishing Corporation

Follow this link:
Stem Cell Niches for Skin Regeneration

Read More...

anti-aging stem cells – innovative treatments for skin …

Thursday, August 4th, 2016

Stem Cell Technology represents a major breakthrough in anti-aging and regenerative skin care, by protecting, strengthening, and replenishing our own human skin cells. Where Peptides stimulate different functions acting as messengers to skin cells, stem cell technology improves the life of the core of the cell. Working in synergy with peptides, they enhance the effectiveness of peptides and other active ingredients.

Antiaging effects - The stem cells in our skin have a limited life expectancy due to DNA damage, aging and oxidative stress. As our own skin stem cells age, they become more difficult to repair and replenish. Protection of our stem cells becomes more and more beneficial as our skin ages, and with the advent of stem cells, we are now able to delay the natural aging process even further than before.

Expected benefits of stem cells technology for regenerative skin care:

Stem Cell Replenishing Serum Featuring a potent concentration of apple and edelweiss plant stem cells, state-of-the-art peptides, and other cutting edge ingredients, the Stem Cell Replenishing Serum is thoroughly formulated to produce age defying results, restoring the youthful look and vitality to aging skin.

Stem Cell Moisturizing Cream Also featuring a healthy concentration of apple and edelweiss plant stem cells, peptides, and numerous botanical extracts, the Stem Cell Moisturizing Cream is formulated to produce age defying results while also helping to maintain healthy and youthful looking skin as a daily moisturizer.

Our Stem Cell Applications:

LPAR Stem Cell Products contain a wide variety of stem cells with healthy and potent concentrations in order to deliver the results skin care consumers strive for. The first stem cell ingredient discovered and produced is a liposomal preparation based on the stem cells of a rare Swiss apple. The revolutionary active ingredient, Malus Domestica by PhytoCellTec is based on a high tech plant cell culture technology. It has been proven to protect the longevity of skin stem cells and provide significant anti-wrinkle effects. Since the discovery and the worldwide success of Apple Stem Cells introduction to the cosmetic and skin care marketplace, other new and exciting stem cell ingredients have been discovered to provide extraordinary results for all skin types.

We were proud to be the first skin care line to offer the ground-breaking combination of Apple and Edelweiss stem cells, and are dedicated to formulating the best new and existing stem cell ingredients into our product line as the technology continues to develop.

To inquire about purchasing LPAR Stem Cell products. visit our Retail Locator page.

Featuring a luxurious and potent blend of three major botanical stem cells (Apple, Gardenia Jasminoides, Echinacea Angustifolia) two state-of-the-art peptides (Nutripeptides, Matrixyl synthe6), and numerous botanical extracts and minerals, the Stem Cell Nourishing Mask is thoroughly formulated to nourish, firm, and energize mature skin. Total Stem Cell Concentration: 5.5% - Total Peptide Concentration: 9.0%

Directions: Using fingertips, apply on clean, dry skin twice weekly. Avoid the eye area. The mask can be left on the skin for prolonged periods (during the day or overnight). Allow at least 10-15 minutes for the mask to penetrate the skin before rinsing with water or applying additional product For external use only.

Ingredients: Water (Aqua), Glycerin, Glyceryl Acrylate/Acrylic Acid Copolymer, Hydrolyzed Rice Protein (Nutripeptides), Sodium Hyaluronate, Hydroxypropyl Cyclodextrin, Palmitoyl Tripeptide-38 (Matrixyl synthe6), Biosaccharide Gum-1, Olea Europaea (Olive) Fruit Oil, Gardenia Jasminoides Meristem Cell Culture, Xanthan Gum, Malus Domestica Fruit Cell Culture, Lecithin, Porphyridium Polysaccharide, Echinacea Angustifolia Meristem Cell Culture, Carbomer, Triethanolamine, Mentha Pipertita (Peppermint) Extract, Camellia Sinensis (Green Tea) Leaf Extract, Palmaria Palmata (Dulce) Extract, Chamomilla Recutita (Matricaria) Flower Extract, Phenoxyethanol, Caprylyl Glycol, Ethylhexylglycerin, Hexylene Glycol, Copper PCA, Zinc PCA, Dipotassium Glycyrrhizate, Olea Europaea (Olive) Fruit Extract, Aloe Barbadensis Leaf Juice Powder, Fragrance (Parfum)

Featuring a plant and fruit stem cell enhanced blend of three major stem cells (Apple, Edelweiss, Alpine Rose), state-of-the-art peptides (Eyeseryl, Nutripeptides), the Stem Cell Eye Therapy is an advanced eye formula designed to nourish, firm, and increase skin elasticity and skin smoothness around the eye area. Total Stem Cell Concentration: 6.75% - Total Peptide Concentration: 11.0%

Directions: Using fingertips, apply product around both eyes on clean, dry skin once or twice daily before applying a moisturizer or night cream. For external use only.

Ingredients: Water, Acetyl Tetrapeptide-5 (Eyeseryl), Sodium Hyaluronate, Hydrolyzed Rice Protein (Nutripeptides), Glycerin, Leontopodium Alpinum Meristem Cell Culture (Edelweiss Stem Cells), Xanthan Gum, Malus Domestica Fruit Cell Culture (Apple Stem Cells), Lecithin, Porphyridium Polysaccharide, Camellia Sinensis (Green Tea) Leaf Extract, Cucumis Sativus (Cucumber) Fruit Extract, Phenoxyethanol, Caprylyl Glycol, Ethylhexylglycerin, Hexylene Glycol, Carbomer, Triethanolamine, Rhododendron Ferrugineum Leaf Cell Culture Extract (Alpine Rose Stem Cells) Isomalt, Sodium Benzoate, Lactic Acid, Sodium Polystyrene Sulfonate, Allantoin, Copper PCA, Aloe Barbadensis Leaf Juice Powder

Plant stem cells represent a major breakthrough in skin care, launching the beginning of a new system of treating the skin...by protecting and replenishing the building blocks of what makes up our own skin: Stem Cells. Rather than working around the natural aging process of our skin stem cells, we now have the technology available to improve the life of our skins most important and central component.

Featuring a potent combination of apple, edelweiss, and grape stem cells, state-of-the-art peptides, and other cutting edge ingredients, the Stem Cell Replenishing Serum is thoroughly formulated to produce age defying results, restoring the youthful look and vitality to aging skin.

Directions: Apply with fingertips on clean, dry skin once or twice daily. Avoid the eye area by approximately 1 cm. Suitable for mature skin types. For external use only.

Ingredients: Water (Aqua), Glycerin, Dipeptide Diaminobutyroyl Benzylamide Diacetate, Acetyl Octapeptide-3, Malus Domestica Fruit Cell Culture (Apple Stem Cells), Hydrolyzed Ceratonia Siliqua Seed Extract, Palmitoyl Tripeptide-5, PEG-8 Dimethicone, Saccharide Isomerate, Imperata Cylindrica (Root) Extract, Polysorbate 20, Leontopodium Alpinum Meristem Cell Culture (Edelweiss Stem Cells), Leucojum Aestivum Bulb Extract, Triethanolamine, Carbomer, Xanthan Gum, Vitis Vinifera Fruit Cell Extract (Grape Stem Cells), Isomalt, Sodium Benzoate, Lecithin, Disodium EDTA, Allantoin, Aloe Barbadensis Leaf Juice Powder, Phenoxyethanol, Caprylyl Glycol, Ethylhexylglycerin, Hexylene Glycol, PEG-8-Carbomer, Fragrance (Parfum)

Plant stem cells represent a major breakthrough in skin care, launching the beginning of a new system of treating the skin...by protecting and replenishing the building blocks of what makes up our own skin: Stem Cells. Rather than working around the natural aging process of our skin stem cells, we now have the technology available to improve the life of our skins most important and central component.

Featuring a healthy concentration and a diverse group of stem cells (apple, edelweiss, grape), peptides, and numerous botanical extracts, the Stem Cell Moisturizing Cream is formulated to produce age-defying results, while also helping to maintain healthy and youthful looking skin as a daily moisturizer.

Directions: For mature skin and/or skin conditioning, apply onto clean, dry skin with fingertips once daily. Avoid the eye. For external use only.

Ingredient Highlights: Plant/Fruit Stem Cells 4% - Malus Domestica (Apple Stem Cells) - Leontopodium Alpinum Cell Culture Extract (Edelweiss Stem Cells) - Vitis Vinifera Fruit Cell Extract (Grape Stem Cells)

Ingredients: Water (Aqua), Glycerin, Isopropyl Myristate, Caprylic/Capric Triglyceride, Cetearyl Olivate, Sorbitan Olivate, Sorbitol, Saccharide Isomerate, Sodium Hyaluronate, Leucojum Aestivum Bulb Extract, Malus Domestica Fruit Cell Extract (Apple Stem Cells), Leontopodium Alpinum Meristem Cell Culture (Edelweiss Stem Cells), Vitis Vinifera Fruit Cell Extract (Grape Stem Cells), Crambe Abyssinica Seed Oil, Dimethicone, Cetyl Alcohol, Imperata Cylindrica (Root) Extract, Acetyl Octapeptide-3 (SNAP-8), Dipeptide Diaminobutyroyl Benzylamide Diacetate(SYN-AKE), Palmitoyl Tripeptide-3 (SYN-COL), Hydrolyzed Ceratonia Siliqua Seed Extract, Aloe Barbadensis Leaf Juice Powder, Olea Europaea (Olive) Leaf Extract, Glyceryl Stearate, Xantham Gum, Cetyl Palmitate, Sorbitan Palmitate, Bisabolol, Tocopheryl Acetate, Fragrance, Phenoxyethanol, Caprylyl Glycol, Ethylhexyglycerin, Hexylene Glycol, PEG-8, Carbomer, Lecithin, Isomalt, Sodium Benzoate, Disodium EDTA

[ pH: 5.00 ]

Featuring high concentrations of Vitamin C (Tetrahexyldecyl Ascorbate), Orange Stem Cells, and Peptides, this is a multi-beneficial cream with state-of-the-art actives formulated to deliver significant and lasting results.

Tetrahexyldecyl Ascorbate is a stable, oil soluble form of Vitamin C that penetrates deeper into the skin than traditional ascorbic acid based Vitamin C. It's a proven skin lightener, a powerful Anti-Oxidant, DNA protector, and increases collagen synthesis more effectively than ascorbic acid. Orange Stem Cells work to increase elasticity and skin resistance to the dermis, which increase firmness and diminish wrinkles while also working synergistically with peptides to further increase skin elasticity and collagen support.

How to Use: Smooth a pearl sized drop onto the face once daily (morning or evening). Avoid the eye area while applying. Follow with Solar Protection if used during the day.

Ingredients: Water (Aqua), Tetrahexyldecyl Ascorbate (Vitamin C Ester), Glycerin, Hexyl Laurate, Caprylic/Capric Triglyceride, Butylene Glycol, Sorbitol, Stearic Acid, Glyceryl Stearate, PEG-100 Stearate, Cetyl Alcohol, Sorbitan Stearate, Polysorbate 60, Acetyl Hexapeptide-8, Sodium Hyaluronate, Squalane, Dimethicone, PPG-12/SMDI Copolymer, Citrus Aurantium Dulcis Callus Culture Extract (Orange Stem Cells), Tocopheryl Acetate, Cetearyl Ethylhexanoate, Linoleic Acid, Glycine Soja (Soybean) Sterols, Phospholipids, Di-PPG-2 Myreth-10 Adipate, Retinol, Polysorbate 20, Hydrolyzed Glycosaminoglycans, Alcohol, Ectoin, Lecithin, Cyclotetrapeptide-24 Aminocyclohexane Carboxylate, Glucosamine HCl, Algae Extract, Yeast Extract, Urea, Micrococcus Lysate, Plankton Extract, Arabidopsis Thaliana Extract, Magnesium Aluminum Silicate, Xanthan Gum, Phenoxyethanol, Caprylyl Glycol, Ethylhexylglycerin, Hexylene Glycol, Disodium EDTA, Citrus Aurantium Dulcis (Orange) Peel Oil

[ pH: 4.7 ]

The Vitamin C Stem Cell Mask combines a potent blend of Vitamin C Ester (Tetrahexyldecyl Ascorbate), highly concentrated plant and fruit stem cells (Argan, Sea Fennel), and Aldenine, a unique peptide that acts as a cellular detoxifier and a collagen III booster.

Directions: Apply on clean, dry skin. Avoid the eye area. The mask may be left on the skin (i.e. during the day or overnight), or it may be rinsed off with lukewarm water after 10 - 15 minutes. Suitable for mature skin types.

Ingredients: Water (Aqua), Tetrahexyldecyl Ascorbate, Kaolin, Glycerin, Glyceryl Stearate, Sorbitan Olivate, Cetearyl Olivate, Cetyl Palmitate, Sorbitol, Sorbitan Palmitate, Stearic Acid, Caprylic/Capric Triglyceride, Cyclopentasiloxane, Cyclhexasiloxane, Carthamus Tinctorius (Safflower) Seed Oil, Punica Granatum Extract, Butylene Glycol, Ananas Sativus (Pineapple) Fruit Extract, Carica Papaya Fruit Extract, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-1, Argania Spinosa (Argan Stem Cells) Sprout Cell Extract, Crithmum Maritimum (Sea Fennel Stem Cells) Callus Culture Filtrate, Oligopeptide-68, Sodium Oleate, Phenoxyethanol, Caprylyl Glycol, Ethylhexylglycerin, Hexylene Glycol, Polyacrylamide, C13-14 Isoparaffin, Laureth-7, Isomalt, Hydrogenated Lecithin, Lecithin, Sodium Benzoate, Allantoin, Citrus Aurantium Dulcis (Orange) Peel Oil, Magnesium Aluminum Silicate, Xanthan Gum, Disodium EDTA

[ pH: 6.00 ]

Originally designed to prepare and increase the skins receptiveness to our Professional Peptide Peel, the Premier Peptide Serum has gone on to become our most powerful anti-wrinkle product for year-round home care due to its high concentration and diversity of peptides. Composed of a total concentration of 65% peptides, the Premier Peptide Serum is a state of the art facial serum expertly formulated to reduce the signs of aging, energizing mature skin.

The Intensive Clarifying Peptide Cream is a unique and high potency moisturizing cream formulated with an abundance of natural skin lighteners, peptides, and botanical extracts that combine to clarify and firm mature skin, while effectively minimizing fine lines and wrinkles.

The Collagen Peptide Complex builds off of our original Collagen Copper Activating Complex, and includes an advanced formulation of peptides, including Syn-Coll, a small but powerful peptide that stimulates collagen synthesis at a cellular level, helping to compensate for any collagen deficit in the skin.

Boasting a remarkable collection of natural and innovative ingredients from exotic plants and enhanced peptides, the neck firming cream has been designed & tested to firm and energize mature skin, while providing increased smoothness and elasticity to the often neglected neck area.

Providing sufficient hydration is the most essential way to keep our skin healthy and youthful. While many of our products assist in hydrating the skin, hydration is the main focus of the Nano-Peptide B5 Complex, acting as the foundation for your home care regimen. Fortified with Sodium Hyaluronate (30%) and Pantothenic acid, it provides an especially deep and complete hydration. Because of the presence of peptides, it also assists in tightening and firming the skin while allowing for maximum absorption and effectiveness.

Designed for mature skin, this sophisticated moisturizer promotes cell renewal, stimulating the dermis layer of the skin with a high potency blend of peptides (Argireline, Matrixyl, & Biopeptide-CLTM) and botanical extracts that make it a particularly refined and effective moisturizing cream for age management.

The A&M Eye Recovery Therapy is an advanced age management treatment, applying the most tried and true peptides and delivery systems; Argireline & Matrixyl, to the highly wrinkle prone and fragile eye area, providing diminished wrinkle depth, and increased firmness and elasticity. The peptide Eyeliss is added to further enhance this treatment by counteracting skin slackening, puffiness, and decreasing irritation.

The A&M Facial Recovery Therapy is an advanced age-management treatment that blends the most tried and true peptides and delivery systems; Argireline & Matrixyl. Stimulating the deeper layers of the skin, the A&M Facial Recovery Therapy provides diminished wrinkle depth, as well as an increase in skin elasticity and firmness.

Originally designed to prepare and increase the skins receptiveness to our Professional Peptide Peel, the Premier Peptide Serum has gone on to become our most powerful anti-wrinkle product for year-round home care due to its high concentration and diversity of peptides. Composed of a total concentration of 65% peptides, the Premier Peptide Serum is a state of the art facial serum expertly formulated to reduce the signs of aging, energizing mature skin.

Directions: For mature skin types; apply at least three weeks before beginning the Lucrece Professional Peptide Peel treatment, and use twice a day leading up to the Peel. For year round application, apply once per day after the Collagen Peptide Complex. Avoid the eye area by at least 1 cm during application.

Peptides: SYN-AKE: A small peptide (Dipeptide Diaminobutyroyl Benzylamide Diacetate) that mimics the activity of Waglerin 1, a polypeptide that is found in the venom of the Temple Viper, Tropidolaemus wagleri. Clinical trials have shown SYN-AKE is capable of reducing wrinkle depth by inhibiting muscle contractions. SNAP-8: An anti-wrinkle (Acetyl Octapeptide-3) elongation of the famous Hexapeptide Argireline. The study of the basic biochemical mechanisms of anti-wrinkle activity led to the revolutionary Hexapeptide which has taken the cosmetic world by storm. ARGIRELINE: (Acetyl Hexapeptide-8) MATRIXYL: (Palmitoyl Pentapeptide-4) REGU-AGE: (Hydrolyzed Rice Bran Protein - Oxido Reductases - Soybean Protein) BIOPEPTIDE CL: (Palmitoyl Oligopeptide) RIGIN: (Palmitoyl Tetrapeptide-7) EYELISS: (Dipeptide-2 & Palmitoyl Tetrapeptide-7) INYLINE: (Acetyl Hexapeptide 30)

Other Ingredients: Water, Sodium Hyaluronate, Spiraea Ulmaria Flower Extract & Centella Asiatica Extract & Echinacea Purpurea Extract, Phenoxyethanol & Benzyl Alcohol & Potassium Sorbate & Tocopherol, Meadowsweet, Hydrocotyl Extract, Leucojum Aestivum Bulb Extract, Amino Acids, Diazolidinyl Urea, Imperata Cylindrica Extract, SMDI Copolymer, Hydroxyethylcellulose

[ pH: 5.00 ]

This unique and high potency moisturizing cream is formulated with an abundance of natural skin lighteners, peptides, and botanical extracts that combine to help clarify and energize mature skin.

Directions: Smooth a pearl size drop onto the face, gently massaging in with fingertips once per day (morning), avoiding the eye area. Follow with solar protection if applicable.

Skin Lightening Agents: Mulberry Bark, Saxifrage Extract, Grape Extract, Scutellaria Root Extracts, Vitamin C Ester (Tetrahexyldecyl Ascorbate), Emblica Fruit Extract, Licorice Root Extract.

Ingredients: Water (Aqua), Saxifrage Extract & Grape Extract & Butylene Glycol & Water & Mulberry Bark Extract & Scutellaria Root Extract, Prunus Amygdalus Dulcis (Sweet Almond) Oil, Caprylic/Capric Triglycerides, Sesamum Indicum (Sesame) Seed Oil, Cetearyl Olivate & Sorbitan Olivate, Glycerin, Palmitoyl Pentapeptide-4 (Matrixyl), Tetrahexyldecyl Ascorbate (C-Ester), Glyceryl Stearate & PEG 100 Stearate, Stearic Acid, Theobroma Cocao (Cocoa) Seed Butter, PPG-12/SMDI Copolymer, Butyrospermum Parkii (Shea) Butter, Tocopheryl Acetate (Vitamin E), Phyllanthus Emblica Fruit Extract, Palmitoyl Tripeptide-5 (Syn-Coll), Triethanolamine, Phenoxyethanol, Mangifera Indica (Mango) Seed Butter, Darutoside, Tricholoma Matsutake Singer (Mushroom) Extract, Imperata Cylindrica (Root) Extract, Fragrance (Parfum), Glucosamine HCL & Algae Extract & Yeast Extract & Urea, Retinyl Palmitate (Vitamin A), Centella Asiatica Extract & Echinacea Purpurea Extract, Xanthan Gum, Arctostaphylos Uva Ursi Leaf Extract, Glycyrrhiza Glabra Root Extract, Magnesium Aluminum Silicate, Disodium EDTA

[ pH: 5.75 ]

Specializing in firming the skin, the Collagen Peptide Complex builds off of our original Collagen Copper Activating Complex, and adds a combination of (5) major peptides, helping to keep the skin looking its youngest and most alive, as it works to firm, and add elasticity & texture to the skin. For best results, apply directly after the Nano-Peptide B5 Complex.

Directions: Apply a liberal amount on clean, dry face using fingertips, and massage into the skin. Let dry, and follow with a moisturizer and sun-block if used during the day, or the Vitamin A Facial Cream + III if used at night. Warning: For mature skin only. If redness occurs, lessen use to once or twice per week. If reactions persist, discontinue use.

Ingredients: Water (Aqua), Dipalmitoylhydroxyproline, Glycerin, Palmitoyl Tetrapeptide-7 (Rigin), Palmitoyl Oligopeptide (Biopeptide-CL), Butylene Glycol, Yeast (Faex Extract), Hydrocotyl Extract & Coneflower Extract, Aloe Barbadensis Leaf Extract, Palmitoyl Tripeptide-5 (Syn-Coll), Acetyl Hexapeptide-8 (Argireline), Palmitoyl Pentapeptide-4 (Matrixyl), Panthenol, Phenoxyethanol & Caprylyl Glycol & Ethylhexylglycerin & Hexylene Glycol, Triethanolamine, Carbomer, Decarboxy Carsonine HCI, Citrus Grandis (Grapefruit) Seed Extract, Copper PCA, Olea Europaea (Olive) Leaf Extract, Disodium EDTA

[ pH: 5.50 ]

Boasting a remarkable collection of natural and innovative ingredients from exotic plants and enhanced peptides, the neck firming cream has been designed & tested to firm and energize mature skin, while providing increased smoothness and elasticity to the often neglected neck area.

Directions: On clean dry skin, apply onto the neck area with fingertips in an upward motion. Apply twice a day, or as needed.

Key Ingredients: Bio-Bustyl: Stimulates cell metabolism, promotes collagen synthesis, and enhances fibroblast (collagen-producing cell) proliferation. INCI: Glyceryl Polymethacrylate, Soy Protein Ferment, PEG-8, & Palmitoyl Oligopeptide Polylift: Using a cross-linking technology, biopolymerization, Polylift reinforces the natural lifting effect of sweet almond proteins, providing a smooth firmness & radiance to the surface of the skin. INCI: Prunus Amygdalus Dulcis (Sweet Almond) Seed Extract.

Ingredients: Deionized Water, Prunus Amygdalus Dulcis (Sweet Almond Oil), Caprylic/Capric Triglycerides, Sesamum Indicum (Sesame) Seed Oil, Simmondsia (Jojoba) Seed Oil/ Buxus Chinensis, Cetearyl Alcohol, Dicetyl Phosphate, Ceteth-10 Phosphate, Palmitoyl Oligopeptide, Palmitoyl Tetrapeptide-7, Prunus Amygdalus Dulcis Seed Extract, Terminalia Catappa Leaf Extract & Sambucus Nigra Flower Extract & PVP & Tannic Acid, Glyceryl Polymethacrylate & Rahnella/ Soy Protein Ferment & PEG-8 & Palmitoyl Oligopeptide, Glycerin, Glyceryl Stearate & PEG 100 Stearate, Biosaccharide Gim-1, PPG-12/ SMDI Copolymer, Phyllanthus Emblica Fruit Extract, Stearic Acid, Centella Asiatica Extract & Darutosidetriethanolamine, Tocopheryl Acetate, Magnifera Indica (Mango) Seed Butter, Glycerin & Aqua & Lysolecithin & Perilla Frutescens Seed Oil, Xantham Gum, Retinyl Palmitate, Tetrahexyldecyl Ascorbate (Vitamin C Ester), Echinacea Purpurea Extract, Imperata Cylindrica (Root) Extract, Glycyrrhiza Glabra Root Extract, Magnesium, Aluminum Silicate, Disodium EDTA

[ pH: 6.25 ]

Hydration is the most essential way to keep our skin healthy feeling and healthy looking. While many of our products assist in hydrating the skin, hydration is the main focus for this product, making it an essential for all skin types. Fortified with Hyaluronic (30%) and Panthenol (Vitamin B5), the Nano-Peptide B5 Complex provides an especially deep and complete hydration. With the addition of peptides, it also assists in tightening and firming the skin while allowing for maximum absorption and effectiveness.

The Nano-Peptide B5 Complex should be applied directly after cleansing the skin, as the 2nd step in skin care regimens for all skin types (morning & night). For best results, age management regimens should follow with the Stem Cell Replenishing Serum and/or the Collagen Peptide Complex before moisturizing.

Directions: Apply a healthy amount on clean, dry skin. May be used around the eye area.

Key Ingredients: Palmitoyl Pentapeptide-4: Stimulates the skins fibroblasts to rebuild the extra-cellular matrix, including the synthesis of Collagen I and Collagen IV, fibronectin and of Glycosaminoglycans. It also stimulates the production of the dermal matrix (Collagen I & III) resulting in a significant reduction of wrinkles and fine lines. Acetyl Hexapeptide-8: Reduces facial wrinkle depth and the signs of skin aging resulting from facial movements and facial muscle contraction by halting the release of neurotransmitters from SNARE and catecholamine complexes, (which can also induce formation of wrinkles and fine lines to the skin). Hyaluronic Acid (30%): Penetrates deep into the skin, providing ample moisture Panthenol: Enhances formation of skin pigments for younger looking skin, and contains deep penetrating properties that allow a more complete hydration.

Other Ingredients: Water (Aqua), Hyaluronic Acid, Panthenol (Vitamin B5), MDI Complex, Palmitoyl Pentapeptide-4, Acetyl Hexapeptide-8, Phenoxyethanol, Hydrolyzed Wheat Protein, Butylene Glycol, Hydrocotyl & Coneflower Extract, Glycosaminoglycans.

[ pH: 5.5 ]

Designed for mature, sun damaged, and/or dehydrated skin, the Anti-Wrinkle Facial Cream is a peptide enriched moisturizer focused on increasing skin firmness & elasticity, and fortifying the skin with anti-oxidants & botanical extracts to facilitate healthy feeling and healthy looking skin.

Directions: Smooth a pearl size drop onto the face, massage into skin thoroughly. For use in the morning (recommended), follow with solar protection.

Ingredients: Water (Aqua), Glycerin, Dimethicone, Caprylic/Capric Triglycerides, C12-15 Alkyl Benzoate, Linoleic Acid & Glycine Soja (Soybean) Sterols & Phospholipids, Acetyl Hexapeptide-8, Butylene Glycol & Carbomer & Polysorbate 20 & Palmitoyl Pentapeptide-4, Cetearyl Alcohol & Dicetyl Phosphate & Ceteth-10 Phosphate, Glyceryl Stearate & PEG 100 Stearate, PPG-12/ SMDI Copolymer, Phyllanthus Emblica Fruit Extract, Darutoside, Cocoa Butter, Cetyl Alcohol, Butyrospermum Parkii (Shea Butter), Saccharomyces/Xylinum Black Tea Ferment & Glycerin & Hydroxyethylcellulose, Glucoseamine HCL & Algae Extract & Saccharomyces Cerevisiae (Yeast Extract) & Urea, Steareth-20 & Palmitoyl Tetrapeptide-7, Centella Asiatica Extract & Echinacea Purpurea Extract, Hydrolyzed Vegetable Protein, Imperata Cylindrica (Root) Extract & PEG-8 & Carbomer, Phenoxyethanol & Caprylyl Glycol & Ethylhexylglycerin & Hexylene Glycol, Polyglyceryl Methacrylate & Propylene Glycol & Palmitoyl Oligopeptide, Cyclopentasiloxane & Dimethicone, Stearic Acid, Mangifera Indica (Mango) Seed Butter, Tocopheryl Acetate, Glycyrrhiza Glabra Root Extract, Arctostaphylos Uva Ursi Leaf Extract, Chlorella Vulgaris Extract, Corallina Officinalis Extract, Dipotassium Glycyrrhizate, PEG-8 & Tocopherol & Ascorbyl Palmitate & Ascorbic Acid & Citric Acid, Disodium EDTA, Magnesium Aluminum Silicate, Xanthan Gum, Triethanolamine, Retinyl Palmitate, Lavandula Angustifolia (Lavender) Oil

[ pH: 5.75 ]

This advanced eye care treatment is expertly formulated to diminish the depth, increase firmness & elasticity, and to counteract skin slackening to the highly wrinkle prone and fragile eye area. Featuring (4) major peptides (Argireline, Matrixyl, Eyeliss, & Regu-age), the A&M Eye Recovery Therapy is our most potent eye treatment, and is recommended for mature skin.

Directions: Using fingertips, massage to surrounding eye areas affected by wrinkles due to muscle contractions. Also use in the nasal labial area. For best results, apply once per evening, followed by the A&M Facial Recovery Therapy, and/or the Vitamin A Facial Cream + III.

Ingredients Highlights: Palmitoyl Pentapeptide-4 (Matrixyl): Stimulates the skins fibroblasts to rebuild the extra-cellular matrix, including the synthesis of Collagen I and Collagen IV, fibronectin and of Glycosaminoglycans. It also stimulates the production of dermal matrix (Collagen I & III) resulting in a significant reduction of wrinkles and fine lines of the skin. Acetyl Hexapeptide-8 (Argireline): Reduces facial wrinkle depth and the signs of skin aging resulting from facial movements and facial muscle contraction by halting the release of neurotransmitters from SNARE and catecholamine complexes, (which can also induce formation of wrinkles and fine lines to the skin). Dipeptide-2 & Palmitoyl Tetrapeptide-7 (Eyeliss): Combats the effect of tiredness and hypertension, as well as the natural effects of aging, which contribute to the formation of bags under the eyes, Eyeliss is an outstanding anti-aging ingredient. Soy Peptides & Hydrolyzed Rice Bran Extract (Regu-Age): A highly active complex of specially purified soy and rice peptides and biotechnologically derived yeast protein, Regu-Age effectively addresses dark circles and puffiness around the eyes.

Other Ingredients: Water, Sodium Hyaluronate, Centella Asiatica Extract & Echinacea Purpurea Extract, Xanthan Gum-Chondrus Crispus & Glucose, Lecithin & Dipalmitoyl Hydroxyproline, Imperata Cylindrica Extract, PEG-8 Dimethicone, Cyclomethicone

[ pH: 6.25 ]

An advanced age management treatment that blends the most tried and true peptides and delivery systems, Argireline & Matrixyl, helping to prevent skin aging induced by repeated facial movement caused by excessive catecholamine release. Stimulating the deeper layers of the skin, the A&M Facial Recovery Therapy provides diminished wrinkle depth, as well as an increase in the elasticity and firmness of the skin. Recommend for mature skin types.

Directions: Using fingertips apply to facial areas and massage into skin once per evening, allowing it to absorb into the skin. Apply directly after the A&M Eye Recovery Therapy.

Ingredients Highlights: Palmitoyl Pentapeptide-4: Stimulates the skins fibroblasts to rebuild the extra-cellular matrix, including the synthesis of Collagen I and Collagen IV, fibronectin and of Glycosaminoglycans. It also stimulates the production of dermal matrix (Collagen I & III) resulting in a significant reduction of wrinkles and fine lines of the skin. Acetyl Hexapeptide-8: Reduces facial wrinkle depth and the signs of skin aging resulting from facial movements and facial muscle contraction by halting the release of neurotransmitters from SNARE and catecholamine complexes, (which can also induce formation of wrinkles and fine lines to the skin).

Other Ingredients: Deionized Water, Sodium Hyaluronate, Lecithin & Dipalmitoyl Hydroxyproline, Hydrocotyl & Coneflower Extracts, Glycosaminoglycans, Glucosamine HCI & Alagae Extract & Yeast Extract & Urea, Magnesium Ascorbyl Phosphate, Glycine HCL, Retinyl Palmitate

[ pH: 6.25 ]

Addressing the multiple problems of sun and age damaged skin, the Intensive Clarifying Facial Cream + III is a glycolic acid based moisturizer featuring three potent skin lighteners; Kojic Acid, Licorice, and Hydro- quinone (2%), which quickly & effectively treat hyperpigmentation & discolorations.

Vitamin C Ester (Tetrahexyldecyl Ascorbate) is a stable, oil-soluble form of Vitamin C, providing high level skin lightening, enhanced collagen synthesis, and increased DNA & UV protection with higher absorption capabilities and less irritating than Ascorbic Acid.

Because of how well it protects the skins collagen fibers, ascorbic acid based Vitamin C is widely considered one of the most effective antioxidants for skin rejuvenation & revitalization. The 20% Vitamin C Lightening drops combine a potent concentration of ascorbic acid with aloe, green tea leaf extract, and mushroom extract. *Also available is our original Vitamin C Serum, containing a milder blend of ascorbic acid (14%).

The Anti-Wrinkle Eye Cream contains a high potency blend of peptides, including EyelissTM & Regu-age (in addition to Argireline & Matrixyl) which work synergistically to improve firmness, elasticity, and reduce puffiness & dark circles around the eye area.

Addressing the multiple problems of sun and age damaged skin, the Intensive Clarifying Facial Cream + III moisturizer combines three powerful lightening. Agents: Hydroquinone, Kojic Acid, & Licorice, with Alpha Lipoic Acid, Vitamin C, & Co-enzyme Q10, minimizing fine lines, evening skin tone, and naturally exfoliating the outer layer of the skin while providing a 15 sun protection factor (SPF).

Directions: Smooth a pearl sized drop onto the face once or twice daily. Avoid eye area. If used during the day, apply additional sun protection if skin is in contact with the sun for an extended period (twenty minutes or more).

Active Ingredients: Octyl Methoxycinnamate - 7.5% Octyl Salcylate - 5% Glycolic Acid - 4% Benzophenone - 3% Hydroquinone - 2%

Inactive Ingredients: Deionized Water, Glyceryl Stearate & PEG-100 Stearate, Ascorbic Acid (Vitamin C), Alpha Lipoic Acid, Co-enzyme Q 10, Kojic Acid, Cetyl Alcohol, Licorice, Palmitic Acid, Octyl Salcylate, Phenoxyethanol, Tocopheryl Acetate, Essential Oil of Rosewood, Disodium tEDTA

[ pH: 4.5 ]

Vitamin C Ester is a stable, oil-soluble form of Vitamin C, providing high level Skin Lightening, enhanced Collagen Synthesis, and increased DNA & UV protection with higher absorption capabilities than Ascorbic Acid.

Directions: On clean, dry skin, apply four to five drops directly onto the face once a day, avoiding the eye area.

Ingredients: Cyclomethicone, Tetrahexyldecyl Ascorbate (Vitamin C Ester 10%), PPG-12/SMDI Copolymer, Santalum Album Extract, Phellodendrone Amurense Bark Extract, Barley Extract, Jojoba Seed Oil/Buxus Chinensis, Tocopheryl Acetate, Phenoxyethanol, Tricholoma Matsutake Singer (Mushroom Extract), Ascorbyl Palmitate, Bisabolol

[ pH: 7.0 ]

Ascorbic acid based Vitamin C is widely considered one of the most effective antioxidants for rejuvenating mature skin due to its ability to protect the skins collagen fibers, and for its ability to help inhibit melanin production, creating a lightening effect to the skin. The 20% Vitamin C Lightening Drops combine a potent concentration of ascorbic acid with aloe, green tea extract, and an exotic mushroom extract (Tricholoma Matsutake Singer) for additional lightening.

Directions: On clean, dry skin apply four to five drops directly onto the face once daily. Avoid the eye area. Thoroughly wash hands after use. Though a light tingling sensation is normal, if irritation (redness) results after application, discontinue or reduce the frequency of use of the product.

Ingredients: Water (Aqua), Ascorbic Acid -20%, Ethoxydiglycol, Hydroxyethylcellulose, Phenoxyethanol, Polysorbate 20, Camellia Sinensis Leaf Extract, Aloe Barbadensis Leaf Extract, Mushroom Extract (Tricholoma Matsutake Singer)-Enzymes- Alcohol, Sodium Sulfite, Disodium EDTA

[ pH: 3.00 ]

The Anti-Wrinkle Eye Cream is formulated to reduce puffiness, enhances firmness, strengthens connective tissues, and to help diminish dark circles around the eye area. In contrast to the A&M Eye Recovery Therapy, the Anti-Wrinkle Eye Cream concentrates on the upper layers of the skin, making it a great day moisturizer for the eyes.

Directions: Apply around the eye area with the ring finger once daily. For best results, follow with a moisturizer and solar protection.

Go here to read the rest:
anti-aging stem cells - innovative treatments for skin ...

Read More...

Page 36«..1020..35363738..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick